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Abstract
A ngioim m unoblastic T-cell lymphoma (AITL), although initially thought to be an 
atypical reactive process - angioim m unoblastic lymphadenopathy with 
dysproteinaem ia (AILD), has since been proved to be a T-cell lymphoma and is 
categorised as a subtype o f  peripheral T-cell lymphoma. It is an aggressive disease, 
in which the biology is poorly understood. Defining histological criteria apply only 
to typical exam ples, while many features overlap with reactive conditions and other 
lymphomas.
In this thesis, CD10 was investigated as a possible phenotypic m arker o f  AITL. As 
the neoplastic cells com prise the minority, individual CD 10 positive lymphoid cells 
were m icrodissected for m olecular genetic analysis. The results showed that the 
neoplastic T-cells in AITL expressed CD 10, thus providing a m arker to identify the 
neoplastic T-cell. It was also shown that in the assessm ent o f  nodal peripheral T-cell 
lymphomas, CD 10 expression appears to be a sensitive and specific m arker for 
AITL. CD 10 expression was m aintained in most extranodal sites o f  involvement, and 
correlated well w ith the presence o f  a follicular dendritic cell m eshwork.
AITL showed 3 overlapping histological patterns, depending on the presence o f  
hyperplastic follicles (pattern I), regressed follicles (pattern II) or absence o f 
identifiable follicles (pattern III). H istologic progression was studied in consecutive 
biopsies and it was shown that pattern I represented early lymph node involvement, 
which progressed to pattern III w ith disease progression. Furthermore, when AITL 
was complicated by a “ large cell lym phom a” it was usually an EBV-associated 
diffuse large B-cell lymphoma. EBV-associated B-cell proliferations complicated 
25%  o f  cases.
Using CD 10 as a phenotypic m arker o f  the neoplastic cell it was shown that the latter 
expressed CXCL13 and BCL-6 consistent with a germinal centre T-cell origin.
Finally, the correlation between EBV-load and histological patterns was studied and 
the presence o f  HHV-8 investigated. A high EBV load was mainly observed in 
pattern III histology, a feature that probably parallels the increasing degree o f 
immune suppression. HHV-8 infection was not found to be a feature o f  AITL.
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Chapter 1 
INTRODUCTION
1.1 LYMPHOMA
1.1.1 Definition and Classification
Lymphoma is defined as a neoplastic proliferation o f lymphoid cells. Similar to other 
neoplasms, lymphoma evolves from a monoclonal proliferation in most instances 
(Medeiros LJ et al, 1995). Due to their propensity for dissemination, all lymphoid 
neoplasms are considered malignant or potentially malignant (Jaffe, 1995). In terms o f 
behaviour, some are aggressive from the outset while others behave indolently for long 
periods, but may transform over time into more aggressive, overtly malignant tumours 
(Jaffe, 1995).
Classification o f lymphomas has been at the center o f controversy for many decades. 
Over the years, the schemes that emerged reflected the knowledge (or lack of 
knowledge) o f the normal immune system at the time. However, the overall aim o f all of 
these systems has been to stratify lymphoid neoplasms into reproducible categories that 
would also be acceptable to clinicians, i.e. have prognostic relevance. The Rappaport 
classification (1966) and the subsequent modified Rappaport classification for non- 
Hodgkin lymphoma (NHL) and the Lukes-Butler classification for Hodgkin lymphoma 
as modified at the Rye conference (1966) were based on the patterns o f growth and the 
cytologic characteristics o f the neoplastic elements (Lukes & Butler, 1966;Rappaport, 
1966). The subsequent Kiel (Lennert’s) classification (1974) and the Lukes-Collins 
classification (1974), although based on immunological concepts were also primarily 
morphological, as was the unifying classification scheme developed at the time, the
Working Formulation for Clinical Usage (1982;Gerard-Marchant et al, 1974;Lennert et 
al, 1975;Lukes & Collins, 1974). With the advent o f immunophenotyping, cytogenetic 
studies and clonality analysis by southern blotting and polymerase chain reaction (PCR), 
it became clear that immunological and genetic approaches were essential to the 
recognition o f individual disease (clinical) entities. The “Revised European-American 
Classification o f Lymphoid neoplasms” (REAL) classification, published by the 
International Lymphoma Study Group (ILSG) in 1994, a consensus list o f lymphoid 
neoplasms uses morphology, immunophenotype, genetic features and clinical features to 
define a disease entity. The World Health Organization (WHO) classification is based on 
the principles defined in the REAL classification, but also incorporates input from 
additional experts in order to update and broaden the consensus on lymphoid neoplasms, 
and extends the principles o f disease definition and consensus building to the 
classification o f myeloid neoplasms, myelodysplastic syndromes, and mast cell and 
histiocytic/dendritic-cell neoplasms (Harris et al, 1994;Harris et al, 2000;Harris et al, 
2001a). The WHO classification o f haematological tumours, thus stratifies neoplasms 
primarily according to lineage, and within each category, distinct entities are defined 
according to a combination o f morphology, immunophenotype, genetic features and 
clinical syndromes. For each neoplasm, a cell o f  origin, representing the stage o f 
differentiation o f the tumour cells as seen in the tissues, and not necessarily the cell in 
which the initial transforming event occurred, is postulated. The classification 
recognizes three major categories o f lymphoid neoplasms: B-cell neoplasms, T-cell and 
NK-cell neoplasms and Hodgkin Lymphoma. The B-cell neoplasms and T-cell and NK- 
cell neoplasms are in turn subcategorized into precursor neoplasms, mature neoplasms 
and proliferations o f uncertain malignant potential (Table 1.1) (Harris et al, 2001a).
Table 1.1 Section of WHO Classification that stratifies tumours of lymphoid tissues
B-CELL NEOPLASMS
P recu rso r B -cell neo p lasm s_____________________________________________________________________________
P recu rso r B lym phob lastic  leu k aem ia  /  lym phom a
M ature  B -cell neop lasm s_______________________________________________________________________________
C hron ic  lym phocy tic  leu k aem ia  /  sm all lym phocy tic  lym phom a
B -pro lym phocy tic  leukaem ia
L ym phop lasm acy tic  ly m phom a
S plen ic m arg inal zone  lym phom a
H airy cell leukaem ia
P lasm a cell m ye lom a
S olitary  p la sm acy to m a o f  bone
E xtraosseous p la sm acy to m a
E xtranodal m arg inal zone  B -cell lym phom a o f  m uco sa -asso c ia ted  lym phoid  tissue  (M A L T  lym phom a)
N odal m arg inal zone B -cell lym phom a
F ollicu la r lym phom a
M antle  cell lym phom a
D iffuse large B -cell lym phom a
M ediastinal (th y m ic) large B -cell lym phom a
In travascu lar large B -cell lym phom a
Prim ary  effu s ion  lym phom a
B urk itt lym phom a /  leukaem ia
B-cell p ro life ra tions  o f  un ce rta in  m a lig n a n t p o ten tia l___________________________________________________
L ym phom ato id  g ran u lo m ato sis
P o st-tran sp lan t lym p h o p ro life ra tiv e  d iso rder, p o lym orph ic
T-CELL AND NK-CELL NEOPLASMS
P recu rso r T -cell neop lasm s__________________________
P recursor T  lym p h o b lastic  leukaem ia  /  lym phom a 
B lastic  N K  cell ly m phom a
M ature  T -cell and  N K  cell neop lasm s_______________
T -cell p ro lym phocy tic  leukaem ia
T -cell large g ran u la r lym phocy tic  leukaem ia
A ggressive N K  cell leukaem ia
A dult T -cell leukaem ia /lym phom a
E nteropathy-type  T -cell lym phom a
H epatosp len ic T -cell lym phom a
S ubcu taneous p an n icu litis -lik e  T -cell lym phom a
M ycosis fungo ides
Sezary syndrom e
Prim ary  cu tan eo u s an ap las tic  la rge cell lym phom a 
P eripheral T -cell lym phom a, u nspecified  
A ng io im m u n o b la stic  T -cell lym phom a 
A nap lastic  large cell lym phom a
T -cell p ro lifera tions  o f  u n ce rta in  m a lignan t poten tia l 
L ym phom ato id  pap u lo sis
HODGKIN LYMPHOMA
N o du lar lym phocy te  p red o m in an t H odgk in  lym phom a 
C lass ica l H odgk in  lym phom a
N o du la r sc le ro sis  c lassica l H odgk in  lym phom a 
L ym phocy te -rich  c lassica l H odgk in  lym phom a 
M ixed ce llu larity  c lassica l H odgk in  lym phom a 
L ym phocy te -dep le ted  c lassica l H odgk in  lym phom a
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Both lymphomas and leukaemias are included, as both solid and circulating (leukaemic) 
phases may be present.
Although uncommon, mature T-cell and NK-cell neoplasms include some o f the most 
(clinically) aggressive lymphomas (1982;Coiffier et al, 1990;Gisselbrecht et al, 
1998;Melnyk et al, 1997). In the sections that follow, mature T-cell and NK-cell 
neoplasms will be discussed and angioimmunoblastic T-cell lymphoma (AITL) 
reviewed in detail. As these neoplasms retain many o f the properties o f various subsets 
o f normal T-cells it would be appropriate to first briefly review normal T-cell biology, 
followed by an overview o f clonality analysis in lymphoid proliferations.
1.2 T-cell biology
1.2.1 T-cell subsets: phenotypic properties and function
T-cells constitute 50-70% o f circulating lymphocytes, and like B-cells harbour 
diversified, antigen specific receptors on their surface. T-cells identify and bind peptide 
antigens displayed at the host cell surface by the glycoproteins o f the major 
histocompatibility complex (MHC) (Davis & Bjorkman, 1988;Kay, 1991). Two main 
subsets o f T-cells, a/(3 T-cells and y/5 T-cells, distinguished by the expression o f a /p  or 
y/5 T-cell receptor complex, respectively (Bentley & Mariuzza, 1996;Goodman & 
Lefrancois, 1988). Over 95% o f T-cells in the peripheral blood, lymph nodes and spleen 
are a /p  T-cells whereas the y/8 T-cells, which are not MHC restricted, comprise less 
than 5% o f all normal T-cells and are mainly confined to the splenic red pulp, intestinal 
epithelium and other epithelial sites (Asamow et al, 1989;Bucy et al, 1989;Delves & 
Roitt, 2000a;Goodman & Lefrancois, 1988;Sciammas et al, 1994).
26
As oc/p and y/S T-cell receptors are non-covalently linked to the CD3 molecular
complex, which contains y,8 and £ chains, CD3 is expressed on both a /p  and y/5 T-cells
(Delves & Roitt, 2000b;Jaffe & Ralfkiaer, 2001b). NK-cells usually express £ chain o f
CD3 in the cytoplasm, which can be detected by polyclonal antibodies to CD3 (Jaffe &
Ralfkiaer, 2001b;Lanier et al, 1992a). The ot/p T-cells are divided into two subtypes
depending on whether they are CD4-positive or CD-8 positive. In normal lymphoid
tissues the CD4-positive (helper) T-cells exceed the CD-8 positive
(cytotoxic/suppressor) T-cells (Reinherz & Schlossman, 1980). The CD4-positive T-
cells recognize peptides at the antigen presenting cell surface in the context o f the MHC
class II molecules, whereas the CD8 positive T-cells recognize antigen in the context o f
MHC class I molecules (Delves & Roitt, 2000a). All mature a /p  T-cells in addition to
CD3, express CD2, CD5 and CD7 (Bemey et al, 2000;Bemey et al, 2001 ;Haynes et al,
1988;Reinherz & Schlossman, 1980). The y/8 T-cells are negative for CD4, CD5 and
usually for CD8, although a subpopulation has been shown to express the latter. NK-
cells show some characteristics o f cytotoxic T-cells and can express CD2, CD7, CD8,
CD56 and CD57, antigens that may also be expressed by T-cells (Berney et al,
2000;Jaffe & Ralfkiaer, 2001b;Lanier et al, 1992b). With regard to leucocyte common
antigen (LCA) or CD45 expression by mature T-cells, naive T-cells express the 205-kd
isoform that is recognized by the anti-CD45, CD45RA (CD45RA positive) but not by
CD45RO (CD45RO negative), while in contrast the memory T-cells express the 180-kd
isoform that is CD45RA negative but CD45RO positive (Beverley, 1992).
TCR binding in the context o f MHC also requires a co-stimulatory signal in order to
trigger a T-cell response to antigen. This co-stimulatory signal is provided by CD28,
which binds to CD80 (B7-1) or CD86 (B7-2) expressed by antigen presenting cells (June
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et al, 1994). Upon activation in secondary lymphoid tissues naive CD4 positive T-cells 
undergo clonal expansion and differentiation to become memory or effector cells. 
According to their effector function and cytokine secretion profile, memory and effector 
CD4 positive T-cells, are divided into nonpolarised T-cells, T-helper 1 (T hl), T helper 2 
(Th2) and regulatory T-cells (Kim et al, 2001a). Thl cells secrete interleukin (IL) 2 and 
interferon y(IFy), which promote cellular immunity, whereas the Th2 cells induce 
humoral immunity by the production o f cytokines IL4, 5, 6 and 10 (Delves & Roitt, 
2000b). According to their chemokine receptor profile, effector and memory T-cells 
may also be classified into “central memory cells” that are CXCR5+, CCR7+ and 
“effector memory cells” that are predominantly CCR7- (Kim et al, 2001b;Kim et al, 
2001a;Sallusto et al, 1999). Thl and Th2 cells are derived from the latter. CCR5 and 
CXCR3 chemokine receptors are markers o f Thl cells, while CXCR4, CCR3 and CCR4 
are preferentially expressed by Th2 cells (Bonecchi et al, 1998;Kim et al, 2001a;Weng 
et al, 2003). Germinal centres (GCs) have a population o f CD4 positive, helper T-cells 
that express CD57 and also express CXCR5 but not CCR7 (Chtanova et al, 2004;Kim et 
al, 2001b;Velardi et al, 1988). They are distinct from Thl and Th2 cells both in terms o f 
effector functions and cytokine secretion profile.
1.2.2 T-cell ontogeny
Progenitor cells produced in the bone marrow are processed in thymus, due to their 
interaction with cytokines and thymic stroma. The pluripotent cells that arrive in the 
thymus give rise to the earliest definitive T-cells, the pro-thymocytes that express CD2 
and CD44 (Schattner EJ & Casali P, 2001). The latter, located in the subcapsular region 
o f the thymic cortex have their TCR-p gene in germ line configuration and can thus
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develop into either a /p  or y/8 subsets. Maturation within the thymus and movement from 
the thymic cortex to the medulla results in the stepwise acquisition/loss of surface 
antigens (Figure 1.1), TCR gene rearrangement (see below) and T-cell selection, the 
latter depending on their affinity for MHC binding and lack o f auto-reactivity (Delves & 
Roitt, 2000a).
1.2.3 T-cell receptor genes
The T-cell receptor (TCR) is the means by which T-cells recognize and interact with 
processed antigen. The function o f this receptor involves interaction with a multitude of 
foreign molecules. To meet this challenge, complex processes of gene rearrangement 
have evolved to provide the required diversity (Delves & Roitt, 2000a). There are 4 TCR 
proteins, a, p, y and 5, which give rise to 2 types o f heterodimeric T-cell receptors, the 
a/p and y/5 heterodimers (Delves & Roitt, 2000a).
Prothymocyte Subcapsular Cortical Medullary Peripheral T-
Thvmocvte Thvmocvte Thvmocvte cells
Figure 1.1 Stepwise acquisition/loss of surface antigens during T-cell ontogeny
(adapted from (Stetler-Stevenson et al, 1995)
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All 4 TCR genes are composed o f many non-identical gene segments that must 
rearrange into a functional unit prior to transcription and production o f the protein. The 
human TCR-a chain and TCR-p chain genes are located at 14q 11 (Croce et al, 1985) and 
7q34 (Caccia et al, 1984), respectively. Both genes are composed o f multiple segments 
in the germline that rearrange to form functional variable regions that combine with 
constant (C) regions. The TCR-a chain gene has 50-100 variable (V) segments, 50-100 
joining (J) segments and 1 C region (Pan et al, 2001). The TCR-p gene has 75-100 V 
segments along with 2 arrays composed o f a single D (diversity) segment, 13 J segments 
and 2 C regions (Figure 1.2) (Pan et al, 2001). In the case o f TCR-p, rearrangement o f 
the gene involves excision o f DNA between the D and J clusters resulting in D-J joining 
followed by a second excision between the D and V cluster resulting in V-DJ joining 
(Figure 1.2) (Pan et al, 2001). The VDJ unit becomes the coding sequence for the 
variable part o f the TCR protein, which is expressed in conjunction with C region exons. 
Variable numbers o f untemplated nucleotides (N regions) are inserted at the junctions 
between the V, D and J segments in TCR-P and between V and J in the case o f TCR-a. 
Diversity o f the TCR structure is achieved by unique combinations o f different V, D and 
J regions (recombinatorial diversity) and by variability in precise joints between the 
segments (junctional diversity) (Delves & Roitt, 2000a). Somatic mutations although not 
a well recognized feature, have been reported in the TCR-a chain (Zheng et al, 1994) 
and TCR- p chain gene (Cheynier et al, 1998).
The TCR-y chain gene is expressed in a subset o f T-cells as a heterodimer with the 
TCR-5 chain (Delves & Roitt, 2000a).The TCR-y chain gene is located at 7pl5 . The 
locus contains 14 V segments, which can be divided into 6 families by sequence 
homology, 5 J segments in 2 clusters and 2 C regions (Figure 1.2) (Pan et al, 2001). N
regions are found at the V-J junctions, but no evidence of somatic hypermutation has 
been reported. The delta chain gene is situated at 14ql 1 within the TCR-a chain gene 
(Chien et al, 1987;Pan et al, 2001). It is composed o f at least 10 V segments, 3 D 
segments, 3 J segments and 1 C region. Variable N regions are found at the V-D and D-J 
junctions, but somatic mutations have not been reported (Pan et al, 2001). 
Rearrangements of the y, 8 and p genes occur simultaneously, prior to rearrangements of 
the a  gene. Therefore mature T-cells of either a /p  or y/8 type, have rearranged y  and 8 
TCR genes. (Schattner EJ & Casali P, 2001)
LlV fll
T-cell receptor p gene 
LnVBn D pi Jpl (6) CBl DB2 Jp2 (7) Cp2
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recom bination
Ll VBl NDB1N JBl C pl
Transcription and 
RNA splicing
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5 ’
I -  A
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Figure 1.2 Diagramatic representation of T-cell receptor gene rearrangement
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As B-cell proliferations may be present in association with mature T-cell neoplasms 
immunoglobulin (Ig) gene rearrangement will also be discussed briefly at this point.
1.2.3.1 Immunoglobulin gene rearrangement in B-cells
Immunoglobulin molecules are composed o f two identical heavy and two identical light 
chain proteins. Each B-cell expresses a heavy chain in combination with either a k  or X. 
molecule (Delves & Roitt, 2000a). The heavy chain, k  and X undergo somatic gene 
rearrangement. The gene encoding the human heavy chain gene is located 
onchromosome 14 at q32 (Hobart et al, 1981), while the two light chain genes are 
located at 2 p l2  ( k )  and 22ql 1 (A.) (Hobart et al, 1981;Pan et al, 2001 ;Vasicek & Leder, 
1990). The Ig heavy chain gene consists o f clusters o f V (>100), D (about 30) and J (9) 
regions (Pan et al, 2001). As described previously for TCR, the rearranged VDJ unit 
becomes the coding sequence for the variable part o f the Ig protein, which is expressed in 
conjunction with C region exons. Variable numbers o f untemplated nucleotides (N regions) 
are inserted at the junctions between the V, D and J segments. As for TCR, diversity o f Ig 
structure is achieved by recombinatorial diversity, junctional diversity, but in addition also 
importantly by somatic point mutations. The latter are introduced into the variable regions 
o f fully assembled genes as part o f an "affinity maturation" process in follicle centres in 
which antibody binding is enhanced during the immune response. The k and X light chain 
genes have equivalent structures to the heavy chain gene and also undergo somatic 
rearrangement as well as hypermutation (Pan et al, 2001).
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1.3 Clonality analysis in the evaluation of lymphoid 
proliferations
The discovery that the genes for the immune recognition molecules (the Igs and T-cell 
receptors) in lymphocytes undergo somatic rearrangements that are unique to a given 
lymphocyte and its progeny, has provided a means for clonality analysis in 
lymphoproliferative disease o f both B- and T-cell lineages. The genes encoding these 
molecules are useful markers o f T and B-cell clonality and are used as targets for 
detection o f tumour clones using Southern blot and PCR.
1.3.1 Southern blot analysis
For many years, Southern blot analysis has been the gold standard technique for 
clonality analysis in lymphoid proliferations. It is used to determine gene structure by 
restriction fragment size analysis (Southern, 1975). The technique involves the use o f a 
probe (most frequently, a J segment probe) which hybridises to the variable region of 
TCR or Ig heavy or light chain genes and detects a germline band o f predictable size in 
DNA from non-T-cells (in the case o f TCR) or non-B-cells (in the case o f Ig), which do 
not carry rearranged antigen receptor genes. Rearrangement o f the TCR and Ig genes 
generate restriction fragments o f different sizes. Monoclonal populations carry identical 
antigen receptor gene rearrangements, and therefore Southern blot analysis o f tumour 
DNA results in a hybridising fragment (or two fragments if both alleles are rearranged) 
o f different size to the germline. Typical clinical samples, containing both tumour and 
other cells, yield both a germline band and novel rearranged fragments. Tumour samples 
must contain at least 1-2.5% of tumour cells to allow a confident interpretation of
monoclonality (Cleary et al, 1984). In the evaluation o f T-cell proliferations, the TCR-a, 
TCR-p, TCR-y and TCR-5 genes have all been targeted, although the TCR-p and TCR-y 
have been the most frequently used (Davey et al, 1986;0'Connor et al, 1985;Yokota et 
al, 1991). Studies o f the TCR-a and TCR-5 chain genes have been less frequent because 
blotting o f the TCR-a gene results in complex germline patterns and the TCR-5 chain 
gene is deleted by rearrangement o f the TCR-a chain gene and therefore DNA extracted 
from such clones does not hybridise with the probe (Cossman & Uppenkamp, 
1988;Hockett et al, 1988). Due to limitations to its application, although highly reliable, 
Southern blotting is increasingly replaced by PCR. The method is time consuming, 
expensive, requires radioactive isotopes, is technically demanding, and has a limited 
sensitivity o f 5-10%. However the most important limitation o f Southern blot analysis in 
diagnostic histopathology is the requirement for high quality DNA, i.e. fresh or frozen 
tissue samples, only available in a minority o f cases. Attempts have been made to use 
DNA extracted from formalin fixed, paraffin embedded tissues but the results have been 
unreliable (Warford et al, 1988).
1.3.2 Polymerase chain reaction (PCR)
PCR was first described in practice by Saiki and co-workers (Saiki et al, 1985) who 
amplified specific p-globin gene fragments from genomic DNA. PCR has since become 
one o f the most widely used analytical tools in molecular genetics as it permits rapid in 
vitro amplification o f specific DNA sequences from minute, complex and even degraded 
nucleic acid sources and is technically simple. Amplified DNA can be readily examined 
for structural changes. These features are o f particular importance in histopathology 
because PCR allows molecular genetic analysis o f formalin fixed, paraffin embedded
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biopsies in which the nucleic acid is highly degraded and present in small quantities. 
(Diss & Pan L, 1997;Goudie, 1989;Pan et al, 1995;Quirke & Taylor, 1989). PCR is a 
single tube reaction which relies on a thermostable DNA polymerase (usually Taq 
polymerase) to duplicate DNA sequences from a template using oligonucleotide primers 
which flank, and specifically bind to, the DNA region o f interest (Saiki et al, 1988). 
Amplification is achieved by multiple repetition (30-40 times) o f cycles o f temperature 
changes, in which each cycle is composed o f three stages. These are (1) denaturation o f 
template at 90-95°C, (2) annealing o f primers to their complementary sequences at each 
end o f the target gene fragment at 50-60°C, (3) new strand polymerisation by extension 
from the primers at 72°C. Primer extension occurs in a 5’ to 3' direction only, so only 
DNA between the primers is amplified. The consequence o f a single cycle o f PCR is a 
doubling o f specific double stranded DNA sequence. Thus specific target fragments 
increase exponentially upon repetition o f the cycle (Pan et al, 1995). Computer 
controlled heating blocks allow automated temperature cycling and precise control of 
reaction conditions.
Increased sensitivity and specificity can be achieved using nested PCR, which involves 
two rounds o f amplification (Wan et al, 1990). An initial amplification o f the test DNA 
using "outer primers" is followed by amplification o f an aliquot from the first round of 
PCR using "inner primers". Typically 20-30 cycles are used in each round.
PCR products can be analysed using agarose (AGE) or polyacrylamide gel 
electrophoresis (PAGE) (Pan et al, 1995). This allows confirmation o f the presence o f 
target template DNA, and shows the size o f the DNA fragment under study. Any gross 
changes such as deletions or insertions can be identified. Restriction analysis o f PCR 
products can be carried out to search for mutations or polymorphisms. For sequence
related analysis, temperature gradient or denaturing gradient gel electrophoresis (DGGE) 
(Bourguin et al, 1990), or single strand conformational polymorphism (SSCP) analysis 
may be employed (Orita et al, 1989).
For the purpose o f clonality analysis, primers are designed so that they flank known
rearranged segments o f Ig/TCR genes. Although in fresh/frozen tissue the distance
between primers may approach 500 base pairs (bp), in formalin-fixed tissues this should
be less than 300 bp. Due to the limited number o f primers required, Ig heavy chain (IgH)
and TCR-y gene rearrangements were commonly used for B- and T-cell clonality studies
respectively. As TCR-y gene rearrangements are a feature o f all T-cell types, including
those expressing TCR-a/|3 chains, the TCR-y gene has been considered a useful target
for clonality detection in all T-cell proliferations (Diss et al, 1995). Although PCR as a
technique for clonality detection has clear advantages, false negative results due to
improper primer annealing and difficulties in discriminating monoclonal from
polyclonal gene rearrangements are known problems. This prompted the initiation o f
BIOMED-2 concerted action BMH4-CT98-393 with the aim of overcoming these
shortcomings by careful selection o f PCR targets, the use o f multiple primer sets
designed for multiplex reactions and standardized protocols developed on pre-existing
experience from previous European collaborative studies (van Dongen et al, 2003). In
the BIOMED-2 protocol for Ig gene rearrangements, IgH (complete VH-JH
rearrangements and incomplete DH-JH rearrangements), IgK (Vk-Jk and K-deletion
rearrangements) and IgX, (V^-JX) are all targeted in order to include GC or post-GC
derived B-cell proliferations with somatic hypermutations that may otherwise be missed.
For TCR-gene rearrangements, targets include both TCR-p and TCR-y genes, while
TCR-5 primers are added only for precursor malignancies and y5 T-cell proliferations
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(van Dongen et al, 2003). Due its complexity, with numerous V and J gene segments 
TC R -a is not included. However this does not appear to be a problem as all T-cell 
neoplasms with TC R -a gene rearrangements contain TCR-P gene rearrangements and 
TCR-y gene rearrangements as well (van Dongen et al, 2003).
1.4 Mature T-cell and NK-cell neoplasms
1.4.1 Definition
Mature T-cell neoplasms are derived from mature /post-thymic T-cells. As NK-cells are 
closely related and share some characterististics with T-cells, NK-neoplasms and mature 
T-cell neoplasms are categorized together (Jaffe & Ralfkiaer, 2001b). WHO histological 
classification o f mature T-cell and NK-cell neoplasms is presented in Table 1.1.
1.4.2 Epidemiology
Mature T-cell and NK-cell neoplasms account for only approximately 12% o f all NHL, 
worldwide. The incidence o f individual subtypes is summarized in Table 1.2 (1997) 
Mature T-cell and NK-cell neoplasms show a geographic variation in incidence, being 
more common in Asia (2000). This is partly accounted for by the increased incidence of 
Human T-cell lymphoma virus-1 (HTLV-1) associated adult T-cell 
leukaemia/lymphoma (ATLL) in endemic regions in Japan and the apparent racial 
predisposition o f Asians for the development o f Epstein Barr virus (EBV) associated 
nasal and nasal type NK/T-cell lymphomas and aggressive NK/T-cell leukaemia (2000). 
Mature T-cell lymphomas or peripheral T-cell lymphomas (PTLs), generally affect older 
people (>50-years o f age) and males are more frequently affected than females (Savage
et al, 2004). Anaplastic large cell lymphoma (ALCL), however, is an exception in that it 
tends to affect children and young adults (Stein et al, 2000). The occurrence o f mature 
T- and NK-cell neoplasms in patients with a prior history o f a B-cell lymphoma, or 
presenting concurrent with or prior to the development o f a B-cell lymphoma has been 
reported (Abruzzo et al, 1993;Xu et al, 2002a).
1.4.3 Immunophenotype and cytokine secretion profile
Although mature T-cell neoplasms (PTLs) show the immunophenotypic features o f 
mature post-thymic T-cells, they may display an abnormal or aberrant phenotype such as 
loss o f CD5 expression or co-expression or loss o f CD4 and CD8 in <x/p T-cells, a 
feature which when present, is o f use in distinguishing lymphoma from a reactive T-cell 
proliferation (Stetler-Stevenson et al, 1995).
The predominance o f ex/p T-cells in normal T-cells, is also reflected in mature T-cell 
lymphomas where ex/p T-cell lymphomas far exceed the rare y/8 T-cell lymphomas 
(Table 1.2). Although cytokine secretion profiles do not determine subtypes of T-cell 
lymphomas, cytokine production by neoplastic cells plays an important role in the 
clinical manifestations o f T-cell lymphomas. For example, the haemophagocytic 
syndrome associated with PTLs is attributed to the secretion o f cytokines (Teruya- 
Feldstein et al, 1999). Studies show that cytokine or more specifically chemokine 
receptors specific for Thl or Th2 cells are expressed in more or less non-overlapping 
subsets o f PTLs. For example, the chemokine receptor CXCR3, expressed in Thl T-cells 
is expressed mainly by some PTL, unspecified (PTLu), and by most AITL, whereas the 
CCR4 and CXCR4, chemokine receptors, expressed by Th2 cells are a feature o f ALK-
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positive anaplastic large cell lymphoma (Ishida et al, 2004;Jones et al, 1999;Ohshima et 
al, 2004;Tsuchiya et al, 2004).
Table 1.2 Incidence of peripheral T-cell lymphomas
Diagnosis % of all NHLs
Peripheral T-cell lymphoma, unspecified 3.7%
Angioimmunoblastic T-cell lymphoma 1.2%
Anaplastic large cell lymphoma 2.4%
Extranodal NK/T-cell lymphoma, nasal type 1.4%
Enteropathy-type T-cell lymphoma <1%
Hepatosplenic T-cell lymphoma <1%
Adult T-cell leukaemia/lymphoma <1%
Data taken from “A clinical evaluation o f  the International Lymphoma Study Group classification o f  non- 
Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project” 1997.
1.4.4 Survival
With the exception o f anaplastic large cell lymphoma (ALCL), most mature T-cell and 
NK-cell lymphomas are clinically aggressive with a much poorer response to therapy 
and a shorter survival than B-cell lymphomas (Gisselbrecht et al, 1998;Melnyk et al, 
1997;Rudiger et al, 2002). Although the T-cell phenotype is by itself an independent 
adverse prognostic factor in non-ALCL, PTL (Gisselbrecht et al, 1998), the poor 
response to therapy may be in part due to the fact that many patients present at an 
advanced stage o f the disease and also that the treatment regimens employed are those 
developed for B-cell lymphomas, rather than specifically for T-cell lymphomas. This 
may be due to the rarity o f T-cell lymphomas, as a result o f which they are less well 
characterised compared to B-cell lymphomas, and few trials have been restricted to 
them.
In the following sections leukaemic/disseminated, cutaneous, other extranodal mature T-
cell and NK-cell neoplasms and blastic NK-cell lymphoma, a neoplasm o f uncertain
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lineage and stage o f differentiation will be mentioned briefly, followed by a more 
detailed review o f nodal T-cell lymphomas, with special emphasis on AITL (AITL).
1.4.5 Leukaemic/ disseminated mature T-cell and NK-cell neoplasms
1.4.5.1 T-cell prolymphocytic leukaemia (T-PLL)
T-PLL is an aggressive leukaemia comprising small to medium sized “pro­
lymphocytes”. They express CD2, CD3 and CD7. Although the majority is CD4+, CD8- 
, they may be CD4+, CD8+ (a feature almost unique to T-PLL) or CD4-, CD8+. 
Consistent with a mature phenotype they are TdT (terminal deoxynucleotidyl 
transferase) and CD1 a negative. Patients characteristically have disseminated disease 
with involvement o f blood, bone marrow, lymph nodes, liver, spleen and skin (Matutes 
e ta l, 1991).
1.4.5.2 T-cell large granular lymphocytic leukaemia (T-LGL)
T-LGL is characterised by a persistent increase in the number o f large granular 
lymphocytes in the peripheral blood, without an identifiable cause. Most cases show a 
CD3+, CD4-, CD8+ phenotype, but rarely CD4+ CD8-, CD4+ CD8+ or CD4-, CD8- 
may be seen. The disease is often indolent with a minority which may transform to an 
aggressive PTL (Harris et al, 1994;Harris et al, 2000).
1.4.5.3 Aggressive NK-cell leukaemia
This disease is an aggressive leukaemia that shows an NK-cell CD2+, surface CD3-, 
CD3e+, CD56+ phenotype. CD1 lb  and CD16 may be positive but CD57 is usually
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negative. Most cases are EBV positive (Chan et al, 2001b;Cheung et al, 2003;Imamura 
eta l, 1990).
1.4.5.4 Adult T-cell leukaemia/lymphoma (ATLL)
ATLL is caused by the HTLV-1 and characterised by systemic disease with
involvement o f lymph nodes, blood, bone marrow, spleen, liver, skin, lung, gastro­
intestinal tract and central nervous system. The neoplastic cells are medium to large in 
size and show marked nuclear pleomorphism often with polylobated nuclei. The 
neoplastic cells are CD2+, CD3+, CD5+ but usually CD7-. Most cases are CD4+ CD8-, 
but rare cases o f CD4- CD8+, or CD4+ CD8+ may be seen (Harris et al, 1994;Harris et 
al, 2000).
1.4.6 Cutaneous mature T-cell and NK-cell neoplasms
1.4.6.1 Mycosis fungoides (MF)
MF presents in the skin with patches and / or plaques and is characterised by an 
epidermotropic and dermal infitrate o f small to medium-sized cells with “cerebriform” 
nuclei. The typical phenotype is CD2+, CD3+, CD5+, CD4+ and CD8-. CD7 is often 
negative, although o f limited diagnostic value as this phenomenon may be seen in 
benign cutaneous lymphoid lesions. Patients with limited disease usually have an 
excellent prognosis whereas those with more advanced disease have a poorer prognosis 
(Harris et al, 1994;Harris et al, 2000;Willemze et al, 1997;Willemze et al, 2005).
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1.4.6.2 Sezary syndrome (SS)
SS is characterised by erythroderma, lymphadenopathy and neoplastic T-cells (with 
cerebriform nuclei) in the peripheral blood. Although traditionally regarded as a variant 
o f MF this tumour is usually much more aggressive. The tumour cells are CD2+, CD3+, 
CD5+ and CD7+/- and most cases are CD4+ and CD8- (Harris et al, 1994;Harris et al, 
2000;Willemze et al, 1997;Willemze et al, 2005).
1.4.6.3 Primary cutaneous CD30+ T-cell lymphoproliferative disorders
There are 3 primary cutaneous CD30+ lympho-proliferative disorders (Harris et al,
1994;Harris et al, 2000;Willemze et al, 1997;Willemze et al, 2005). These are:
1. Primary cutaneous anaplastic large cell lymphoma (C-ALCL): C-ALCL is 
defined as a T-cell lymphoma presenting in the skin and comprising anaplastic 
lymphoid cells, the majority o f which are CD30+. This condition needs to be 
distinguished from systemic ALCL with secondary cutaneous involvement for 
which careful staging is required and also from other PTL with CD30 expression. 
C-ALCL is generally associated with a good prognosis.
2. Lymphomatoid papulosis (LyP): LyP is a chronic recurrent, spontaneously 
regressing papular skin condition. Morphologically it is characterised by an 
atypical T-cell infiltrate. The disease has a benign course and is therefore 
categorised as an atypical lympho-proliferation that can be clonal and sometimes 
progress to lymphoma.
3. Borderline lesions: These are lesions where there is a discrepancy between the 
clinical features and the histology, i.e patients with clinical features o f LyP but 
with the histology more in keeping with C-ALCL and vice versa.
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1.4.7 Other extranodal mature T-cell and NK-cell neoplasms
1.4.7.1 Extranodal NK/T-cell lymphoma, nasal type
This is a predominantly an extranodal lymphoma that can show varied morphology. As 
the name implies, the nasal cavity is the commonest site o f involvement. The neoplastic 
infiltrate is often angiocentric with prominent necrosis. EBV is usually present in the 
clonal episomal form. Most cases are CD56+ (NK-cell phenotype) and rarely CD56- 
(cytotoxic T-cell phenotype). The disease is most prevalent in Asia and Central and 
South America. The prognosis o f the nasal tumours is variable while those occurring 
outside the nasal cavity are often highly aggressive (Cheung et al, 2003;Harris et al, 
2000).
1.4.7.2 Enteropathy-type T-cell lymphoma (ETTL)
ETTL is defined as a tumour o f intra-epithelial lymphocytes, which usually present 
following transformation with a tumour composed o f large lymphoid cells. There is a 
clear association with celiac disease and hence the previous term for this disease 
“Enteropathy-associated T-cell lymphoma” (Isaacson, 1994). The neoplastic cells are 
CD3+, CD5-, CD7+, CD8 -/+, CD4-, CD 103+ and are also positive for cytotoxic 
granule associated proteins. The disease is one o f the most aggressive lymphomas with a 
poor prognosis (Harris et al, 2000;Isaacson et al, 2001).
1.4.7.3 Hepatosplenic T-cell lymphoma
This is a rare and aggressive T-cell lymphoma characterised by extranodal disseminated 
disease. The tumour, derived from cytotoxic T-cells and usually o f the y8 T-cell receptor 
type, shows prominent sinusoidal infiltration o f liver, spleen and bone marrow (Belhadj 
et al, 2003;Cooke et al, 1996).
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1.4.7.4 Subcutaneous panniculitis-like T-cell lymphoma
It is a rare, aggressive form o f lymphoma derived from cytotoxic T-cells with a
predilection for subcutaneous tissue. The phenotype is usually CD8+ with expression of 
cytotoxic granule associated proteins. Most cases are derived from a(3 cells but a 
significant minority is y8 positive (Go & Wester, 2004;Kumar et al, 1998).
1.4.8 Neoplasm of uncertain lineage and stage of differentiation
1.4.8.1 Blastic NK-cell lymphoma
Blastic NK-cell lymphoma is rare, aggressive and is composed o f lymphoblast-like cells 
showing evidence o f commitment to the NK-lineage. Some cases represent precursor 
NK-cell lymphoblastic lymphoma/leukaemia. The disease tends to involve multiple sites 
with a predilection for skin and is probably identical to “primary cutaneous CD4+, 
CD56+ haematodermic neoplasm” . The precise lineage o f this neoplasm is still not 
entirely resolved (Koita et al, 1997;Petrella et al, 2002).
1.4.9 Nodal peripheral T-cell lymphomas
Nodal PTLs include PTLu, anaplastic large cell lymphoma (ALCL) and AITL. PTLu 
will be discussed in some detail while anaplastic large cell lymphoma will be touched on 
briefly. The main emphasis o f the following review will however be on AITL.
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1.4.9.1 Peripheral T-cell lymphoma, unspecified (PTLu)
1.4.9.1.1 Definition (WHO classification)
There is a large group o f predominantly nodal T-cell lymphomas that cannot be 
categorized into any o f the recognized subtypes o f T-cell neoplasms. These are referred 
to in the WHO classification as PTL with the optional addition o f “unspecified”, to 
indicate that they cannot be designated to any o f the currently recognized entities. 
Although various morphological patterns, included as subtypes in other classification 
systems are described, these are not considered as subtypes by the WHO classification, 
because o f lack o f evidence for a clinico-pathological basis for such a distinction 
(Ralfkiaer et al, 2001).
1.4.9.1.2 Synonyms in previous classification systems
(1982;Gerard-Marchant et al, 1974;Harris et al, 1994;Harris et al, 2000;Lennert et al, 
1975;Lukes & Collins, 1974;Ralfkiaer et al, 2001):
Lukes-Collins classification: T-immunoblastic lymphoma
Kiel classification: Includes a number o f categories - T-zone lymphoma, lympho-
epithelioid (Lennert) lymphoma, medium sized, and large cell types, T-immunoblastic
lymphoma.
Working formulation: Includes a number of categories -  diffuse small cleaved cell, 
diffuse mixed small and large cell, diffuse large cell and immunoblastic subtypes.
REAL classification: PTLu (provisional categories: large cell, medium-sized cell and 
mixed large/medium sized cell)
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1.4.9.1.3 Epidemiology
This category, which includes a heterogeneous group o f yet undefined entities, accounts 
for approximately 3.7% o f all lymphomas and for more than half o f the PTLs in the 
West (Table 1.2). PTLu affects mainly adults, although children may also be affected. 
Males and females are affected equally (1997).
1.4.9.1.4 Clinical features
Most patients present at an advanced stage o f the disease with constitutional symptoms 
(B-symptoms). Involvement is predominantly nodal, but any site may be affected, and 
bone marrow, spleen, liver and extranodal sites including skin are often involved with 
disseminated disease. Peripheral blood is often involved. Paraneoplastic features such as 
eosinophilia and haemophagocytic syndrome may occur (1997;Gutierrez et al, 
2003;Savage et al, 2004).
1.4.9.1.5 Morphology
In lymph nodes, the architecture is effaced by a diffuse infiltrate, which in most cases 
shows a predominance o f medium to large pleomorphic cells with irregular nuclei, 
prominent nucleoli and many mitoses. Clear cells and Reed-Sternberg (RS)-like cells 
may be present. In rare cases, small atypical lymphoid cells may predominate. The 
background often comprises a polymorphic reactive infiltrate o f small lymphocytes, 
many eosinophils, plasma cells and in some cases, clusters o f epithelioid histiocytes.
High endothelial venules are often prominent and may show an arborising pattern.
There is no increase in FDC meshworks as described in AITL. (see below). Rare
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morphological patterns such as the T-zone variant, lympho-epthelioid variant (Lennert 
lymphoma) are described (Harris et al, 1994;Harris et al, 2000).
T-zone variant shows an interfollicular growth pattern with preserved or hyperplastic 
follicles. Neoplastic cells are small to medium sized and do not show marked nuclear 
atypia. Clusters o f clear cells are often a feature and RS-like cells may be present. High 
endothelial venules are increased. The inflammatory background is prominent and 
includes eosinophils, plasma cells and epithelioid histiocytes. On morphology and 
immunophenotyping alone it is difficult to differentiate this variant from reactive 
hyperplasia without resort to molecular genetic studies (Ralfkiaer et al, 2001). 
Lympho-epithelioid cell variant (Lennert lymphoma) was first described Karl 
Lennert in 1968, who regarded this as a mixed entity that included cases o f Classical 
Hodgkin Lymphoma (Kim et al, 1980).
This variant shows a diffuse or rarely an interfollicular infiltrate o f predominantly small 
cells with only mild nuclear atypia. It is characterised by numerous small clusters o f 
epithelioid cell histiocytes. Eosinophils and plasma cells are often part o f the reactive 
background. Clear cells may be seen but are reported to be less frequent than in the T- 
zone variant and AITL. RS-like cells are common, but high endothelial cells are not 
usually prominent (Patsouris et al, 1990;Ralfkiaer et al, 2001;Suchi et al, 1987).
Not included among the subtypes o f PTLu by the WHO classification, but reported as a 
more recent series are 3 cases of PTL with a follicular growth pattern (de Leval et al, 
2001). See section 1.4.9.1.6 for immunophenotype o f these cases.
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1.4.9.1.6 Immunophenotype
The immunophenotype reflects a mature post-thymic T-cell phenotype. Aberrant T-cell 
phenotypes (such as loss o f CD5) are common and a useful feature for diagnosis. Most 
cases are CD4 positive, CD8 negative (Harris et al, 1994;Harris et al, 2000). Rare nodal 
PTLu show a cytotoxic phenotype and some o f the latter may be associated with CD56 
expression (de Bruin et al, 1994). When CD30 is expressed by many of the tumour cells 
it needs to be differentiated from ALCL (see below).
In 3 cases o f PTL reported to show a follicular growth pattern -  based on FDC 
meshworks -  the tumour cells showed a CD4 positive BCL-6 positive phenotype, with 
co-expression o f CD 10 in 2 o f the cases (de Leval et al, 2001). Epstein Barr virus 
although absent in neoplastic cells may be present in reactive B-cells. The latter may be 
RS-like, express CD30, and even on occasion express CD 15 mimicking classical 
Hodgkin lymphoma (CHL) (Quintanilla-Martinez et al, 1999).
1.4.9.1.7 Genetics
TCR genes show a monoclonal pattern o f gene rearrangement in most cases (Theodorou 
et al, 1994). Although many cytogenetic abnormalities have been reported none is 
consistent or specific. Trisomy 3 has been reported in the lympho-epithelioid cell 
(Lennert) and T-zone variants (Schlegelberger et al, 1994a).
1.4.9.1.8 Postulated cell o f origin
Peripheral T-cells in various stages o f transformation. (Harris et al, 1994;Harris et al, 
2000).
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1.4.9.1.9 Survival and prognosis
PTLu are aggressive, often responding poorly to therapy. (Gisselbrecht et al,
1998;Savage et al, 2004). The overall complete remission rate is 40-64% but the 5-year 
overall survival rate is 35-40%. (Pellatt et al, 2002;Savage et al, 2004).
1.4.9.2 Anaplastic large cell lymphoma (ALCL)
1.4.9.2.1 Definition (WHO classification)
A T-cell lymphoma comprising lymphoid cells that are usually large with abundant 
cytoplasm and atypical, often horseshoe-shaped nuclei (hallmark cells). The latter are 
CD30 positive and most cases express cytotoxic granule associated proteins. Most are 
positive for anaplastic lymphoma kinase (ALK) protein, but ALK negative cases are also 
included in this category (Delsol et al, 2005;Stein et al, 2000).
1.4.9.2.2 Epidemiology and clinical features
The ALK-positive ALCL occurs mainly in the 1st 3 decades o f life, with a male 
predominance. The ALK negative ALCL generally affects older individuals. Most cases 
present with disseminated disease (Stein et al, 2000).
1.4.9.2.3 Morphology
The common variant (70%) comprises large pleomorphic cells many of which are 
“hallmark” cells. In the lymphohistiocytic variant (10%) the neoplastic cells are 
intimately admixed with and often hidden by a prominent histiocytic component. 
However, CD30 positive tumour cells tend to concentrate around blood vessels where 
they can be identified fairly easily. The small cell variant (5-10%) comprises a
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predominance o f small to medium sized neoplastic cells, but hallmark cells are always 
present and are often in the vicinity o f blood vessels. This variant may easily be 
misdiagnosed as PTLu. Others include the giant cell-rich variant and Hodgkin-like 
variant. Rare variants included the sarcomatoid, “signet ring”, neutrophil-rich and 
eosinophil-rich subtypes (Delsol et al, 2005;Stein et al, 2000).
1.4.9.2.4 Immunophenotype
The neoplastic cells are characterised by CD30 expression. The large cells show strong 
staining whereas the smaller tumour cells may show weak/negative staining. ALK 
expression is seen in 53-89% o f cases (Stein et al, 2000). Most cases are epithelial 
membrane antigen positive. The majority express one or more T-cell antigens, but due 
to loss o f pan T-cell antigens it may show an apparent “null” cell phenotype. CD3 is 
negative in most cases, but CD2 and CD4 are often expressed, as are cytotoxic 
associated antigens T cell intracellular antigen (TIA-1), granzyme B, and or perforin. 
CD8 is usually negative. The ALK negative ALCL is less well characterised. However, 
except for ALK expression it shows morphological and immunophenotypic features of 
ALCL (Stein et al, 2000).
1.4.9.2.5 Genetics
Approximately 90% o f ALCL’s show TCR gene rearrangements. ALK expression is due 
to an abnormality o f the ALK locus on chromosome 2. Although many different 
abnormalities may occur, the commonest is the translocation t(2;5) (p23;35) between the 
ALK gene on chromosome 2 and the nucleophosmin (NPM) gene on chromosome 5 
(Stein et al, 2000).
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1.4.9.2.6 Survival and Prognosis
The most important prognostic indicator is ALK positivity, which is associated with a 
favourable prognosis. The overall 5-year survival in ALK positive cases is close to 80% 
whereas the survival in ALK negative cases is approximately 40% (Delsol et al, 2005). 
In fact some studies have shown that the prognosis in ALK-negative cases is similar to 
PTLu (ten Berge et al, 2003). There is an ongoing debate as to whether the ALK- 
negative cases should be considered a phenotypic variant o f ALCL or be categorized as 
a different entity. The latter is supported by the recent study by Zettl and and co-workers 
(Zettl et al, 2004) where using comparative genomic hybridization (CGH), they found 
frequent recurrent chromosomal gains and losses in the ALK-negative group. In 
contrast, the ALK-positive and cutaneous ALCL showed few recurrent chromosomal 
imbalances.
1.4.9.3 Angioimmunoblastic T-cell lymphoma (AITL)
1.4.9.3.1 Background
The disease currently recognized as AITL was first described in the 1970s as a clinical 
syndrome characterized by generalized lymphadenopathy, hepatosplenomegaly, anaemia 
and hypergammaglobulinaemia (Frizzera et al, 1974;Lennert, 1979;Lukes & Tindle, 
1975). The lymph node histology was observed to show a number o f distinctive features 
such as the partial effacement o f normal architecture by a polymorphic inflammatory 
infiltrate, including large blasts and marked vascular proliferation. Based on these 
histological appearances, the disease was initially referred to by a variety o f terms, 
including immunoblastic lymphadenopathy (Lukes & Tindle, 1975),
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lymphogranulomatosis X (Lennert, 1979), and angioimmunoblastic lymphadenopathy 
with dysproteinaemia (AILD) (Frizzera et al, 1974). The latter term was accepted by 
most investigators and has come to define this clinical syndrome. AILD was initially 
thought to be an atypical lymphoid hyperplasia, a pre-malignant lesion, with a tendency 
to develop into a lymphoma rather than a frank neoplasm at onset. With the advent of 
immunophenotyping and molecular techniques, it became apparent that most cases of 
AILD contained monoclonal T-cell populations as well as clonal cytogenetic 
abnormalities, strongly suggesting that the majority o f the patients were neoplastic from 
the onset. However there is still some dispute over whether it represents a de novo 
lymphoma or whether it is preceded by an atypical reactive process, AILD (Jaffe & 
Ralfkiaer, 2001a). AITL was included in the Updated Kiel Classification for 
Lymphomas (Stansfeld et al, 1988), and is accepted as a distinct clinicopathological 
entity in the current WHO classification (Jaffe & Ralfkiaer, 2001a). It is likely that 
earlier series, published before the availability o f immunophenotyping and molecular 
tests, are diluted by a number o f reactive proliferations.
1.4.9.3.2 Definition (WHO classification)
AITL is a PTL characterised by systemic disease, a polymorphous infiltrate involving 
lymph nodes, with a prominent proliferation o f high endothelial venules (HEV) and 
follicular dendritic cells (FDCs) (Jaffe & Ralfkiaer, 2001a).
1.4.9.3.3 Synonyms in previous classification systems 
(1982;Gerard-Marchant et al, 1974;Harris et al, 1994;Harris et al, 2000;Jaffe & 
Ralfkiaer, 2001a;Lennert et al, 1975;Lukes & Collins, 1974)
Lukes-Collins classification: immunoblastic lymphadenopathy
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Kiel classification: AILD-type (Lymphogranulomatosis X) T-cell lymphoma 
Working formulation: includes number o f categories -  diffuse mixed small and large 
cell, diffuse large cell, immunoblastic and atypical hyperplasia.
REAL classification: angioimmunoblastic T-cell lymphoma
1.4.9.3.4 Epidemiology
AITL is a disease o f the middle aged and elderly with a peak onset in the 6th and 7th 
decade o f life (median age reported: 53 -  65 years) (Ohsaka et al, 1992;Pautier et al, 
1999;Rudiger et al, 2002;Siegert et al, 1995;Tobinai et al, 1988). There have been rare 
reports in children in earlier literature (Fiorillo et al, 1981;Stensvold et al, 1984), 
showing some overlapping clinical features but no specific morphologic features, no 
immunophenotypic evidence to demonstrate expansion o f the FDC meshwork and no 
molecular genetic evidence to support a diagnosis o f lymphoma, and therefore may not 
represent examples o f AITL. There is no sex predilection for the disease (male to female 
ratio: 1.3-0.7:1) (Ohsaka et al, 1992;Pautier et al, 1999;Siegert et al, 1995). AITL is 
reported to account for 1-2% of all NHL, and 5-20% of all PTL (Lu et al, 2004;Savage 
et al, 2004). The patients have a wide geographical distribution and have been reported 
in the Americas, Europe, Asia and Africa (Au et al, 2005;Chen et al, 2004;Kim et al, 
2002b;Lopez-Guillermo et al, 1998;Montalban et al, 1993;Naresh et al, 2004;Savage et 
al, 2004;Schetelig et al, 2003). One small series suggests that the incidence o f AITL 
may be higher in Hong Kong than Europe (Rudiger et al, 2002).
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1.4.9.3.5 Risk factors and aetiology
No consistent risk factors for the development o f the disease have been reported and to 
date no aetiological agent has been identified. A significant proportion o f patients have a 
history o f drug use (Sasaki & Sumida, 2000;Tobinai et al, 1988) in particular antibiotics 
(Batinac et al, 2003;Knoops et al, 2002;Sasaki & Sumida, 2000). These are more likely 
to represent drugs prescribed to the patients because o f systemic illness clinically 
mimicking an infectious process, rather than the primary cause o f the disease. A number 
o f infectious diseases and agents have been reported to be associated with AITL, 
including bacterial infections such as tuberculosis and fungal infections such as 
cryptococcus (Konig et al, 1991 ;Rho et al, 1996). Perhaps most intriguing is the 
relationship o f AITL with a number lymphotropic viruses. The most significant o f these 
is the Epstein-Barr virus (EBV), which is discussed separately below. The presence o f 
other viruses, including human Herpes virus 6 (HHV-6) (Daibata et al, 1997;Luppi et al, 
1993), Herpes virus 8 (HHV-8) (Luppi et al, 1996) and hepatitis C virus (Luppi & 
Torelli, 1996) have been reported in AITL. Other than EBV, the evidence for the role o f 
a viral infection in the pathogenesis o f AITL remains tenuous. HHV-6 was reported in 
seven out o f 12 AITL patients identified by PCR (Luppi et al, 1993), but 
immunohistochemistry (Luppi et al, 1998) and in situ hybridization studies (Khan et al, 
1993) showed that the expression o f HHV-6 antigens was absent in the T cells and 
present in reactive plasma cells, which suggests a o f a lack o f a direct role for HHV-6. 
Occasional cases o f AITL have also been described to have HHV-8 infection by PCR 
(Luppi et al, 1996) but Chadburn and co-workers (Chadburn et al, 1997) failed to 
observe any evidence o f HHV8 infection by PCR or immunohistochemistry which, once 
again, argues against a causal relationship. Although no clear association with human
immunodeficiency virus (HIV) infection has been reported, Muta and Yamano (Muta & 
Yamano, 2003) report a case o f a patient with generalized lymphadenopathy, polyclonal 
hypergammaglobulinaemia and a lymph node biopsy diagnosis o f AITL, whose enzyme 
immunoassay test for HIV gave a positive (antibody) result for HIV recombinant 
proteins p24, gp41, and gp36. Western blot analysis provided confirmation o f antibodies 
cross-reacting with HIV p24 gag protein, but HIV RNA was not detected by means o f a 
reverse transcriptase-PCR assay. Thus the patient although not an HIV carrier, gave a 
“false positive” HIV antibody test, probably due to cross-reacting gammaglobulins. 
Association with HTLV-1 has been reported but is probably coincidental (Ohshima et al, 
1998).
1.4.9.3.6 Clinical features
AITL typically presents with systemic illness, characterized by B symptoms and 
generalized lymphadenopathy, often mimicking an infectious process. The majority o f 
patients show hepatosplenomegaly and pruritus, and a skin rash is also seen in a half o f 
patients. The reported frequency o f common presenting symptoms and signs observed in 
AITL are summarized in Table 1.3 (Pautier et al, 1999;Siegert et al, 1995;Tobinai et al, 
1988). Laboratory investigations often show the presence o f anaemia and occasionally 
pancytopenia. Typically, there is polyclonal hypergammaglobulinaemia, and both the 
lactate dehydrogenase and the erythrocyte sedimentation rate (ESR) are often elevated.
A significant proportion o f patients have circulating autoantibodies, including a positive 
Coomb’s test, cold agglutinins, cryoglobulins and circulating immune complexes. The 
most common laboratory findings and their frequencies are shown in Table 1.4 (Pautier 
et al, 1999;Siegert et al, 1995;Tobinai et al, 1988). A number o f autoimmune
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phenomena have been reported in association with AITL. These include autoimmune 
haemolytic anaemia (Brearley et al, 1979), vasculitis (Hamidou et al, 2001 ;Seehafer et 
al, 1980;Sugaya et al, 2001), polyarthritis, rheumatoid arthritis (Pautier et al, 
1999;Pieters et al, 1982), and autoimmune thyroid disease (Ambepitiya, 1989;Pautier et 
al, 1999) which suggests an abnormalitiy in humoral immunity.
Patients also show features o f immunodeficiency, believed to be secondary to the T-cell 
lymphoma, and are thus susceptible to infectious complications. The immune 
abnormalities and cytokine profiles are discussed below in section 1.9.7.3.4.
Table 1.3. Presenting symptoms and signs in AITL.
Symptoms and signs Frequency (% o f  patients)
B symptoms 68-85
Generalised lymphadenopathy 94-97
Splenomegaly 70-73
Hepatomegaly 52-72
Skin rash 48-58
Polyarthritis 18
Ascites /  effusions 23-37
Data from grouped from Tobinai et al (1988), Siegert et al (1992, 1995) and Pautier et al (1999)
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Table 1.4. Laboratory findings in AITL
Laboratory finding Frequency (% o f  patients)
Anaemia 40-57
Other cytopenias 20
Eosinophilia 39
Hypergammaglobulinaemia 50-83
Hypogammaglobulinaemia 9-27
Autoantibodies 66-77
Elevated LDH 70-74
Elevated ESR 45
Bone marrow involvement 61
Data from grouped from Pautier et al (1999), Siegert et al (1995) and Tobinai et al (1988).
1.4.9.3.7 Pathology
1.4.9.3.7.1 Histology
The WHO classification (2001) defines o f the histology o f AITL (see section 1.9.3.2) as 
a polymorphous infiltrate involving lymph nodes, with a prominent proliferation o f 
HEV and FDCs. The lymph node architecture is at least partially effaced and regressed 
residual follicles are often present. The polymorphous infiltrate initially involves the 
paracortex and comprises small, to medium-sized lymphocytes and transformed blasts 
admixed with eosinophils, plasma cells and histiocytes. Clusters o f lymphocytes with 
pale to clear cytoplasm and distinct cell membranes may be present (Frizzera, 2001 ;Lee 
et al, 2003b;Lorenzen et al, 1994). In the past some authors considered these clusters o f 
clear cells to be essential for the diagnosis o f AITL and a useful feature to distinguish 
lymphoma from “AILD” (Nathwani & Jaffe, 1995). Although earlier studies (Aozasa et
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al, 1989) attached prognostic value to the presence o f clear cells, this has not been 
validated by more recent studies (Ch'ang et al, 1997). In AITL, the lymphocytes may 
show minimal cytologic atypia. The lymph node sinuses are often preserved but the 
infiltrate spills over into the perinodal tissue (Frizzera, 2001 ;Jaffe & Ralfkiaer, 2001a). 
The presence o f eosinophilic amorphous, generally periodic acid-Schiff (PAS) positive, 
material described in the past in “AILD” (Frizzera et al, 1974) and “immunoblastic 
lymphadenopathy” (Lukes & Tindle, 1975) is not essential for the diagnosis o f AITL. 
Large basophilic blasts (of B-cell phenotype) may be present. Reed-Stemberg-like cells 
may also be seen (Quintanilla-Martinez et al, 1999). On haematoxylin and eosin (H&E) 
stained sections, the expanded FDC meshwork is seen as ill defined, stretched pale 
eosinophilic spindle cellular collections (Frizzera, 2001). These are best appreciated and 
evaluated on immunohistichemistry. Hyperplastic follicles, was for many years believed 
to exclude the diagnosis o f AILD or AITL. However, Ree and colleagues (Ree et al, 
1998) described 7 cases with molecular genetic evidence o f T-cell clonality, that 
showed hyperplastic follicles, 2 cases o f which on subsequent lymph node biopsy 
showed typical features o f AITL. These hyperplastic follicles described were large, with 
prominent tingible body macrophages and ill-defined borders with indistinct mantle 
zones. Subsequent to this report, Kojima and co-workers (Kojima et al, 2001) 
described 10 cases o f AITL with hyperplastic GCs. In AITL, HEV are prominent and 
characteristically show arborisation (Frizzera et al, 1974;Frizzera, 2001). Lymphocytes 
may be seen traversing the walls o f these vessels. (Frizzera, 2001) In a recent study, 
Ottaviani and co-workers (Ottaviani et al, 2004) have noted that in partial nodal 
involvement or early AITL, there is minimal displacement o f follicles with preservation 
of GCs and prominent perifollicular sinuses. They also observed that in these nodes the
tumour cells are localized to the paracortex with minimal infiltration into the follicular 
compartment. They also state that in later stages o f AITL, the follicular B-cells shift 
location to patent trabecular sinuses and stress the importance o f shifts in lymphatic 
patency in the histological features that define AITL.
Although generalized lymphadenopathy is the main presenting sign and the diagnosis of 
AITL rests on histological examination of the lymph node, many patients have evidence 
o f extranodal involvement at the time of diagnosis. The most frequently involved 
extranodal sites include the bone marrow, spleen, skin and lungs (Frizzera et al, 
1974;Ghani & Krause, 1985;Pautier et al, 1999;Siegert et al, 1992;Siegert et al, 
1995;Weisenburger et al, 1977). As the histologic criteria for diagnosis o f AITL have 
largely been defined for lymph node involvement and relate to the architecture o f the 
lymph node, and since many o f the histological features overlap with reactive conditions 
and other lymphomas, a primary diagnosis o f AITL at an extranodal site cannot be made 
with certainty, without an accompanying lymph node biopsy. Bone marrow is biopsied 
as a part of staging procedure and is often involved at diagnosis (Pautier, et al 1999). 
There are many reports o f skin involvement by AITL (Chang et al, 2003;Huang & 
Chuang, 2004;Martel et al, 2000;M atloff & Neiman, 1978;Murakami et al, 2001 ;Suarez- 
Vilela & Izquierdo-Garcia, 2003), the histology o f which is mainly that o f a non-specific 
or atypical T-cell infiltrate. There are a few early reports describing the histology o f 
visceral organ involvement, where the diagnosis, although correlated with lymph node 
histology, was made largely on a morphological basis with little immunophenotyping 
and no resort to molecular genetic studies (Moreb et al, 1983). Overall, histological 
appearances in extranodal sites are usually non-specific but mimic some of the features 
described in the lymph nodes (Brown et al, 2001;Ghani & Krause, 1985;Seehafer et al,
1980). Cytological features o f malignancy can rarely be identified, and tumour 
involvement can only be reliably shown by immunohistochemistry and molecular 
clonality analysis (Martel et al, 2000;Murakami et al, 2001).
1.4.9.3.7.2 Immunophenotype
Immunohistochemistry shows the expansion o f the inter-follicular areas by a diffuse 
infiltrate o f CD3 positive T cells (Jaffe & Ralfkiaer, 2001a). In most patients, CD4 
positive T cells dominate but there is usually an intermixed population o f small CD8 
positive T cells (Jaffe & Ralfkiaer, 2001a;Nathwani & Jaffe, 1995). In a few reports 
(Hodges et al, 1997;Watanabe et al, 1986) however, CD8 positive cells predominated. 
By using double layered immunohistochemistry (Feller et al, 1988;Namikawa et al,
1987), and by PCR analysis o f microdissected CD4 and Ki 67 positive cells 
(Willenbrock et al, 2001), it has been shown that the proliferating cells are 
predominantly o f the CD4 positive subtype. In fact even in cases where CD8 positive T- 
cells predominate, the atypical clear cells and proliferating cells are CD4 positive (Lee et 
al, 2003b). Loss o f pan-T-cell markers has been shown by some, (Weiss et al, 1986) but 
not by others (Feller et al, 1988; Weiss et al, 1986). Lee and co-workers (Lee et al, 
2003b) reported partial loss o f detectable CD4 in the neoplastic cells in some of their 
cases. A circulating population (believed to be neoplastic) o f CD4 positive, CD5 
positive, CD7 negative T-cells that express cytoplasmic but not surface CD3, has been 
reported in AITL (Serke et al, 2000). Ree and colleagues (Ree et al, 1999) observed 
BCL-6 expression, in varying intensity (from weak to strong), in small to medium sized 
CD3 positive T-cells and also in clearly atypical neoplastic cells. They also report that in 
“AITL with GCs” (3 cases), many GCs were devoid o f CD57 positive cells while others
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were loosely populated with CD57 positive cells and scattered CD57 positive cells were 
also seen in the interfollicular areas, suggesting outward migration o f intra-follicular T- 
cells. In their study, double staining for CD57 and BCL-6 showed that 90% o f CD57 
positive cells were negative for BCL-6, while in the remaining 10% the staining was 
equivocal, concluding that they are probably separate populations (Ree et al, 1999). In a 
recent study (Rudiger et al, 2004), the tumour cell identified by an antibody directed at 
the Vbeta family used by the tumour clone showed that they were CD3 positive, CD4 
positive, CD5 positive, but CD45RO positive, CD45RA negative and CD27 negative, 
consistent with a terminally differentiated T-cell phenotype.
The B-cell markers CD20 and CD79a highlight the residual follicle centre and mantle 
zone B cells as well as many o f the large transformed blasts and RS-like cells in the 
interfollicular areas (Lorenzen et al, 1994;Smith et al, 2000). Transformed blasts 
including the RS-like cells are highlighted by CD30. CD 15 expression has also been 
reported in the CD30 positive RS-like cells (Quintanilla-Martinez et al, 1999). As 
described by histology, one o f the most distinctive features o f AITL is the proliferation 
of FDCs which is best appreciated with immunostaining for the FDC markers CD21, 
CD23 orCD 35 (Bagdi et al, 2001;Jones et al, 1998;Leung et al, 1993;Raymond et al,
1997). These expanded FDC meshworks usually surround HEV. One study (Jones et al,
1998) describes a zonated, pattern o f desmin-positive fibroblastic reticulum cells (FRC) 
in AITL, but not other PTLs. In this study, the areas o f the lymph node with FDCs were 
reciprocal to the desmin-positive FRC proliferations. As FDC proliferation is an 
important feature in AITL, to follow (section 1.4.9.3.7.3) is a brief review of the origin, 
structure and function o f this specialized cell.
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1.4.9.3.7.3 Follicular dendritic cells (FDCs)
FDCs represent a cell population that provides a meshwork that B-cells lie in to form 
primary and secondary lymphoid follicles (van Nierop & de Groot, 2002). These cells 
are derived either from mesenchymal reticular fibroblasts or haematopoietic precursors 
(Kapasi et al, 1994;Kim et al, 1994). They possess long cytoplasmic dendrites and are 
able to retain large immune complexes on their surface for a long period (Wolf-Peeters 
et al, 2001). FDCs present antigens in the form o f immune complexes on their surface 
and switch off the apoptotic machinery of high affinity B-cells, and are thus essential for 
antigen-triggered B-cell development within the micro-environment o f the GC 
(Lindhout et al, 1995;van Eijk & de Groot, 1999;van Eijk et al, 2001). FDCs inhibit 
apoptosis in binding B-cells by up-regulating cFLIP (cellular flice-like inhibitory 
protein)-expression in attached B-cells, thereby preventing activation o f caspase-8 (van 
Eijk et al, 2001). The exact mechanism of this cFLIP up-regulation is not yet known. 
FDCs also contain high quantities o f cystatin A, which acts as an inhibitor o f the pro- 
apoptotic cathepsin recently identified in B-cells (van Nierop & de Groot, 2002). Some 
studies also suggest a pro-apoptotic role for the FDC in the B-cell selection process, by 
demonstrating Fas Ligand (FasL) expression in a subset o f FDCs in the light zone o f the 
GC, indicating possible Fas-FasL interaction between GC B-cells and FDCs (Hur et al, 
2000;Verbeke et al, 1999). FDCs are also possibly required for the maintenance o f 
memory B-cell clones (Gray et al, 1991). All FDCs express the monocyte marker CD 14 
and the complement receptors CD35 (CR-1), the long isoform o f CD21 (CR-2) and 
CD1 lb  (CR-3) and the Ig Fc receptor CD32 (Dijkstra & Van den Berg, 1991 ;Tew et al, 
1990). A subset o f FDCs in the light zone o f the GC also expresses CD23, a low affinity 
receptor for IgE and one o f the ligands for CD21 (Maeda et al, 1992;Payet-Jamroz et al,
2001;Wolf-Peeters et al, 2001). The CD23 staining coincides with the FasL expressing 
subset o f FDCs (Verbeke et al, 1999). FDCs secrete the chemokine B-cell 
chemoattractant 1 (BCA-1)/CXCL-13, which binds to Burkitt lymphoma receptor 1 
(BLR1) /CXCR5 on B-cells, an important step to attract B-cells to the follicle (Estes et 
al, 2004). Adhesion between FDCs and B-cells occurs between ICAM-l/LFA-1 
(intercellular cell adhesion molecule-/lymphocyte function-related antigen) and VCAM- 
1 /VLA4 (vascular cell adhesion molecule-1/ very late activation antigen 4) (Freedman et 
al, 1990;Koopman et al, 1991). In vitro studies have shown that FDCs adhere to 
malignant B-cells by the adhesion molecules VLA4 and VCAM-1 (Freedman et al,
1992).
Unlike other antigen presenting cells, the FDCs do not internalize and process antigens, 
and do not synthesize MHC-II molecules (Denzer et al, 2000). They however carry 
peptide-MHC class II expressing microvesicles (exosomes derived from B-cells) on 
their surface, enabling interaction with CD4 positive T-cells (Denzer et al, 2000). 
Interaction with T-cells also occurs by CD40-CD40 ligand binding (Banchereau, et al
1994). FDCs up-regulate chemokine receptor CXCR4 on CD4 positive cells, but inhibit 
signaling through this receptor by up-regulating regulator o f G protein signaling (RGS), 
RGS13 and RGS 16 (Estes et al, 2004). Therefore, despite high levels o f CXCR4, GC T- 
cells do not migrate to the CXCR4 ligand, CXCL12 (Estes et al, 2004). Nevertheless as 
GC CD4 positive T-cells migrate to BCA-1/CXCL13 produced by FDCs, the latter 
appears to play an active role in GC T-cell migration (Estes et al, 2004). In vitro studies 
have also shown that highly purified FDCs are able to induce the proliferation of 
allogeneic T-cells or T-cell lines (Butch et al, 1994).
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In a recent study it was shown that FDCs and endothelial cells in AITL express FasL 
and the tumour T-cells express Fas (CD95) and caspase 3, indicating Fas-FasL 
interaction between the neoplastic T-cell and the FDC (Kim, et al 2002) (to be discussed 
below). However, despite these immunohistochemical findings, as o f now, there is 
however no direct evidence demonstrating interactions between FDCs and neoplastic T- 
cells in AITL.
1.4.9.3.8 Immunology /cytokines in AITL
There appears to be a substantial immune activation in the peripheral blood and lymph 
nodes o f AITL patients compared with the reactive lymph nodes or other PTLs. The 
evidence for this includes increased levels o f serum soluble interleukin 2 (IL-2) receptor, 
CD30 and CD8 molecules (Pizzolo et al, 1990), and also the expression o f an array o f 
cytokines such as tumour necrosis factor alpha, lymphotoxin, IL-1 beta, IL-2, IL-4, IL-6, 
IL-13 and interferon gamma (Foss et al, 1995;Ohshima et al, 2000). Recent studies 
examining the expression o f T-cell activation markers have shown an increased 
expression o f the TNF receptor family member CD 134 (0X 40) (Jones et al, 
1999;Tsuchiya et al, 2004), chemokine receptor CXCR3, (Ishida et al, 2004;Jones et al, 
1999;Ohshima et al, 2004;Tsuchiya et al, 2004) CD69, which is a marker o f early T-cell 
activation (Dorfman & Shahsafaei, 2002) and T-box transcription factor, T-bet 
(Dorfman et al, 2003). These molecules are preferentially associated with the Th-1 
phenotype in normal T-cells, suggesting that Th-1-type differentiation is a feature o f the 
neoplastic cell in AITL. AITL express T-cell factor-1 (TCF-1) and lymphoid enhancer 
factor-1, components o f the W NT/p-catenin signal transduction pathway, a feature also
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seen in other “Th-1-like” PTL, but not “Th-2-like” PTL such as ALCL (Dorfman et al, 
2003).
In contrast to this marked immune activation, the functional studies performed on T cells 
recovered form lymph nodes and peripheral blood o f AITL patients have shown 
defective T-cell responses supporting an underlying immunodeficiency. The immune 
abnormalities reported include a decrease in circulating T-cells, an altered CD4: CD8 
ratio, altered absolute levels o f CD4 negative or CD8 positive T-cells, and high 
percentages o f activated T cells (CD8+/HLA-DR+), defective T-cell response in vitro to 
the phytohaemagglutinin (PHA) mitogen, and minimal helper and enhanced in vitro 
suppressor functions (Ganesan et al, 1987;Pizzolo et al, 1983). Lymphopaenia has been 
reported with a frequency o f -50%  and skin test anergy in 68% o f patients (Archimbaud 
eta l, 1987).
Vascular endothelial growth factor (VEGF), one o f the main angiogenic cytokines in 
human solid tumours, is expressed at high levels by the stromal cells in AITL (Foss et 
al, 1997). Over-expression o f VEGF-A gene and expression o f VEGF-A protein have 
been demonstrated in both microdissected lymphoma cells and endothelial cells, while 
VEGF-R co-expression has been shown in endothelial cells. Zhao and co-workers (Zhao 
et al, 2004) also report a correlation between increased levels o f VEGF-A gene 
expression and survival. It has been hypothesized that VEGF expression may be 
responsible for the vascular proliferation observed in AITL. Interestingly, the increased 
VEGF signal appears to correlate with the number o f mast cells infiltrating the tumour, 
suggesting that mast cell activation may also play a role in the pathogenesis (Fukushima 
et al, 2001).
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1.4.9.3.9 Possible normal counterpart o f AITL:
Mature CD4 positive T-cell is considered the putative “cell o f origin” (WHO, 2001).
The findings o f Rudiger and colleagues (Rudiger et al, 2004) that the tumour cells were 
o f the CD45RO positive, CD45RA negative, CD27 negative phenotype (see above in 
section 1.5.3.7) suggest that the neoplastic T-cell in AITL is derived from a terminally 
differentiated CD4 helper T-cell. Cytokine profiling suggests a Thl cell-type (Dorfman 
& Shahsafaei, 2002;Dorfman et al, 2003;Ishida et al, 2004;Jones et al, 1999;Ohshima et 
al, 2004;Rudiger et al, 2004;Tsuchiya et al, 2004), and the close association with the 
follicle center/FDC microenvironment suggests that a CD4 positive GC T-cell origin is 
a possibility.
1.4.9.3.10 EBV infection
Prior to EBV infection in AITL, it may be appropriate to briefly review EBV infection 
in healthy individuals, in the immune-deficient and its association with lymphomas.
1.4.9.3.10.1 EBV primary infection and latency in healthy individuals 
Over 95% o f the world’s population is infected with EBV, a gamma herpes virus with a 
double stranded DNA genome o f 172 kb pairs. EBV infects mainly B-cells, but they are 
also known to infect T-cells and epithelial cells (Kuppers, 2003). EBV infection usually 
occurs in childhood and results in an asymptomatic or mild self-limiting illness. If the 
infection is delayed until adolescence or young adulthood, infectious mononucleosis 
occurs in around half the infected individuals (Kuppers, 2003). In healthy carriers, 
primary infection occurs via the oropharyngeal route with productive infection o f B-cells 
or epithelial cells. The released virus then infects B-cells circulating through the
oropharynx, resulting in a latency type 3 infection with expression of nine viral proteins, 
the nuclear antigens Epstein Barr virus nuclear antigen (EBNA) 1, 2, 3A, 3B, 3C, the 
latent membrane proteins (LMPs) 1, 2A and 2B, 2 small RNAs and transcripts from the 
BamHX A region o f the genome (Tierney et al, 1994). This type o f latency is highly 
immunogenic and induces a massive, virus-specific and non-specific T-cell response. A 
small number o f B-cells, escape this immune response by expressing a minimal form of 
latency in which only one viral protein (LMP-2) is expressed (Tierney et al, 1994). The 
virus persists in this latent state for the life o f the individual (Yao et al, 1985).
1.4.9.3.10.2 EBV in the immunosuppressed
In those with impaired cellular immunity increased virus reactivation occurs (Babcock et 
al, 2000) and in immunosuppressed individuals an uncontrolled EBV-driven B-cell 
proliferation may lead to a lymphoproliferative disorder (Ho et al, 1988;Shapiro et al,
1988).
1.4.9.3.10.3 EBV-infection and lymphomas
The EBV positive B-cell lymphomas include CHL, Burkitt lymphoma, which occur in 
the immunocompetent and also as mentioned above, in the immunocompromised 
(Brousset et al, 1991;Carbone, 2003;Klumb et al, 2004;Niedobitek et al, 1995;Tinguely 
et al, 1998). Pyothorax associated lymphoma is associated with EBV in seemingly 
immunocompetent individuals (Fukayama et al, 1993;Kanno & Aozasa, 1998;Sasajima 
et al, 1993). Lymphomatoid granulomatosis, an angiocentric and angiodestructive 
lymphoproliferative disease comprising EBV positive B-cells amidst numerous reactive 
T-cells, often occurs in the setting o f immunodeficiency (Guinee, Jr. et al, 1994;Haque
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et al, 1998;Jaffe & Wilson, 2001;Nicholson et al, 1996;Taniere et al, 1998), as does the 
Human Herpes virus-8 (HHV-8) associated primary effusion lymphoma which usually 
shows co-infection with EBV and develops most often in the setting o f HIV infection 
(Banks & Wamke, 2001;Horenstein et al, 1997;Nador et al, 1996).
O f the mature T/NK-cell neoplasms, EBV is universally associated with extranodal 
NK/T-cell lymphoma nasal-type and in the majority o f aggressive NK-cell leukaemias 
(Chan et al, 2001a;Chan et al, 2001b;Kanavaros et al, 1993;Nava & Jaffe, 2005). EBV- 
has been reported in bystander B-cells in cases o f PTLu and have been associated with a 
poor outcome (d'Amore et al, 1996).
1.4.9.3.10.4 EBV and AITL
A characteristic feature o f AITL, seen in over 95% of all patients, is the presence of 
increased numbers o f EBV-infected cells compared with both normal lymph nodes and 
PTLs (Weiss et al, 1992). Initial studies using Epstein Barr virus encoded RNA (EBER)- 
in situ hybridization and comparing the results with immunohistochemical sections 
stained for T- and B-cell markers suggested the EBV-infected cells might be within both 
the T-cell and B-cell population (Anagnostopoulos et al, 1992). However, studies using 
double immunohistochemistry, in situ hybridization and microdissection have shown 
that virtually all cells infected by EBV are B cells, and that EBV infection is unlikely to 
play a primary role in the lymphomagenesis o f AITL (Brauninger et al, 2001;Ohshima 
et al, 1994;Weiss et al, 1992). In AITL, the EBV infected B-cells are somatically 
mutated consistent with a GC or memory gentotype. The majority o f EBV infected B- 
cells show ongoing hypermutation during clonal expansion (Brauninger et al, 2001). It 
has also been shown that many o f these clones have destructive “crippling” mutations
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without selection for expression o f a functional antigen receptor and that the somatic 
hypermutation process is active even in these clones (Brauninger, et al 2001). These 
findings suggest that EBV infection may in some way influence the survival o f these 
cells that would otherwise be destined to undergo apoptosis. However, in AITL, 
occasionally, EBV negative “crippled” B-cells can also survive and expand (Brauninger 
et al, 2001). The EBV protein expression pattern in AITL B cells is usually consistent 
with latency (Anagnostopoulos et al, 1995;Zettl et al, 2002). The causes for the 
expansion o f EBV-infected cells are not known. It is likely that an underlying 
immunodeficiency with reduced cytotoxic activity, and the presence o f growth factors 
favouring the outgrowth o f EBV-infected cells play roles. The EBV-infected cells have 
a variable cytology, with some having an immunoblast-like and others having an RS-like 
appearance. They account for most o f the large B cells present in the interfollicular zone 
o f the AITL lymph nodes. EBV-associated large B-cell lymphoma (Abruzzo et al, 
1993;Matsue et al, 1998;Xu et al, 2002a;Zettl et al, 2002) and EBV positive CHL 
(Nakamura et al, 1995) have been reported as complications o f AITL. Knecht and 
colleagues (Knecht et al, 1995) reported the presence o f an LMP-1 deletion mutant, 
identical to that reported in CHL.
1.4.9.3.11 Clonality analysis
Before the availability o f molecular tools that can demonstrate the presence o f expanded 
clones o f T and B cells, the neoplastic nature o f AITL was not fully appreciated and the 
disease was considered to be a premalignant state from which high-grade, large cell 
lymphomas occasionally arose. When Southern blotting technology became available, 
Weiss and colleagues were the first to investigate the clonality o f lymphocytes in AITL
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(Weiss et al, 1986). They demonstrated the presence o f clonal T-cell populations, not 
only in patients with histologically apparent lymphoma, but also in patients diagnosed as 
AILD who lacked the cytological features o f malignancy. This was followed by a 
number o f similar publications confirming the presence o f a monoclonal T-cell 
population in virtually all patients with AILD /AITL (Feller et al, 1988;Lipford et al, 
1987;0'Connor et al, 1986;Ree et al, 1998;Smith et al, 2000;Tobinai et al, 
1988;Willenbrock et al, 2001). Hodges and colleagues (Hodges et al, 1997) report a case 
showing an oligoclonal T-cell proliferation on PCR and sequencing where most o f the 
infiltrating atypical T-cells (CD3 and CD8 positive) belonged to the Vp5.1 family. In 
the study by W illenbrock and co-workers (Willenbrock et al, 2001), they report the 
over-usage o f the V-gene segment, V p l3 S l, while Smith and co-workers (Smith et al, 
2000) found restricted usage o f VP2S1 in 4/11 cases. Restricted usage o f certain V-gene 
segments in AITL raises the possibility o f specificity o f the neoplastic cell for a yet 
unknown, shared common antigen, in some of the cases. However, in their series, 
Willenbrock and co-workers (Willenbrock et al, 2001), failed to demonstrate an MHC II 
allele that was common to all cases with Vp 13S 1 -expressing neoplastic clones. The 
results o f clonality analyses from some reported series are summarized in Table 1.5. One 
of the unusual observations to be made during these studies was the presence o f an 
expanded monoclonal B-cell population in a significant minority o f patients. This has 
led to the suggestion that AITL is a mixture o f T-cell lymphomas and B-cell 
lymphomas, but not a single clinicopathological entity. However, the current evidence 
suggests that these patients also fall within the framework o f AITL. These patients 
typically exhibit increased numbers o f EBV-infected B-large cells, and it is thought that 
the B-cell clone detected by molecular analysis o f whole lymph node extracts lie within
this population. It is likely that this is an EBV-driven lymphoproliferation that occurs 
secondary to the immuno-deficiency associated with the underlying AITL, perhaps 
similarly to other EBV-driven lymphoproliferations that are associated with 
immunosuppression (Zettl et al, 2002). Not surprisingly, a subset o f AITL patients go on 
to develop full-scale EBV-associated, diffuse, large B-cell lymphomas (Abruzzo et al, 
1993;Knecht et al, 1995;Zettl et al, 2002) or Burkitt’s lymphoma. (Mazur et al, 1979).
Table 1.5. T- and B-cell clonality in AITL.
Study Method T-cell clonal 
Patients
B-cell clonal 
Patients
Weiss et al (1986) SB 8/10 0/10
Lipford et al (1987) SB 5/5 4/5
Feller et al, (1988) SB 24/24 7/24
Tobinai et al (1988) SB 8/10 0/10
Lorenzen et al (1994) PCR 9/15 5/15
Ree et al (1998) SB/PCR 7/7 0/7
Smith et al (2000) PCR 21/22 9/22
Willenbrock et al (2001) PCR 12/18 1/13
SB, Southern blotting; PCR, polymerase chain reaction.
1.4.9.3.12 Genetic changes
The studies on the genetic changes occurring in AITL have been hampered by a number 
o f factors, including the relative rarity o f the tumour and dilution o f tumour cells by a 
large number o f reactive cells. Most o f our knowledge on genetic changes comes from 
cytogenetic-based studies. These are summarized in Table 1.6. Approximately 90% of 
AITL patients have cytogenetic alterations observed by the use o f combined metaphase 
and interphase cytogenetics (Cosimi et al, 1990;Godde-Salz et al, 1987;Kaneko et al, 
1982;Lepretre et al, 2000;Schlegelberger et al, 1990a;Schlegelberger et al, 1994b). 
Clonal chromosomal aberrations are seen in approximately 70% of the patients. Trisomy
3, trisomy 5 and gain o f an X chromosome are the most frequent recurrent abnormalities 
seen in AITL, but these are also present in other PTLs. These abnormalities have also 
been reported using fluorosence in situ hybridization (FISH) (Kumaravel et al, 1997). 
Trisomy 3 and 5 are reported to be less frequent in AITL in the Far East than in the West 
(Chen et al, 2004). Schlegelberger and colleagues showed that half the patients 
harboured cytogenetically unrelated clones, which is a unique phenomenon that is 
exceptional in other lymphomas (Schlegelberger et al, 1990a;Schlegelberger et al, 
1994b). This was hypothesized to be consistent with the stepwise development o f 
chromosomal aberrations in AITL. The steps being the appearance o f chromosomal 
abnormalities in different cells because o f genetic instability and the impaired 
elimination o f aberrant cells due to the immune defect, followed by the establishment o f 
chromosomally aberrant clones, and finally a cytogenetically detectable level of 
monoclonal proliferation. However, at the first step, T-cell receptor gene rearrangement 
shows clonal T-cell proliferation, indicating that the abnormal tumour clone is present at 
the onset, although perhaps not detectable by cytogenetic methods that have a low 
sensitivity. The presence o f T-cell clones and the EBV-driven expansion o f B-cell clones 
raises the question as to which cells harbour the aberrant karyotype. In one patient, using 
a method involving the simultaneous demonstration o f immunophenotype and 
karyotype, it was shown that the aberrant mitoses with trisomy 3 were CD3 positive and, 
therefore, T cells (Schlegelberger et al, 1990b). It is possible that the non-clonal 
aberrations seen in AITL originate from EBV-infected B cells that are likely to have an 
in-vitro growth advantage. The lower proportion o f aberrant cells reported on interphase 
cytogenetics compared with metaphase cytogenetics is consistent with the morphology 
of AITL, with a few neoplastic cells amidst an abundance o f reactive cells
(Schlegelberger et al, 1994a). In a study assessing the significance o f cytogenetics on 
clinical outcome, only the presence o f complex aberrant clones was determined to be an 
independent prognostic factor, and trisomy 3 had no effect on survival (Schlegelberger 
et al, 1996). Genes known to be critical in lymphomagenesis have rarely been studied in 
AITL. Petit and colleagues examined p53 expression and mutations, and report that both 
are rare, suggesting that this pathway is not altered in the majority o f AITL patients 
(Petit et al, 2001). The other gene that has been examined is BCL-6. Rearrangements 
and /or mutations o f the 5 non-coding region o f the BCL-6 gene play a role in the 
development o f diffuse large B-cell lymphoma (DLBCL). Despite the reports o f BCL-6 
expression in the tumour cells in AITL (Ree et al, 1999), no mutations were detected in 
the 5 non-coding region o f the gene o f 33 cases o f PTLs which included 2 cases o f 
“angioimmunoblastic lymphadenopathy” and 2 cases o f “ immunoblastic lymphoma” 
(Kerl et al, 2001).
Table 1.6. Cytogenetic alterations in AITL
Study Patients with
cytogenetic
alterations
Patients with clonal
cytogenetic
alterations
Cytogenetic alterations frequently 
encountered
Kaneko et al (1982) 5/6 4/6 +3 in 4/6 patients
+5, +15, +19, +21, +22 in 2/6 
patients
Godde-Salz et al (1987) 13/18 7/18 +3,+5
Kaneko et al (1988) 10/10 9/10 +3, +5, 6q-
Cosimi et al (1990) 3/6 - t(7; 14)(q35 ;q 11)
Schlegelberger et al 
(1990a)
35/42 25/42 +3, +5, +X
Schlegelberger et al 
(1994a)
32/36 32/36 +3, +5, +X
All studies have used metaphase cytogenetics; Schlegelberger et al (1994) have used both metaphase and interphase 
cytogenetics. +3, +5,+ 15, +19, +21, +22 and +X refer to trisomy of chromosomes 3, 5, 15, 19, 21, 22 and X 
respectively.
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1.4.9.3.13 Diagnosis
The clinical syndrome o f AITL overlaps with a wide range o f inflammatory and 
neoplastic processes, and the changes in peripheral blood and bone marrow are usually 
non-specific. Fine needle aspiration o f the enlarged lymph node may be helpful (Dey et 
al, 1996;Kerl et al, 2001;Ng et al, 2002;Yao et al, 2001), but is rarely diagnostic 
because cytological appearances can be within normal limits and architectural features 
cannot be obtained. For the same reasons, a needle core also has limited value. The 
diagnosis o f AITL can only be achieved by biopsy and histological examination o f the 
enlarged lymph nodes, where characteristic morphological features can be best 
appreciated.
1.4.9.3.14 Clinical outcome
Publications regarding the outcome and clinical management o f AITL are limited due to
the rarity o f the disease. Most o f the information is based on retrospective studies, small
patient numbers and a limited number o f case reports. The clinical outcome of the AITL
remains dismal, with a median survival o f less than 36 months and a 5-year survival of
around 30-35%  (Pautier et al, 1999;Pellatt et al, 2002;Siegert et al, 1992;Siegert et al,
1995). Most patients die o f infectious complications rather than tumour load, suggesting
that an underlying immunodeficiency significantly contributes to the AITL-associated
mortality. In the few patients where there has been a record o f consecutive lymph node
biopsies, these have included, subtle changes with follicular hyperplasia in the first
biopsy and “typical” AITL in the second biopsy (Ree et al, 1998). There are some earlier
reports o f histologic transformation to an “ immunoblastic lymphoma” (Bauer, et al
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1982; Pangalis, et al 1983), but due to the limited immunophenotyping available at the 
time it is difficult to determine whether this transformation is o f T- or B-cell phenotype. 
As mentioned previously in the section on EBV and AITL (section 1.5.3.5), there are 
reports o f EBV-positive DLBCLs complicating AITL (Abruzzo et al, 1993;Matsue et al,
1998) and o f EBV-positive CHL (with no histologic, immunophenotypic or genetic 
evidence o f T-cell lymphoma) subsequent to AITL (D'Arrigo et al, 1985;Melato et al, 
1983;Nakamura et al, 1995). Higuchi and co-workers (Higuchi et al, 1998) describe a 
case o f “immunoblastic lymphadnopathy-like T-cell lymphoma” which on biopsy during 
chemotherapy, was found to be overrun by a massive plasma cell proliferation giving 
rise to a paraproteinaemia with biclonal peaks.
Both single agent and combination chemotherapeutic regimens such as CHOP 
(cyclophosphamide, doxorubicin, Oncovin, prednisone), CVP (cyclophosphamide, 
vincristine, prednisone), VAP (vincristine, asparaginase, prednisone), steroids with or 
without cyclophosphamide, and high-dose methylprednisolone, prednisone with or 
without COPBLAM (cyclophosphamide, Oncovin, prednisone, bleomycin, Adriamycin, 
Matulane) or IMVP-16 (ifosfamide, methotrexate, V P -16) have been reported (Awidi et 
al, 1983;Colbert et al, 1982;Pautier et al, 1999;Siegert et al, 1992;Siegert et al, 1995). 
Although a complete remission rate o f 50% can be achieved with combination 
chemotherapy, relapse rates remain high. Overall, combination chemotherapy appears to 
be superior to steroids alone (Pautier et al, 1999;Siegert et al, 1992). Other therapeutic 
approaches, including low-dose methotrexate together with steroids (Gerlando et al, 
2000), fludarabine (Hast et al, 1999;Ong et al, 1996;Tsatalas et al, 2003) and 2- 
chlorodeoxyadenosine (Sallah & Bernard, 1996;Sallah et al, 1999) can be beneficial, 
but again studies are based on a small number o f patients, which does not allow
statistically significant conclusions. Interferon-alpha has been used for consolidation- 
maintenance therapy following conventional treatment to prolong chemotherapy- 
induced remissions as a result o f its differentiating, immunomodulating and anti­
proliferative effects (Feremans & Khodadadi, 1987;Hast & Gustafsson, 1991;Pautier et 
al, 1999;Schwarzmeier et al, 1991;Siegert et al, 1991). In the majority o f the patients, 
the remission duration is variable but is not longer than that observed with conventional 
treatments. Cyclosporin A, which has a suppressive effect on the immune system, most 
notably on T cells, and a direct cytotoxic/apoptosis-inducing effect on lymphocytes, has 
also been given (Advani et al, 1997;Murayama et al, 1992;Takemori et al, 1999). Its 
combined effects on neoplastic T cells may play an important role in the achievement of 
remission, but once again at present, studies are limited to a few case reports. There is 
however, a phase II clinical trial, set up to evaluate the use o f cyclosporine A in the 
treatment o f recurrent or relapsed AITL (Eastern Coorporative Oncology Group, 2003), 
the results o f which will determine its application on a wider basis. Thalidomide has 
been used as anti-angiogenetic agent in a few patients, either following relapse or in 
refractory AITL, with promising results (Strupp et al, 2002). There are reports that 
patients treated after relapse with high-dose chemotherapy followed by autologous bone 
marrow/blood stem cell transplantation responded favourably (Blystad et al, 
2001;Lindahl et al, 2001;Pautier et al, 1999;Schetelig et al, 2003;Schmitz et al, 1991) 
and a few recent publications on its effectiveness as the first line o f treatment, in 
selected patients (Reimer et al, 2004;Schetelig et al, 2003). One o f the latter studies 
(Reimer et al, 2004) is a prospective study o f 30 patients that includes 12 patients with 
AITL but needs longer follow up to draw definite conclusions on survival benefits.
76
EBV-driven DLBCL is a complication o f AITL that may benefit from anti-viral therapy 
(Battegay et al, 2004). Park, and co-workers (Park et al, 2002) report a case o f EBV- 
related DLBCL following autologous transplantation for AITL, that was successfully 
treated by Rituximab (monoclonal anti-CD20 antibody). The success o f Rituximab plus 
CHOP over CHOP alone for the treatment o f DLBCL in the elderly has already been 
evaluated in a randomized clinical trial by Groupe d'Etudes des Lymphomes de 1'Adulte 
(GELA), France (Coiffier, 2002). Rituximab in conjunction with CHOP has also shown 
good results in 4 patients with AITL rich in large B-cells (Joly et al, 2004) and requires 
evaluation in a phase II trial before application on a wider basis.
1.4.9.3.15 Problems related to definition and diagnosis
Unlike in the classification o f B-cell lymphomas where many o f the neoplasms have 
well defined morphologic and immunophenotypic features, the world Health 
Organization (WHO) classification emphasizes that due to the lack o f specific 
morphologic, immunophenotypic features, and in most instances, the lack o f specific 
genotypic features, clinical features play an important role in the subclassification of 
mature T/NK-cell neoplasms.
In AITL when the typical morphology with pronounced FDC proliferation is 
encountered, diagnosis is fairly straightforward. Although reproducibility by experts is 
reported to be high (Rudiger et al, 2002), diagnosis can be complicated by the fact that 
the neoplastic T-cells often are in the minority, and are greatly outnumbered by the 
reactive cells (Willenbrock et al, 2005). Cytologic features o f malignancy may not be 
evident in the tumour cells and many o f the morphologic features considered 
“characteristic” o f AITL, are not specific and overlap with reactive conditions and other
lymphomas. The presence o f a “polymorphous infiltrate” and “prominence o f HEV” 
shows overlap with the histology o f reactive hyperplasia and PTLu. Even the “clusters 
o f clear cells” when present are not specific, as it may be a seen in PTLu. The “expanded 
FDC meshwork that usually surrounds HEV” is the only relatively specific feature that 
is useful in distinguishing AITL from other PTL. Although this feature is well developed 
in “typical” AITL, it may be fairly subtle in “early” cases with hyperplastic follicles. In 
this situation, the distinction from reactive lymphoid hyperplasia on morphology alone 
and from “T-zone morphologic variant” o f PTLu, even with the support of 
immunophenotyping and molecular genetic analysis, is difficult and at times impossible. 
Those with a high content o f epithelioid histiocytes show a histiologic overlap with 
Lennert-morphological variant o f PTLu (Patsouris et al, 1989).
The prominence o f regressed follicles in some cases may cause confusion with 
Castleman disease (Frizzera, 2001). There is an older report o f “AILD” which followed 
cutaneous kaposi’s sarcoma (Suster et al, 1987) and another two reports o f the two 
conditions occurring simultaneously in the same patient (Friedman-Birnbaum et al, 
1985;Kluin-Nelemans et al, 1984). Considering the morphologic overlap between the 
two conditions, these may represent examples o f HHV-8 related Castleman disease 
rather than AITL.
The presence o f prominent EBV-infected B-blasts may lead to an erroneous diagnosis o f 
a DLBCL, especially if there is outgrowth o f a dominant clone giving a monoclonal 
molecular genetic result. Reed Sternberg-like cells in a mixed “inflammatory” 
background mimics classical Hodgkin Lymphoma, mixed cellularity subtype.
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1.5 Aims of this project
Despite the advances made in the last 3 decades, the biology o f the disease remains 
poorly understood, and there is no specific phenotypic marker that distinguishes the 
early cases o f AITL and those with less typical histology, from reactive conditions and 
other lymphomas. Except for a few anecdotal reports there is no proper study into the 
histology o f disease progression. No aetiological agent has yet been identified and there 
is no consensus regarding the approach to management.
The general aim of this study is to further characterize AITL.
The specific aims are:
1. Identify a specific phenotypic marker for diagnosis o f AITL that would help 
distinguish the disease from reactive proliferations and other nodal PTLs.
2. Study the histologic progression o f the disease in sequential biopsies.
3. Study the cell o f origin
4. Study the role o f EBV and HHV8 infection in the development and progression 
o f AITL.
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Chapter 2
MATERIALS AND METHODS
2.1 Detection kits used for immunohistochemistry
ChemMate™ Detection Kit, Peroxidase/DAB, Rabbit/Mouse [DakoCytomation, 
Cambridge, UK (Code no: 5001)] containing ChemMate™ Link, Biotinylated 
Secondary Antibodies (AB2), ChemMate™ Streptavidin Peroxidase (HRP), 
ChemMate™ DAB+ Chromogen,and ChemMate™ HRP Substrate Buffer were used for 
single layered immunohistochemistry and for detection o f the 1st antibody during 
double-layered immunohistochemistry.
ChemMate™ Detection Kit, APAAP, mouse [DakoCytomation, (Code no: 5000)], was 
used for visualization o f the 2nd antibody in double layered immunohistochemistry. The 
reagents used from this kit were the ChemMate™ Link, Secondary Antibody (LINK) 
and ChemMate™ APAAP Immunocomplex (APAAP). The chromogen used for this 
step was fast blue, as the blue would contrast well with the brown DAB stain. For this 
purpose, Vector® Blue Alkaline Phosphatase Substrate Kit III [Vector Laboratories, 
Peterborough, UK (Cat. No. SK-5300)] was used.
80
2.2 Solutions
2.2.1 Solutions used in immunohistochemistry and in-situ 
hybridization
2.2.1.1 Tris buffered saline pH 7.6 (TBS)
6.05 g o f Tris[hydroxymethyl] aminomethane (Sigma Chemical Co Ltd, Poole, Dorset, 
UK) and 80 gN aC l (BDH Laboratory Supplies, M erck Ltd, Lutterworth, Leicestershire, 
UK) were dissolved in 8 litres o f distilled water, pH was adjusted to 7.6 with 1 M HC1 
(BDH) and the volume was brought to 10 litres with distilled water.
2.2.1.2 TBS-Tween
Tween 20 (Sigma) was added to TBS to give a final concentration o f 0.05%.
2.2.1.3 Tris-HCl buffer (pH 8.2)
Stock A (0.2M Tris) -  was made up by dissolving 2.42 g o f Tris[hydroxymethyl] 
aminomethane (Sigma) in 100 ml of distilled water.
Stock B (0.2M HC1) was made up by mixing 1.7 ml of 1M HC1 (BDS) in 100 ml of 
distilled water. To obtain pH 8.2, 25 ml o f Stock A and 11 ml o f Stock B were mixed 
together.
2.2.1.4 0.1M Tris-HCl (pH 9.5)
0.1M Tris-HCl, pH 9.5 buffer consisted o f 10 ml o f 0.1 M Tris solution, made up by 
dissolving 1.21 g o f Tris[hydroxymethyl] aminomethane (Sigma) in 100 ml o f distilled 
water. The pH was adjusted as required with 1M HC1.
The solution was filtered through Whatman N o.l filter paper (BDH) and stored at 4°C.
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2.2.1.5 1M Tris-HCL (pH 7.5)
12.0 g o f tris was dissolved in 40 ml o f distilled water, brought to 100 ml final volume 
with distilled water and the pH tritrated to 7.5 with 1M H C1. The solution was filtered 
through Whatman N o.l filter paper (BDH) and stored at 4°C.
2.2.1.6 Peroxidase block solution
This solution was always prepared fresh just prior to use and composed o f 200 pi o f 
H2O2 (hydrogen peroxide) (Sigma) in 12 ml o f methanol (BDH).
22.1 .1  ChemMate™ HRP Substrate Buffer
Commercially available (DakoCytomation,), ready to use buffered solution containing 
hydrogen peroxide and preservative.
2.2.1.8 Solution of Chemmate™ DAB+ Chromogen in Chemmate™ HRP 
substrate buffer
1 volume o f ChemMate™ DAB+ Chromogen (DakoCytomation) that contains 50 x 
concentrated 3,3'-diaminobenzidine tetrahydrochloride in organic solvent, dissolved in 
50 volumes o f ChemMate™ HRP Substrate Buffer (DakoCytomation), made up just 
prior to use.
2.2.1.9 Alkaline Phosphatase-Substrate solution
Commercially available, Vector® Blue Alkaline Phosphatase Substrate Kit III [Vector
Laboratories (Cat. No. SK-5300)] was used. The Vector® Blue substrate working
solution was made up immediately before use in a test tube. The kit provides all reagents
except the buffer. Two drops o f Reagent 1 were added to 5ml o f Tris-HCl, pH 8.2 buffer
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and mixed well. This was followed by 2 drops o f Reagent 2 followed by mixing, and 
finally 2 drops o f Reagent 3 followed by mixing.
2.2.1.10 Citrate buffer pH 6.0
Monohydrate citric acid (BDH) o f 2.1 g was dissolved in 1 litre o f distilled water and 
pH was adjusted to 6.0 with 1 M HC1.
2.2.1.11 Dako target retrieval solution pH 6.0
60 ml o f Dako target retrieval solution pH 6.0 (.DakoCytomation) was mixed with 540 
ml o f distilled water.
2.2.1.12 Dako target retrieval solution pH 9.9
60 ml o f Dako target retrieval solution pH 9.9 {DakoCytomation) was mixed with 540 
ml o f distilled water.
2.2.1.13 2 x SSC solution
The solution was made up by adding 5 ml o f 20 x SSC (3.0 M Sodium Chloride, 0.3 M 
Sodium Citrate, pH 7.0) (Sigma) to 45 ml o f double distilled water (DDW).
2.2.1.14 1 x SSC solution
The solution was made up by adding 2.5 ml 20 x SSC (Sigma) to 47.5ml o f DDW.
2.2.1.15 Proteinase K buffer (for in situ hybridisaton)
2ml o f 0.5M EDTA (ethylene diamine tetra-acetic acid) (Sigma) was added to 10 ml o f
1M Tris-HCl (pH 7.5) and the volume brought up to 200 ml with DDW. The final
concentration o f Tris-HCl was 50 mM and EDTA 5mM.
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2.2.1.16 Hybridisation buffer
1. 250 |iil Sodium dodecyl sulphate (SDS) (BDH) was dissolved in 10 ml o f DDW
(heated to 60°C using a hot water beaker on a hot plate).
2. In a separate bottle (bottle 1), lg  dextran sulphate (Sigma) was added to 1 ml o f 20 
x SSC (Sigma) and dissolved at 60°C.
3. In another bottle (bottle 2), 25 mg Ficoll (Sigma), 25 mg Polyvinyl Pyrrolidone 
(PVP) (Sigma), 50 mg sodium pyrophosphate (Sigma) were added to 1 ml of 
DDW and dissolved with heat as before. 25 mg bovine serum albumin (BSA) 
(Sigma), was then added with 2.5 ml o f 2M Tris (Sigma) into the second bottle.
4. Contents o f the two bottles (bottles 1 and 2) were then mixed together and 5 ml o f 
Formamide (Sigma) and 250 pi of SDS (from step 1) added, and the contents 
gently mixed. 1ml aliquots were then prepared and the hybridisation buffer stored 
at -20°C.
2.2.1.17 Nitroblue tetrazolium chloride (NBT) -  5-Bromo-4-Chloro-3-Indolyl 
phosphate (BCIP) substrate solution
Substrate kit was purchased ready-made from Life science technologies, Paisley, UK. 
The substrate solution was prepared just prior to use by mixing 44 pi o f NBT solution 
and 33 pi o f BCIP solution to 10.0 ml o f 0.1 M Tris-HCl (pH 9.5), 0.1 M NaCl, 50 mM 
M gCh (Sigma).
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2.2.1.18 0.1% Nuclear Fast Red in 5% Aluminium Sulphate solution
5g aluminium sulphate (Sigma) was dissolved in 100 ml o f distilled water, heated and
stirred to dissolve O.lg nuclear fast red (Sigma) to achieve a final concentration o f 0.1% 
nuclear fast red. The solution was then filtered and stored at 40°C and re-filtered prior to 
use.
2.2.2 Solutions used in PCR, cloning and sequencing
2.2.2.1 DNA extraction
2.2.2.1.1 Proteinase KJ (extraction) digestion buffer
Concentration used was 300mg/ml proteinase K (Sigma) in 1 x PCR buffer. To make up 1 
ml of extraction buffer, 100 pi o f 10 x PCR buffer (Promega, Southampton, UK) and 30 
ml proteinase K (lOmg/ml stock -  Sigma) were added to 870 pi o f ultrapure water 
(Sigma).
2.22.2 PCR
2.2.2.2.1 10 XPCR buffer
Commercially available lOx PCR buffer (Promega) containing lOOmM Tris pH 9, 
500mM KC1 and 1% Triton X-100.
2.2.2.3 Electrophoresis
2.2.2.3.1 10% Ammonium persulphate solution
1 g o f ammonium persulphate (Bio-Rad, Hertfordshire, U K ) was dissolved in 10 ml o f 
distilled water.
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2.2.2.3.2 10 x  Tris Borate EDTA (TBE)
108g Tris, 55g boric acid (Sigma) and 9.3g EDTA (Sigma) are dissolved in distilled 
water to a volume of 1 litre.
2.2.2.3.3 Electrophoresis loading buffer
A pinch (0.25%) o f bromophenol blue, a pinch (0.25%) o f xylene cyanol, and 4g o f 
sucrose (to make a final concentration o f 40% sucrose) are added to 10 ml o f 5X TBE
2.2.2.4 Cloning and sequencing
2.2.2.4.1 LB (Luria-Bertani) medium
The medium contained 1% tryptone, 0.5% yeast extract, 1% NaCl and has a pH of 7.0. 
To make up 1L volume, lOg tryptone (Sigma), 5 g o f yeast extract (Sigma) and lOg o f 
NaCl (Sigma) were dissolved in 950 ml o f de-ionized water. The pH o f the solution was 
adjusted to 7.0 with NaOH (BDH) and the volume brought up to 1L. The solution was 
autoclaved on liquid cycle for 20 minutes at 15 psi. The solution was allowed to cool to 
55°C and 4 ml o f ampicillin (5 mg/ml in 1M MgS0 4 ) (Sigma) and the solution was 
stored at 4°C.
2.2.2.4.2 LB (Luria Bertani) agar
LB-medium was prepared as described above, but 15g/L agar (Sigma) as added before 
autoclaving on liquid cycle for 20 minutes at 15 psi. After cooling and adding of 
ampicillin, and X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) [640 (il 
(50mg/ml in dimethyl formamide)] (Promega), the agar was poured into 100 mm plates
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and left for about 20 minutes in a microbiological cabinet to harden. The plates were 
then stored at 4°C.
2.2.2.4.3 “Blue dye mix” usedfor sequencing
6pl Blue Dye (150mg/ml blue dextran, 25mM EDTA) and 72 p.1 Fresh Formamide 
(deionised) (Sigma) were added to a fresh tube. This was mixed with a pipette and 
vortexed for 10 seconds.
2.2.2.4.4 3Msodium acetate (pH 5.2)
40.83g o f sodium acetate.3 H2O was dissolved in 80ml o f DDW. The pH was adjusted to
5.2 with 1 MHC1.
2.3 Antibodies
A wide range o f murine monoclonal antibodies was used in the studies described in this 
thesis. The antibodies used and their specificities, dilutions, and sources are summarized 
in Table 2.1. The secondary antibodies and reagents used to detect the reactivity o f 
primary antibodies are shown in Table 2.1.
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Table 2.1. The characteristics of primary monoclonal antibodies used in 
_________ immunohistochemistry_________________  _^
SPCIFICITY CLONE DILUTION PRETREATMENT SOURCE
CD21 1F8 1/50 PC 2 min DakoCytomation
CD 3 Polyclonal
anti-CD3
1/50 PC 2 mins DakoCytomation
CD20 L26 1/400 MW pH 6 DakoCytomation
CD 10 56C6 1/10 MW pH 9.9 Novocastra
BCL6 M7211 1/50 (IHC) MW pH 9.9 DakoCytomation
CD57 NK-1 1/50 PC 2 mins Novocastra
MUM-1/IR4 M U M lp 1/200 MW pH 9.9 DakoCytomation
CD4 1F6 1/200 MW pH 9.9 Vector Labs
CD8 C8/144B 1/50 MW pH 9.9 DakoCytomation
CD79a JCB117 1/50 PC 2 min DakoCytomation
CD23 1B 12 1/10 PC 2 min Novocastra
CD35 RLB25 1/40 MW pH 6 Novocastra
CD138* 5G10 1/50 MW pH 6 Novocastra
CD34 QBEnd/10 1/50 PC 2 min Novocastra
CD30* Ber-H2 1/20 PC 2 min DakoCytomation
CD15* C3D-1 1/10 PC 2 min DakoCytomation
ALK-1* ALK1 1/50 MW pH 9.9 DakoCytomation
CXCL-13** 53610 1/200 MW pH 6 R&D Systems, 
Minneapolis, Minnesota, 
USA
Ki 67 MIB-1 1/50 PC 3 min DakoCytomation
LMP-1* CS1-4 1/2000 PC 3 min DakoCytomation
IgD* Polyclonal
anti-IgD
1/500 PC 3 min DakoCytomation
Kappa* Polyclonal
anti-kappa
1/2000 MW pH 6 DakoCytomation
Lambda* Polyclonal
anti-lambda
1/2000 MW pH 6 DakoCytomation
*CD30, CD15, ALK-1, LMP-1, CD138, Kappa, Lambda,and IgD immunostaining was performed by the 
immunohistochemistry laboratory at University College London
**CXCL13 immunostaining was performed by the Pathology Department, Mayo Clinic, Rochester 
Minnesota.
Abbreviations: PC, pressure cooking; MW, microwave oven; min, minute
2.4 Tissues
Biopsies from 169 cases o f nodal peripheral T-cell lymphoma were used in this study. 
Paraffin embedded tissue from all 169 cases and frozen tissue specimens from 5 cases 
were obtained from the surgical archives of Department of Histopathology, Royal Free 
and University College Medical School, London (137 cases), Departement de
Pathologie, CHU Henri Mondor, Creteil, France, Department o f Histopathology (10 
cases), The Royal Marsden NHS Foundation Trust, London (3 cases), Department o f 
Pathology, Mayo Clinic, Rochester, Minnesota, USA (14), Servico de Anatomia 
Patologica, Instituto Portugues de Oncologia de Francisco Gentil, Lisbon, Portugal (2) 
and the Department o f Pathology, Chi-Mei Medical Centre, Taiwan (2). Ethical approval 
was obtained for the use o f archival tissues. The histology o f all cases was reviewed by 
Professor Ahmet Dogan, Department o f Histopathology, University College London. 
They were were categorized as follows: AITL (120 cases), PTLu (22 cases), ALCL (16 
cases), AITL/PTL indeterminate (10 cases), nodal involvment by mycosis fungoides (1 
case).
2.5 Methods
2.5.1 Immunohistochemistry
Immunohistochemical studies were carried out on paraffin-embedded tissue sections 
using protocols described below unless specified.
2.5.1.1 Single layered immunohistochemistry
Paraffin sections (4 pm) were cut from tissue blocks onto microscopic slides 
{DakoCytomation). These were de-paraffinized in xylene {BDH), rehydrated using 
decreasing concentrations o f ethanol (BDH), and incubated in peroxidase block solution 
for 10 minutes to block the endogenous peroxidase activity. Antigen retrieval was 
carried out prior to immunostaining. For optimisation, serial dilutions o f the primary 
antibody were systematically tested, and the conditions that gave the best staining were 
used in subsequent experiments. The antigen retrieval methods used for different
antibodies are summarized in Table 2.1. Sections were then incubated with primary 
antibody at optimal dilution for 1 hour followed by biotinylated secondary antibody 
(ChemMate™ Link, Biotinylated Secondary Antibodies (AB2), and Streptavidin 
Peroxidase (ChemMate™ Streptavidin Peroxidase [HRP]) for 30 minutes, respectively. 
Finally, the staining was visualized with DAB in H2O2 and counter-stained with M ayer’s 
haematoxylin (BDH). Throughout all immunohistochemistry procedures, the slides 
were washed in TBS-Tween (three times for 5 minutes each), between all incubation 
steps. For each antibody tested a positive control was used.
2.5.1.2 Double-layered immunohistochemistry
The pre-treatment method used had to be appropriate for both antibodies to be tested. In 
cases where CD 10 staining was performed, the slides were always pre-treated using 
microwave retrieval (25 minutes) in pH 9.9 retrieval solution. The procedure o f the first 
primary antibody was the same as that of immunohistochemistry on formalin-fixed and 
paraffin-embedded tissue sections. After development with DAB, slides the slides were 
rinsed with Tris buffered saline(TBS)/Tween for 2 x 5 minutes and were then incubated 
with the second primary antibody at an appropriate dilution for 3 hours. This was 
followed by application o f the secondary antibody (AB2, ChemMate™ Link, Secondary 
Antibody) for 30 minutes. The latter was rinsed o ff by TBS/Tween followed by 
application o f ChemMate™ APAAP Immunocomplex (APAAP) for 30 minutes. This 
was rinsed off by TBS/Tween and the staining was visualized with Fast blue (Vector® 
Blue Alkaline Phosphatase Substrate Kit III) substrate solution for 15 minutes (in the 
dark), rinsed in water and mounted with an aqueous mountant, as the fast blue reaction 
product is alcohol and xylene soluble. For each antibody demonstrated, a positive
control and negative control and a control for double staining were used. e.g.
CD10/CD20 would need CD10/CD20, CD 10/- and -/CD20.
Assistance with double-layered immunohistochemistry was provided by Ms Phillipa 
Munson, MSc
2.5.2 EBER (Epstein Barr virus encoded RNA) in situ hybridisation
Paraffin sections (4 pm) were cut from tissue blocks onto microscopic slides 
{DakoCytomation). These were de-paraffinized in xylene {BDH) 2 X 5  minutes.
In the mean time, an incubation tray and the Proteinase K buffer were placed in a 37 °C 
oven to keep warm and the Proteinase K {Sigma), probe (in-house PCR generated 
ssDNA EBER-probe) and hybridisation buffer were removed from freezer and kept at 
room temperature to thaw.
The de-paraffinized sections were re-hydrated as follows:
3 minutes in 95% ethanol [47.5 ml of ethanol {BDH) and 2.5 ml o f DDW]
2 minutes in 70% ethanol [35 ml of ethanol {BDH) and 15 ml o f DDW]
3 minutes in DDW
The sections were then rinsed in TBS for 3 minutes, and digested with 5pg/ml 
Proteinase K (Sigma) for 15 minutes at 37°C (500pl per slide).
Following the digestion, the sections were rinsed in TBS, 2 x 3  minutes, and then in 
ethanol, 2 x 3  minutes and air-dried for 7-10 minutes.
15 -  30 pi o f the ssDNA EBER probe in hybridisation buffer (made up by mixing probe
and hybridisation buffer in the following proportions: 1 pi o f  probe to 50pl of
hybridisation buffer) were applied on sections and covered with a cover-slip. The
amount of probe required depended on the size of the section (e.g. 30pl, for 24 x  32 mm
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cover-slip, and 15 p.1 for 22 x 22 mm cover-slip). Rubber cement was placed around the 
edges o f the coverslip to prevent dehydration, and the slides were placed in the warm 
moist incubation tray in a 37°C oven overnight. Both 1 x SSC and 2 x SSC were kept 
warm at 37°C overnight.
Following overnight incubation, the rubber cement and coverslips were removed from 
the slides and the slides were placed in 2 x SSC for 20 minutes at 37°C and then 1 x 
SSC for 20 minutes at 37°C, following which the sections were rinsed in TBS/Tween for 
3 minutes. The slides were then drained and alkaline phosphatase-labelled anti- 
digoxigenin (Boehringer Mannheim, Germany) diluted by adding 1/500 to 1/25 normal 
human serum (Chemicon, Hampshire, UK), was applied for 60 minutes. Following this, 
the sections were rinsed with TBS/Tween for 5 minutes and tipped off. NBT-BCIP 
chromogen was then applied and the sections were kept in the dark for 60 minutes. The 
slides were then washed in tap water and counterstained with 0.1% Nuclear Fast Red in 
5% Aluminium Sulphate for 1 minute. After the staining was complete, the sections 
were dehydrated in alcohol series, cleared with xylene and mounted.
2.5.3 Double layered immunohistochemistry and EBER in situ 
hybridization (EBER-ISH)
EBER in situ hybridisation was performed as described previously in section 2.5.2 but 
not counterstained. The sections were then subject to immunohistochemistry by pre­
treating the slides as needed and then immunohistochemistry performed using the 
ChemMate™ Detection Kit, Peroxidase/DAB, Rabbit/Mouse {DakoCytomation [Code 
no: 5001]). The method used was the same as described in section 2.5.1.1, except that
the primary antibody was applied for 3 hours.
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Assistance with double layered immunohistochemistry and EBER-ISH was provided by 
Ms Phillipa Munson, MSc.
2.5.4 PCR for T-cell receptor y  chain gene and immunoglobulin
heavy chain gene framework 3 (FR3) PCR
2.5.4.1 DNA extraction from paraffin-embedded tissue sections
Methods for extraction o f DNA from paraffin embedded material were evaluated and 
modified to suit the available material. The following method was employed for extraction 
o f DNA from unstained and stained paraffin material:
One to five (depending on the size o f the block) 5 pm sections were cut from tissue blocks 
and placed into clean microtubes. Unstained or stained cut sections were scraped from 
slides, after removal o f coverslips and mountant using xylene if necessary, and placed into 
microtubes. 400pl o f xylene were added, the tubes mixed for 1-2 minutes and spun at full 
speed on a microcentrifuge for 5 minutes. The supernatants were removed using pipettes, 
400 pi o f absolute ethanol added to the pellets and the tubes mixed briefly. The tubes were 
spun at full speed for 5min and the supernatants removed as described above. The pellets 
were allowed to dry completely at room temperature before addition o f 50-200pl 
proteinase-k/buffer. Digestion was carried out at 37°C overnight, or for three hours at 55°C 
after which the tubes were heated at 95°C for 5min to destroy proteinase-k activity. After 
briefly spinning, l-5pl o f the resulting solutions were used in the PCR reactions, or stored 
at -20°C.
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2.5.4.2 Method for T-cell receptor y chain gene and immunoglobulin heavy chain
gene FR3 PCR
The following reagents were added to a final volume o f 50pl:
5jil 10 x PCR buffer {Promega,), 200pM (4pM/pl) each dNTP {Promega) ,250ng 
(5ng/pl) each primer (see below), MgCh (Promega) in an optimum concentration o f 1.5 
mM, 0.015 U/pl Platinum® Taq DNA polymerase {Inxitrogen Ltd, Paisley, UK) and 
ultra-pure H2O {Sigma) added to 45|il. 50-100ng high molecular weight DNA or 2-5pl of 
paraffin embedded tissue extract was then added into each tube with an added volume of 
ultra-pure water to make up a volume of 5 pi. This was overlayed with 50pl o f mineral oil 
{Sigma). Tubes were spun briefly and placed on a thermal cycling machine [Phoenix 
thermal cycler {Hybaid, Techne, U.K.)] that was programmed to heat (hot start) to 95°C 
for 2 minutes. This was followed by 40 cycles o f 93°C x 45 seconds (denaturation), 55°C 
for 45 seconds (annealing) and 72°C for 90 seconds (extension). After completion o f 40 
cycles, a final primer extension step at 72°C for lOmin was carried out. Products (lOpl) 
were run on 10% polyacrylamide minigels (section 2.5.4.3). All product analyses were 
performed in a separate room to PCR set-up and DNA extraction to reduce the risk of 
cross-contamination.
Primers targeting the T-cell receptor y gene
Name Sequence
VG-I TCT GG (G/A) GTC TAT TAC TGT GC
VG-II GAG AAA CAG GAC ATA GCT AC
VG-III/IV CTC ACA CTC (C/T)CA CTT C
JG-12 CAA GTG TTG TTC CAC TGC C
JPG-12 GTT ACT ATG AGC (T/C)TA GTC C
Reference
(McCarthy et al, 1992) 
(Goudie et al, 1990) 
(McCarthy et al, 1992) 
(McCarthy et al, 1992) 
(McCarthy et al, 1992)
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TCR-y chain gene was amplified using the method described by McCarthy (McCarthy et 
al, 1992) using two reactions with primers Vyl+Vyll + VyIII/rV+ Jyi/2 (product sizes 
approximately 70-95 base pairs) and Vyl+ Vyll + VyIM V+ JPyi/2 (product sizes 80-110 
base pairs)
Primers targeting the immunoglobulin heavy chain gene
Name Sequence Reference
Ig-FR3 ACA CGG C(C/T)(G/C) TGT ATT ACT GT (Trainor et a l, 1990)
Ig-LJH TGA GGA GAC GGT GAC C (Trainor et al, 1990)
2.5.4.3 PAGE of T-cell receptor y chain gene and immunoglobulin heavy chain 
gene FR3 PCR products
Minigel apparatus was used for PAGE of PCR products. The protocol for polymerisation of
acrylamide (to make a 10% gel) was:
Reagents were mixed as follows- 13ml H2O, 5ml Acrylogel 5 (Acrylamide: N-N '- 
Methylene bis-acrylamide 19:1) (Sigma), 2ml 10 x TBE, 200pl 10% ammonium 
persulphate (Sigma), 20pl TEMED (N,N,N,N -Tetramethyl-Ethylenediamine) (Sigma).
The gel mixture was immediately loaded between the glass plates and well-forming combs 
slotted into place. After 15min the combs were carefully removed and the sample wells 
rinsed three times with 1 x TBE buffer. The apparatus was assembled according to the 
manufacturers recommendations, using 1 x TBE buffer. 10 pi o f the PCR products were 
mixed with 2.5 pi o f loading buffer before loading into wells. The gels were run at the 
appropriate voltage, usually 150V, for 45min- lh. The gels were removed from the glass
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plates, stained in ethidium bromide (lpg/m l) for 10-15min and viewed under ultra-violet 
light. Digital photographs were taken to provide a permanent record o f the results.
2.5.5 Laser capture microdissection
Microdissection o f CD 10 positive cells and CD 10 negative areas, CD57 positive cells, 
and EBER-ISH positive cells was performed by using PixCell II Laser Capture 
Microdissection system (Arcturus, Mountain View, CA), using 4-5-p.m sections 
immunostained for CD 10, CD57 or subject to EBER in situ hybridisation. The sections 
used were always recently stained/hybridised (within 24 hours o f microdissection) and 
no mount was applied. They were dehydrated in increasing concentrations o f alcohol 
that ended in absolute alcohol (ethanol -  BDH).
A laser beam diameter o f 7.5 mm was used to achieve single cell microdissection. For 
CD 10 and CD57 stained sections, between 30 and 50 single cells were microdissected 
onto Capsure Transfer film {Arcturus). Extreme care was taken to prevent cross 
contamination during this procedure. The DNA was extracted by fitting the caps with 
microdissected material onto 0.5ml microtubes (which had their own caps cut off) 
containing 20 pi o f proteinase K/buffer. The tubes were inverted and placed in a moist 
box and left at room temperature for 24 hours following which the proteinase K was 
inactivated by heating the tubes at 95°C for 5min. PCR for TCR-y chain gene or IgH 
(FR3) gen was performed as described above in section 2.5.4.2. 5pl o f extracted DNA 
was used for each PCR reaction, which was estimated to contain DNA from 6 CD 10 
positive /CD57 positive cells or a single EBER positive cell.
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2.5.6 Cloning of PCR products
2.5.6.1 TA cloning vectors
The pGEM-T vector system (Promega) was used for the cloning o f PCR products in 
chapter 3. In this system, the presence o f single 3 ’-T overhangs at the insertion site ensures 
efficient ligation by taking advantage o f the non-template dependent addition o f a single 
deoxyadenosine to the 3 ’end o f the PCR products by the thermostable Taq polymerase. T7 
and SP6 RNA polymerase promoters flank the cloning region.
2.5.6.2 Ligation of PCR products into the pGEM-T plasmid vector system
PCR products were purified using QIA Quick Gel extraction Kit (QIAGEN, West Sussex, 
UK). Ligation o f PCR products into TA cloning vectors was performed according to the 
manufacturer’s instructions. 7pl o f gel-purified PCR product were mixed with lp l 
(50ng) o f vector, 1 unit o f T4 ligase (1 Weiss unit/ pi) and lp l o f T4 ligase 10 x buffer, 
and incubated for 3 hours at 15°C. At this point, a 3pl aliquot was removed for the 
transformation step. The remainder o f the ligation reaction was allowed to incubate 
overnight at 4°C, so that the extended ligation reaction could be used as a back up if 
necessary.
2.5.6.3 Transformation of ligated PCR product:pGEM-T vector
Two duplicate sets o f LB/ampicillin/X-gal plates were used for each ligation reaction.
Manufacturer’s instructions were followed and 2pl o f ligated product: pGEM-T vector
was added to a 1.5 ml microcentrifuge tube on ice. The JM109 competent cells
{Promega) were removed from -70°C storage and allowed to thaw for about 5 minutes
on ice and mixed gently. 50 pi o f cells were aliquoted into each tube containing 2pl o f
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ligated product: pGEM-T vector. The tubes were gently mixed and placed on ice for 30 
minutes and then heat shocked for 45 seconds at exactly 42°C. The tubes were then 
returned to ice for 2 minutes and 1ml LB broth was added to the tubes. The tubes were 
inverted to mix and then incubated for one hour at 37°C. The transformation culture was 
plated on duplicate plates (50 pi on one and 100 pi on the other) and incubated overnight at 
37°C. Each white colony was transferred into 150pl of LB/Ampicillin broth using a 
micropipette tip and cultured at 37°C for 3 hours in a shaking incubator. The culture was 
then spun down and the supernatant discarded, 20 pi of PCR water added and the mixture 
was vortexed vigourously for 10 seconds. The mixture was centrifuged and the supernatant 
used as PCR template.
2.5.6.4 PCR of cloned products
PCR reaction o f cloned products was set up as follows:
The total volume for each PCR reaction was 25pl. Each reaction contained 2.5 pi o f 10 
x PCR buffer (Promega) (final concentration o f 1 x ), M gCh (Promega) in an optimum 
final concentration o f 1.6 mM, 100 pM each dNTP {Promega) final concentration and 
0.5 pi o f T7 (5 pM ) primer (Promega), 0.5 pi o f SP6 (5 pM) primer {Promega) (final 
concentration o f 0.2pmol o f each primer), 0.1 pi o f Platinum Taq polymerase (5U/pl) 
(Invitrogen) (final concentration o f 0.5pmol), 19.2 pi o f ultra pure water {Sigma) and 1 
pi o f LB culture
The PCR reaction was set up to heat for 5 minutes at 94°C to breakup the cell membrane 
and release the recombinant DNA into solution. This was followed by 35 cycles o f 
94°Cx 1 minute (denaturation), 55°C for 1 minute (annealing) and 72°C for 2 minutes
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and a final extension step at 72°C for 10 minutes. The products were run on an agarose 
gel.
2.5.6.5 Verification of cloning vector amplification by agarose gel electrophoresis
Preparation o f a 1% agarose gel was undertaken as follows:- lg  o f agarose (Sigma) was
dissolved in 100ml o f 1 x TBE buffer (containing O.lpg/ml ethidium bromide) by 
boiling. The agarose was poured into the gel apparatus and the comb added. When the 
gel was solid the comb was carefully removed and 1 xTB E buffer added to cover the 
gel. 4-10pl o f the PCR products were mixed with l-2.5pl o f loading buffer before 
loading into wells. The gels were run at 100-150V for 30min. The gels were removed 
from the gel apparatus and viewed under ultra-violet light. Amplification o f products o f 
the sizes predicted by addition o f the insert to vector sequence was interpreted as 
successful cloning and sequencing was subsequently carried out.
2.5.7 Sequencing of cloned PCR products
The cloned PCR products were sequenced in both directions using ABI 377 DNA 
Sequencer.
2.S.7.1 Sequencing reaction
The final volume for each reaction was 10pl. 5 pi o f each PCR product (approximately 
around 500ng total DNA) were mixed with 4 p.1 o f dRhodamine Dye Terminator Mix 
(Applied Biosystems, CA) and lp.1 o f T7 primer (at 5pM concentration) or 1 jllI o f SP6 
primer (at 5jxM concentration) (final concentration at 0.5pmol) -  for sequencing in both 
directons.
99
After denaturation for 30 seconds at 96°C, each reaction mixture was amplified for 25 
cycles as follows: 30 seconds at 96°C, 15 seconds o f annealing at 50°C, and 1 minute of 
extension at 60°C.
2.5.7.2 Purification and precipitation of PCR products
PCR products were cleaned by precipitation with 100 pi o f 80% ethanol and 6 pi o f 3 M 
NaAc (pH 5.2) using a 96 well microtitre plate in the following manner. 100 pi o f 80% 
ethanol and 6 pi o f 3 M NaAc (pH 5.2) were added to each microtitre well and the well 
was placed on wet ice for 30 minutes. Following which, it was spun at 3000rpm for 1 
hour. The plate was then tilted upside down on a paper towel to drain. After draining, the 
plate was placed on a new towel and pulse centrifuged for 5 seconds at 400 rpm. 
Following pulse centrifugation the plate was placed right way up and spun for 15 
minutes to ensure that the pellet was not lost. The plate was then dried at 90°C on a heat 
block for 2 minutes.
2.5.7.3 Sequence analysis
The PCR products were analysed on 4.5% polyacrylamide denaturing gels (Acrylamide: 
N-N'-M ethylene bis-acrylamide 29:1) (NationalDiagnostics, Hull, UK) in lxTBE 
buffer {National Diagnostics) using an ABI 377 automated fluorescent DNA sequencer 
{Applied Biosystems, Foster City, California, USA), which has a four-color detection 
system. The DNA pellet was mixed with 2pL blue dye. The mixture was denatured for 2 
minutes at 94°C and 1.5pl was loaded into every alternate well on a prewarmed gel 
using membrane comb method according to Hamoudi and co-workers (Hamoudi et al, 
2002). The gel was run for 8 hours at 150 watts power, 50 milli amps current, 1650 volts
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voltage, scan rate o f 1200 scans per hour and 50°C temperature. The labeled DNA 
fragments were separated during electrophoresis, the fluorescence was detected in the 
laser scanning region using filter set E. The data was collected and stored using the ABI 
Collection Software 2.0 {AppliedBiosystems). The fluorescent gel data collected during 
the run was automatically analysed by the DNA Sequencing Analysis software 3.0 
{Applied Biosystems). Sample sheets were prepared using in house SampConvertor 
software. Sequence alignment was carried out using Sequence Navigator 1.0.1 {Applied 
Biosystems).
Assistance with sequence analysis was provided by Rifat A Hamoudi.
2.5.8 Quantitative (real-time) EBV-specific PCR on tumour tissues
The following was performed by Dr Yuan Ping Zhou.
2.5.8.1 DNA extraction
5-8 5pm sections cut from formalin-fixed and paraffin embedded tissues were de-waxed 
twice in xylene, washed twice in absolute ethanol, and then air-dried. Tissues were 
digested with proteinase K (2mg/ml) in 30mM Tris-HCl (pH 8.0) buffer containing 
lOmM EDTA and 1% sodium dodecyl sulfate at 55°C for 2 days, followed by 
purification o f DNA with the Wizard genomic DNA purification method {Promega). 
Briefly, the tissue digests were mixed with 1/3 volume of protein precipitation solution 
and centrifuged. The resulting supernatant was transferred into a fresh tube and sample 
DNA was precipitated with isopropanol, washed in 70% ethanol and air-dried. DNA 
pellet was dissolved in 50pl o f lOmM Tris-HCl (pH8.0). Five frozen samples were also
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similarly extracted from whole sections but digested for only 12 hours. The negative 
genomic control DNA and the EBV positive control DNA were prepared from normal 
peripheral blood lymphocytes and Namalwa cell line (diploid and carries 2 copies of 
EBV genome/cell) culture using a QIAGEN blood & cell culture DNA kit (QIAgen,
West Sussex UK) respectively, which was confirmed by serial PCR screening for EBV. 
The DNA samples were quantified using GeneQuant pro (Amersham pharmacia biotech, 
Cambridge, UK).
2.5.S.2 Real-time PCR
Real time PCR was carried out to quantity EBV load in AITL samples using an iCycler 
iQ system {Bio-Rad) with SYBR Green I and iTaq. The primer pairs were designed from 
EBNA region for EBV copy number (product length: 106 bp), and from micro-globulin 
(B2M) region for cell number identification, (product length: 86 bp). 50ng o f DNA was 
used as starting material for each reaction.
The optimum M gCh concentration for PCR was 1.5 mM, and the thermocycler was 
programmed as follows: 94°C for 2 minutes followed by 2 cycles o f 94°C x 30
seconds; 63°C~57°C each 45 seconds; 72°C x 30 seconds followed by 30 cycles of 94°C 
x30 seconds; 56°C x 45 seconds; 72°C x 30 seconds. This was followed by an 
extension time of 7 minutes at 72°C
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The primers were:
Primers Sequence
EBNA106-F CCGGTGTGTTCGTATATGGAG
EBNA106-R GGGAGACGACTCAATGGTGTA
B2M-b-F TGCTGTCTCCATGTTTGATGTATCT
B2M-b-R T CTCT GCT CCCCACCT CT AAGT
Target
EBV EBNA  
EBV EBNA
human Beta 2 Microglobulin 
human Beta 2 Microglobulin
(Abbreviations: EBNA106-F, Epstein Barr virus nuclear antigen 106 forward; EBNA106-R, Epstein Barr 
virus nuclear antigen 106 reverse; EBV Epstein barr virus; B2M-b-F, |32 microglobulin-b-forward; B2M- 
b-R, p2 microglobulin-b-reverse)
2.5.8.3 Quantification of EBV
The conditions for real-time PCR were optimized prior to data collection. The standard 
curves were generated by serial dilutions of 1 x 106 copies/ul o f both EBV and B2M 
extracted from Namalwa cell line (each cell contains 6.6 pg DNA and 2 copies o f both 
EBV genome and B2M gene) (Figure 2.1). Once the experimental conditions had been 
optimized, the real-time PCR was performed in a 25 pi reaction mixture containing 12.5 
pi SYBR Green Super-Mix {Bio-Rad), 200 nM of each sense and anti-sense primer, and 
200 ng AITL sample DNA. All samples were amplified in triplicate. Real-time PCR of 
B2M was run in parallel for each sample. Melt-curve analysis was performed 
immediately after the amplification protocol for each case and only samples that showed 
specific amplification were included in the data analysis (Figure 2.1).
The virus copy number per 1000 cells was calculated after obtaining virus copies and 
B2M copies according to the related Ct (threshold cycle) values and the standard curves 
respectively as described previously (Junying et al, 2003).
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Figure 2.1 Melt curve analysis (left), and real-time PCR graph (right) for EBV
2.5.9 Conventional PCR for detection of HHV8
The following was performed by Dr Timothy C Diss:
The primers were novel and targeted a 200bp fragment o f the putative minor capsid 
protein gene of HHV8:
Primers targeting the gene encoding a minor capsid protein o f HHVtf 
Name Sequence
KS-3 CC ACC ATT GT GCT CGAAT C
KS-4 ACGATATGT GCGCCCCATAA
For HHV-8-specific PCR, the optimum MgCh concentration for PCR was 1.5 mM, and 
the thermocycler was programmed as follows: 95°C for 2 minutes, followed by 40 cycles 
of 93°C x 45 seconds (denaturation), 61°C for 45 seconds (annealing) and 72°C for 90 
seconds (extension). After completion o f 40 cycles, a final primer extension step at 72°C 
for lOmin was carried out.
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2.6 Statistical analysis
Chi square (X2) non-parametric test o f statistical significance for bivariate tabular 
analysis was used in chapter 4.
2.7 Image processing
Images were visualized under an Olympus BX51 microscope equipped with UPlanFL 
x65, x40, x20, xlO, x4 objective lenses and WH 10 x 22 eyepiece (Olympus, Tokyo, 
Japan). Images were captured with an Olympus DP70 camera and processed with 
Adobe PhotoShop 7.0 software (Adobe Systems, San Jose, California, USA).
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Chapter 3
CD10 IS EXPRESSED BY THE NEOPLASTIC T-CELLS 
IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
3.1 Introduction
The diagnostic difficulties and the morphologic overlap o f AITL with reactive 
conditions in early cases, and other lymphomas in those with less typical morphology 
have already been discussed in chapter 1. In this chapter we investigate for a possible 
phenotypic marker that would facilitate accurate diagnosis. The tumour cells, when 
identified in the form of clusters o f clear cells have been reported to show a close 
association with the vascular proliferation that is typical o f AITL (Nathwani & Jaffe, 
1995). As the characteristic FDC proliferation in AITL shows a tendency to surround 
these vessels (Jaffe & Ralfkiaer, 2001a) it is not surprising that we noted a close 
association between the clear cell clusters, and the expanded FDCs and regressed 
follicular structures. Ree and co-workers (1998) and Kojima and co-workers (2001) 
describe cases o f AITL showing hyperplastic GCs with ill-defined mantle zones, 
although the exact location o f tumour cells in relation to these hyperplastic follicles is 
not clear. In peripheral lymphoid tissues expression of the antigen CD 10 is restricted to 
the FDC/GC microenvironment and at the time o f commencement o f this project was 
believed to be confined to GC B-cells only (Arber & Weiss, 1997). In follicular 
lymphomas, CD 10 expression is strongest within follicles and down-regulated in the 
interfollicular areas devoid o f FDCs (Dogan et al, 1998), suggesting that the 
follicular/FDC micro-environment may play a role in CD 10 expression. Although not
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known to be a feature o f mature T-cells or mature T-cell neoplasms, CD 10 expression 
was described in 2 o f 3 cases o f T-cell lymphoma with a follicular growth pattern based 
on an FDC meshwork, described by de Leval and co-workers (2001). The possible 
influence o f the FDC mico-environment on CD 10 expression in mature lymphoid cells 
in turn raised the possibility that the close link between FDCs and the neoplastic T-cell 
in AITL may be associated with CD 10 expression by the latter.
The main aim in this part o f the project was to investigate whether the neoplastic T-cells 
in AITL express CD 10. This was complicated because, unlike in many other lymphoid 
neoplasms where the tumour cells are present as a diffuse monomorphous proliferation, 
the infiltrate in AITL is typically polymorphic and the neoplastic T-cells are greatly 
outnumbered by and intimately admixed with reactive lymphocytes, histiocytes, plasma 
cells, eosinophils and FDCs (Jaffe & Ralfkiaer, 2001a;Willenbrock et al, 2005). 
Furthermore, clear cell clusters are not always present and cytologic features of 
malignancy may not be readily identifiable (Jaffe & Ralfkiaer, 2001a). On morphology 
alone, EBV infected transformed B-blasts could be mistaken for the neoplastic cells 
(Frizzera, 2001 ;Jaffe & Ralfkiaer, 2001a). It was therefore imperative that single cell 
analysis be undertaken to show proof o f CD 10 expression by neoplastic T-cells.
3.2 Results
3.2.1 Tissues used in this part of the project
Thirty formalin-fixed paraffin-embedded, lymph node biopsies from 30 cases o f AITL 
were retrieved from departmental archives. The histology was reviewed and the
diagnosis confirmed in each case. O f the cases o f AITL, 4 were local cases, whereas the
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remaining 26 cases were referrals from other centres for a second opinion. Details o f the 
clinical presentation and the original diagnosis were obtained where possible.
3.2.2 Clinical features
These are summarised in Table 3.1. There were 17 males and 13 females between 37 
and 84 years o f age. Most patients presented with generalised lymphadenopathy. Other 
clinical features included weight loss, fever, skin rash, anaemia and 
hepatosplenomegaly. The initial histological diagnosis was AITL in only 13 cases. In 
the remaining 17 the diagnoses included reactive lymphoid hyperplasia (4 cases), T-cell- 
rich B-cell lymphoma (4 cases) and other lymphomas (8 cases).
3.2.3 Histology
The histological features are summarised in Table 3.2. The cases could be separated 
into three overlapping patterns.
In Pattern I (6 cases) there was partial preservation o f the lymph node architecture. 
Hyperplastic B-cell follicles with poorly developed mantle zones and ill- defined borders 
were easily identifiable in the cortex o f the lymph node (Figure 3.1 A). These merged 
into the expanded paracortex containing a polymorphic infiltrate o f lymphocytes, 
transformed large lymphoid blasts, plasma cells, macrophages and eosinophils within a 
prominent vascular network (Figure 3 .IB and C). Increase in FDCs was not evident.
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Table 3.1. Clinical features of AITL cases
Case A/S 
No
Clinical features Site Initial diagnosis
l 65M F ever, genera lised  lym phadenopathy , haem oly tic  anaem ia lym ph  node A ITL
2 62M G enera lised  lym phadenopathy lym ph node PTL
3 59M F ever, ce rv ica l lym phadenopathy , abnorm al liver function  tests lym ph node A IL
4 37M G enera lised  lym phadenopathy ingu inal lym ph node R eactive
5 82M G enera lised  lym phadenopathy , sp lenom egaly , coom b 's  te st positive , 
n igh t sw eats
lym ph node R eactive
6 59F C erv ica l lym phadenopathy , p leural effusion lym ph node D LB L
7 62F L ym phadenopathy , po lyclonal gam m opathy , hepa tosp lenom egaly lym ph node A IL
8 70M G enera lised  lym phadenopathy , w eight loss, rash ax illa ry  lym ph node HL, T R B L
9 48M N ot av a ilab le lym ph node A ITL
10 64 F G enera lised  lym phadenopathy , fever, p ru ritus, n igh t sw eats axilla ry  lym ph node A IL?, reactive?
11 76F G enera lised  ly m phadenopathy , hepa tosp lenom egaly lym ph  node A IL?, C D ?, reactive?
12 79F N o t ava ilab le lym ph node A IT L ?, PTL?
13 84F lym phadenopathy , rash ingu inal lym ph node PTL?, TR B L ?
14 78M Fever, genera lised  lym phadenopathy , sp lenom egaly , sk in  rash lym ph node N H L
15 42M G enera lised  ly m phadenopathy , fever, hepa tosp lenom egaly , 
haem o ly tic  anaem ia , w eigh t loss
lym ph node R eactive? , C D ?
16 60F F ever, b ila te ra l ingu inal lym phadenopathy , sp lenom egaly ingu inal lym ph node N H L
17 58F G enera lised  ly m phadenopathy , "B" sym ptom s lym ph node D L B L
18 78M G enera lised  ly m phadenopathy , co om b 's  positive  haem oly tic  anaem ia , ce rv ical lym ph node 
h y p ergam m ag lobu linaem ia ,
AIL
19 55M G enera lised  ly m phadenopathy , fever, w eigh t loss ingu inal lym ph node R eactive
20 71M Ingu inal lym phadenopathy , w eigh t loss ingu inal lym ph node D LB L
21 39F G enera lised  lym phadenopathy , n igh t sw eats lym ph node AITL
22 77F G enera lised  lym phadenopathy , sp lenom egaly , "B" sym ptom s axillary  lym ph node PTL?, HL?
23 52F L ym phadenopathy , and  h igh  ESR cerv ica l lym ph node D LB L?, HL?
24 61M A xillary , ingu inal lym phadenopathy , hepa tom ega ly , pneum onia axillary lym ph node A IL
25 61M N ot ava ilab le lym ph node A ITL
26 74F G enera lised  lym phadenopathy , p ru ritu s cerv ica l lym ph node A IL
27 78F ly m phadenopathy , "B" sym ptom s ingu inal lym ph nde T R B L
28 78M G enera lised  lym phadenopathy , rash , w eigh t loss ingu inal lym ph  node T R B L ?, PTL?
29 52M G enera lised  lym phadenopathy , hepa tosp lenom egaly , anaem ia lym ph  node FDC tu m our
30 59M G enera lised  lym phadenopathy lym ph node A IL
A: age, S: sex , M: m ale, F: fem ale, AITL: an g io im m unob lastic  T -cell lym phom a, PTL: periphera l T -cell lym phom a, AIL: 
an g io im m unob lastic  lym phadenopathy , D LBL. d iffu se  large B-cell lym phom a, HL: H o d g k in ’s lym phom a, TR B L : T -cell rich  B-cell 
lym phom a, : n o n -H o d g k in ’s lym phom a, CD : C as tlem a n ’s d isease  FDC: fo llicu lar dend ritic  cell
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Pattern II (9 cases) was characterised by loss o f normal architecture except for the 
presence o f occasional depleted follicles with concentrically arranged FDCs (Figure 
3.2A-C). In some cases FDC proliferation extending beyond the follicles could be 
identified (Figure 3.2D). The rest o f the node showed a polymorphic infiltrate with 
increased numbers o f transformed lymphoid blasts and vascular proliferation similar to 
that described for pattern I (Figure 3.2D-F).
In pattern III (15 cases) the normal architecture was completely effaced and no B-cell 
follicles could be identified. Prominent irregular proliferation o f FDCs could be seen in 
H&E stained sections in most cases and this was accompanied by extensive vascular 
proliferation and a polymorphic infiltrate similar to that seen in patterns I and II (Figure 
3.4A, G and H).
In 16 cases perivascular collections o f cells with clear cytoplasm were evident (Figure 
3.2F).
3.2.4 Immunohistochemistry
In pattern I sprouts o f CD21 positive FDCs extended beyond the confines o f the CD21 
positive GCs and occasionally enveloped small blood vessels (Figure 3 .ID).
Paracortical T-cells, including some transformed blasts expressed CD3 (Figure 3 .IF) 
and predominantly CD4. A smaller CD8 positive population was present. Preserved 
GCs expressed CD20 and CD 10. IgD highlighted the mantle zones (Figure 3.1 E). In 
addition to CD 10 positive GC cells there was a population o f smaller strongly staining 
lymphoid cells at the outer rim o f the GC that extended into the paracortex (Figure 3.1G-
I).
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In pattern II, CD21 positive FDCs extended beyond the follicles into the paracortex 
often surrounding proliferating small vessels (Figure 3.2G).
In Pattern III they showed a more haphazard arrangement, surrounding the arborising 
small vessels (Figure 3.4B, I and L).
In both patterns II and III, CD20, IgD positive but CD 10 negative clusters o f small B- 
cells, mostly not associated with GCs, could be identified within meshworks o f CD21 
positive FDCs. In all but 3 cases (4 lymph node biopsies) there were concentrations o f 
CD 10 positive T-cells around the CD20 positive B-cell clusters as described for pattern I 
(Figure 3.3D-F, Figure 3.4C,F, J and K). In addition isolated CD 10 positive T-cells were 
scattered throughout the entire lymph node and formed perivascular aggregates 
corresponding to the clear cells noted in H&E stained sections (Figure 3.3C and F). 
CD 10 was also expressed by granulocytes most o f which were within blood vessels. 
Their characteristic cytological features easily distinguished them from the CD 10 
positive lymphoid cells. Clear cells when present were CD4 positive (Figure 3.2J, left 
panel) and CD8 negative (Figure 3.2J, right panel). In biopsies showing patterns II and 
III isolated transformed CD20 positive blasts were identified within the predominantly 
CD3 positive infiltrate.
3.2.4.1 Sequential double staining
Double staining with CD20 followed by CD 10 was performed on all lymph node 
biopsies to show that the lymphoid cells expressing CD 10 were not GC B-cells. In 27 
out o f 30 biopsies (27 o f 30 cases) there were varying numbers o f CD20 negative, CD 10 
positive lymphoid cells strongly suggesting that these were T cells (Figure 3.1, Figure
3.3 G-I and Figure 3.4D and E). Double staining with CD79a and CD10 gave identical
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results. The T-cell phenotype o f the CD20 negative, CD 10 positive lymphoid cells was 
also confirmed by CD3/CD10 double staining which showed a population o f “purple” 
cells co-expressing CD3 and CD10. The ratio o f CD10 positive T-cells to all T-cells for 
each case is shown in Table 3.2.
The approximate ratio o f CD 10 positive T-cells to all T-cells was assessed from serial 
sections immunostained for CD3 and CD20/CD10. Further double staining experiments 
showed that the CD10 positive T-cells expressed CD4 but not CD8. Although the 
proliferation fraction as assessed by single layered Ki 67 staining was high (Figure 3 .10  
and Figure 3.2K), double staining o f the CD10 positive cells with Ki-67 showed that 
these phenotypically aberrant T-cells had a low proliferation fraction (Table 3.2 and 
Figure 3.2L). The proliferation fraction was calculated by counting 500 CD10 positive 
cells in 5-7 different areas o f the lymph node on sections double immunostained for 
Ki67/CD10.
3.2.5 In-situ hyridisation for EBV-EBER
All cases o f AITL showed hybridisation for EBV-EBER in a subset o f the cells. The 
number o f cells expressing EBV-EBER varied markedly from case to case, in some only 
scattered cells were positive, in others numerous large blasts were labelled. The 
distribution o f EBER positive cells was similar to the distribution o f large B-blasts and 
did not correspond to the clusters CD 10 positive T-cells.
112
Figure 3.1. Case 2 showing “Pattern I” histology with hyperplastic follicles.
(A-C) Haematoxylin and eosin stained section showing hyperplastic follicles (A, B) and a polymorphous 
infiltrate associated with prominent vascularity in the paracortex (B,C). (D) CD21 stain shows that there is 
no obvious (left panel), or subtle expansion (right panel) o f the follicular dendritic cell meshwork. (E) IgD 
highlights the mantle zones. (F) CD3 highlights numerous T-cells.(G-I) CD 10 highlights many lymphoid 
cells which include the lighter staining GC B-cells and T-cells which show crisp, dark staining. (J-M) 
CD20/CD10 double staining shows many CD 10 positive (blue) cells that are negative for CD20 (brown), 
consistent with T-cells. (O) Ki-67 staining shows a high proliferation fraction.
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Figure 3.2 Case 10 showing “pattern II” histology.
(A-F) Haematoxylin and eosin stained section showing a vague nodularity (A) with regressed follicles 
associated with clusters o f  clear cells (B and C). Fasicles o f  pale cells comprise the hyperplastic follicular 
dendritic cell (FDC) meshwork (D). A rich vascular network is intimately associated with the clear cells 
(E). Panel F shows the clear cells at high power. (G) CD21 stain highlights the hyperplastic FDC. (H,I) 
CD3 stain shows numerous T-cells, including large clear cells. (J) The clear cells are CD4 positive (J, left 
panel), and CD8 negative (J, right panel). (K) Ki 67 shows a high proliferation fraction. (L) CDIO/Ki 67 
stain shows that most CD 10 positive cells (brown) are Ki 67 (blue) negative.
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Figure 3.3 Case 10 showing CD10 positive T-cells that correspond to the clear cells.
Panels A-C show low, medium and high power views o f  haematoxylin and eosin (H&E) stained section 
while panels D-F, show CD 10 immunostaining and panels G-I show CD20/CD10 double staining at 
similar magnifications. CD 10 positive lymphoid population (D-F) correspond to clear cells seen on H&E 
staining (A-C). CD20/CD10 staining shows many CD 10 positive cells (blue) that are CD20 (brown) 
negative, consistent with T-cells (G-l). These also correspond to the clear cell population seen on H&E 
(A-C).
3.2.6 PCR for TCRX and IgH gene re-ararrangement
The results of PCR for TCRy gene and IgH gene are shown in Table 3.2 and Figure 3.6. 
There was a monoclonal (1-2 dominant bands) or oligoclonal (3-4 dominant bands) T- 
cell population in all cases except one. Five o f the cases also showed evidence o f a 
monoclonal B-cell population. In all o f these cases numerous EBV infected transformed 
lymphocytes were present.
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i f  B
Figure 3.4 Cases 28 and 27 showing pattern III histology and CD10 positive T-cells.
Panels A-F show sections from case 28 and panels G-L show sections from case 27.
(A, G, H) Haematoxylin and eosin stained sections showing complete effacement o f architecture with no 
identifiable follicles, prominent vascularity (H) and clear cells (H, inset). (B ,1 and L) CD21 shows marked 
hyperplasia o f the follicular dendritic cell meshwork, which shows a tendency to surround vessels (L). 
(C,F, J and K) CD 10 stain shows numerous CD 10 positive lymphoid cells. (D and E) CD20/CD10 double 
staining shows numerous CD 10 positive (blue) lymphoid cells that are CD20 (brown) negative, consistent 
with T-cells
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Table 3.2. Summary of histological features, immunophenotype and molecular analysis of 
AITL
Case No Pattern* CD10/CD3+ Clear cells*CD10/Ki67§TCR-PCR1 IgH-PCRI
1 1 5% absen t O P
2 1 5% absen t 16% M P
3 1 10% presen t 0 P
4 1 10% absen t M P
5 1 20% presen t 8% M P
6 1 0% absen t M P
7 2 5% absen t P P
8 2 5% absen t M P
9 2 5% absen t 11% M P
10 2 10% presen t 19% O P
11 2 10% presen t M M
12 2 15% presen t M P
13 2 20% absen t M M
14 2 20% absen t O M
15 2 5% absen t M P
16 3 0% absen t M P
17 3 5% presen t M P
18 3 5% presen t M P
19 3 5% presen t M P
20 3 5% presen t O M
21 3 10% absen t M P
22 3 10% absen t M P
23 3 20% presen t M P
24 3 20% presen t M N A
25 3 20% presen t 10% M P
26 3 30% absen t 11% O P
27 3 30% presen t 19% M M
28 3 30% presen t M P
29 3 30% presen t O P
30 3 0% present M P
* The histological pattern as described in 
the results. ** categorized as pattern II t  
Percentage of CD 10 positive and CD3 
positive T-cells. { Cases containing 
aggregates of atypical lymphoid cells with 
clear cytoplasm. § Percentage of CD 10 
positive cells expressing Ki67. % Results 
of PCR performed for T-cell receptor 
gamma chain gene (TCR) and 
immunoglobulin heavy chain gene (IgH). 
M: monoclonal, Oroligoclonal, 
P:polyclonal, NA: no amplification
117
3.2.7 Single cell microdissection
To investigate whether the CD 10 positive T-cells were part o f the neoplastic clone, SO­
SO CD 10 positive cells were microdissected from 5 cases (Figure 3.5) and PCR for 
TCRy gene was performed. In each case analysis o f the PCR products from 
microdissected cells gave a dominant band/s identical in size to that was observed for 
the PCR performed on whole sections. (Figure 3.6) In contrast DNA extracted from 
areas lacking CD 10 positive cells showed a polyclonal ladder or smear.
3.2.8 Cloning and sequencing of PCR products
The cloning and sequencing o f the dominant bands isolated from PCR products o f three 
cases showed a dominant clone with identical sequence, confirming the monoclonal 
nature o f all cases examined. For each o f the three cases the dominant clone from the 
whole sections and from the microdissected CD 10 positive cells were identical (Table 
3.3 and Figures 3.7 and 3.8).
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Figure 3.5. Laser capture microdissection of CD10 positive lymphoid cells in AITL.
(A ) CD 10 stained section before microdissection; the cells targeted for microdissection are indicated 
within the blue circle and by arrowheads. (B) Same area after microdissection; the blue circle and 
arrowheads show the spaces left after cells have been removed. (C) High-power view o f  a cluster o f  CD 10 
positive cells after microdissection. These are the encircled cells/spaces in panels A and B.
Table 3.3: Results of cloning and sequencing of dominant bands obtained from PCR 
amplification of TCR y chain gene from whole lymph node sections and microdissected 
CD 10 positive cells
Case No PCR band W hole lymph node* Microdissected CD10 positive cells f
12 Upper 4/6 6/6
Lower 3/6 6/6
26 Upper 3/5 4/6
Lower 11/13 8/8
28 Upper 7/9 5/7
Lower 10/10 Not done
* The number of clones with identical TCR y chain gene sequence / total number of clones sequenced, 
t  The number of clones with TCR y chain gene sequence identical to the dominant sequence obtained from the whole 
section PCR / total number of clones sequenced.
119
Figure 3.6 Analysis of PCR products for TCR-y chain gene on polyacrylamide gels 
in AITL.
(Top panel) All cases demonstrated in the figure show 1 or 2 dominant bands consistent with a 
monoclonal T-cell population. Lane M, molecular weight markers; lane 1, positive control; lane 1, case 
21; lane 2, case 23; lane 3, case 26; lane 4, case 22; lane 5, case 3; lane 6, case 4; and lane 2, negative 
control. (Bottom panel) Microdissection o f CD 10 positive cells in cases 26 and 13 gave PCR products 
identical in size to products obtained from whole-section PCR. Lane 1, whole-section PCR products o f  
case 26; lanes la,b,c, microdissected PCR products o f case 26; lane 2, whole section PCR products o f  case 
13; lanes 2a,b,c, microdissected PCR products o f  case 13; and lane 2, negative control.
Figure 3.7 Gel image of TCR y chain gene sequences
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CD10 S equences
C T O T TCA TTT 3 U 8 A T 1 C M  CGTQTT C T T Q G A A T T 3T C T C  TOGAOATOGT 
C T G T TCA TTT 3AA3ATA CA G  C G T O T T C T T 3 G A A T T 3T C T C  T 3G A 3A T O O T  
CTG T T C A T T T  3A A 0A T A C A 3 C O T O TTCTTO  G A A T T 3T C T C  T 3 3 A 3 A T 3 0 T  
C TG T T C A T T T  3AA3ATA CA G  C G T O TTCTTO  O A A T T 3T C T C  T 3 3 A 3 A T 3 3 T  
C T 3T T C A T T T  3C  A S AT AC A 3 TO ACW TCTTS G CO TTG TC TC TO GK 3A TO OT 
C TG T T C A T T T  3 C A 3 ATACA 3 TG AG TTCTTO  Q C 3 T T 3 T C T C  T 3G A G A T 33T
__3!____ 3!____ 3!_____3!____ T____ 3?____ JT____ 3!_____I .
GAATCGGCCC TTCACGQAGT CTGCGTAGTA T 3 T G  CTA
3A ATCQGCCC TTCACGQAGT CTOMQTAQTA T 3 T 3 C T A C C A  
3AATCGGCCC TTCACGQAGT CTQMQTAGTA T G T G - - - C T A  
3AATCGGCCC TTCACGQAGT CT3N G TAG TA  T 3 T G - - - C T A  
QAATCGGCCC T T C A C T 3A G T  CTGCGTAGTA TATGTAAC TA 
• QAATCGGCCC T T C A C T 3A 3T  CTQCGTAJTTA T A TGTA A CTA
PT C A TTT SCAGATACAG CG TO TCCTTG  G A A T T 3T C T C  TGGAGATOOT 3AATCGGCCC TTCACGQAGT CTOCATAGTA T T T A T T G C T T
rT C A T T T  QCAOATACAG CO TO TC C T T O G A ATTO TCTC TOGAOATOGT OAATCGGCCC TTCACGQAGT CTOCATAGTA T T T A T T G C T T
PT C A T T T  3CA O A TACAT C 6T Q C T CT T G G A GTTG TCTC TOGAOATOGT 0A A TC T 6C C C  TTCACGQAGT CTOCATAGTA T T T C T T A C T T
PT C A TTT QCAOATACAT CG TG CTCTTO  G A 3TT O T C T C  TOGAOATOGT QAATCTBCCC TTCACGQAGT CTOCATAGTA T T T C T T A C T T
Figure 3.8 DNA sequence alignment of rearranged TCR y chain gene from whole lymph 
node section (upper panel) and microdissected CD10 positive cells (lower 
panel).
3.3 D iscussion
3.3.1 CD10 expression in AITL
The histological diagnosis of AITL may be difficult as is shown by the large error rate 
(13/26; 50%) in referred cases in our series. This is especially true when preservation of 
follicles and only slight expansion of the paracortex are present. The expanded CD21 
positive FDC meshwork is very helpful in making the diagnosis (Leung et al, 1993) but 
can be subtle. Molecular investigation and, in many instances repeated biopsies may be 
required to reach a confident diagnosis. In this study we have shown that CD10 is a
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phenotypic marker that specifically identifies the tumour cells in 90% o f AITL 
including, importantly, the “early” cases with pattern I histology. We believe that this 
provides an objective criterion for the diagnosis o f AITL and should greatly assist in the 
diagnosis o f this disorder.
The CD 10 expressing T-cells must be distinguished from GC B-cells especially in cases 
with pattern I histology. They are typically seen at the margins o f B-cell follicles as 
small to medium sized lymphoid cells with crisp membrane staining in contrast to the 
larger follicle centre B-cells that stain more diffusely and with less intensity. In more 
advanced cases with pattern II or III histology the CD10 positive T-cells are more 
diffusely distributed as single cells and in small clusters. Double staining confirmed that 
these cells are CD3 and CD4 positive T-cells that accounted for a relatively small 
fraction o f all T-cells present in each case. Although it was believed that CD 10 
expression is not a feature o f normal / reactive mature T-cells, this has recently been 
challenged by Cook and co-workers (Cook et al, 2003) who demonstrate a small subset 
of benign CD 10 positive T-cells detected by flow cytometry in 5 o f 28 cases (18%) of 
reactive lymphoid hyperplasia, 4 o f 17 (23%) of follicular lymphoma and 9 o f 19 cases 
(47%) of marginal zone B-cell lymphoma. Using double layered immunohistochemistry 
with CD 10 and PAX-5, the latter, a lineage specific B-cell marker that stains the 
nucleus, they showed that many of the CD 10 positive, PAX-5 negative presumptive T- 
cells were located in the follicle centers. Despite these findngs, several lines o f evidence 
point to the CD 10 positive T-cells in AITL being neoplastic rather than reactive. The 
clusters o f large cells with clear cytoplasm, which occur in some cases and widely 
regarded to represent the neoplastic clone in AITL (Frizzera, 2001 ;Nathwani & Jaffe, 
1995), were consistently CD 10 positive. Most compelling and the ultimate proof is that
clonal analysis following micro-dissection has shown that the neoplastic clonally 
rearranged TCR genes are confined to the CD 10 positive population.
A subset o f AITL cases contains more than one dominant T-cell clone with molecular or 
cytogenetic studies (Feller et al, 1988;Schlegelberger et al, 1990a;Schlegelberger et al, 
1994b;Smith et al, 2000). Although we did not specifically address whether all dominant 
clones in a given case expressed CD 10, all AITL cases with an oligoclonal T-cell 
population contained CD 10 positive T-cells suggesting that at least one o f the dominant 
clones expressed CD 10.
The reasons for the absence o f CD 10 positive T-cells in the small minority o f cases 
(3/30 in the present series) that were otherwise entirely typical o f AITL are unclear. 
Occasionally cells that normally express CD 10, such as GC B-cells, fail to do so 
(Unpublished observations). Sometimes this is due to technical reasons, such as the 
fixation method, but more often it appears that the antigen has been down-regulated.
The reasons for this currently remain obscure.
The cases with the histological patterns II and III fulfill the conventional criteria for the 
diagnosis o f AITL. Thus there was clinical evidence o f a systemic disease characterised 
by generalised lymphadenopathy, hepatosplenomegaly and anaemia together with 
characteristic histological features in lymph node biopsies. These include effacement o f 
lymph node architecture by a polymorphic infiltrate o f lymphoid cells, proliferation of 
FDCs and small vessels, the presence o f varying numbers o f EBV infected transformed 
B-cells, and the presence o f clusters o f large transformed cells with clear cytoplasm. In 
addition there was molecular evidence for the presence o f monoclonal or oligoclonal T- 
cell populations. Whether the cases falling into histological pattern I can also be 
considered within the same spectrum is more controversial. The presence o f hyperplastic
follicle centres in otherwise typical AITL was first described by Ree and co-workes (Ree 
et al, 1998) who reported progression o f two such cases into typical AITL. We observed 
the CD 10 positive T-cells in all histological patterns including the cases with 
hyperplastic GCs. Pattern I cases had the smallest number o f CD 10 positive T-cells 
whilst pattern III cases had the most. These findings suggest that all three histological 
patterns o f AITL described are part o f the same disease process and the histological 
patterns I, II and III form a biological continuum.
In five cases where microdissection was performed only the CD 10 positive T-cells were 
clonal and we failed to detect the presence o f the clonal T-cells in microdissected CD 10 
negative areas. Thus, the proportion o f neoplastic T-cells in AITL would appear to be 
small (5%-30%) and it appears most o f the lymph node enlargement is accounted for by 
reactive cells similar to what occurs in Hodgkin’s lymphoma. This was also shown by 
Willenbrock, et al (2005) using triple immunofluoresent staining with antibodies 
directed against the T-cell receptor (3-family specific epitopes and single cell PCR 
analysis. Their observations were that in some cases o f AITL, the tumour cells 
comprised a minority o f the T-cells present. This was also the conclusion of 
Schegelberger and co-workers (Schlegelberger et al, 1994b) when on interphase 
cytogenetics, the percentage o f cells with cytogenetic abnormalities formed a small 
proportion o f all cells.
3.3.2 CD10 / neutral endopeptidase EC 3.4.24.11 (NEP)
CD 10 in haemaopoeitic tissues was identified by the name “common acute 
lymphoblastic leukaemia antigen (cALLA)” which was originally recognized by using a 
hetero-serum developed in rabbits by immunizing them with malignant lymphoblasts
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obtained from a case o f “non B, non T-cell” acute lymphoblastic leukaemia (Greaves et 
al, 1975). Following this discovery, monoclonal antibodies that recognized cALLA were 
developed and were clustered as CD 10 at the First Leukocyte Differentiation Workshop 
(Bernard et al, 1984;Ritz et al, 1980). CD 10 or neutral endopeptidase EC 3.4.24.11 
(NEP), is a cell surface zinc metallo-proteinase that is expressed by subsets o f lymphoid 
cells, and also by terminally differentiated granulocytes, but not immature myeloid cells, 
and a variety o f non-haemopoietic cells such as bronchial epithelial cells, renal proximal 
tubular cells, endometrial stromal cells, breast myoepithelial cells, and fetal intestine 
among others (Baraniuk et al, 1995 ;McCluggage et al, 2001;McIntosh et al, 
1999;Moritani et al, 2002;Shipp & Look, 1993;Skrzydlo-Radomanska et al, 1993;Sont 
et al, 1997;Trejdosiewicz et al, 1985). CD10/NEP is also widely expressed in a variety 
o f non-haematopoietic neoplasms including renal cell carcinoma (-90% ), endometrial 
stromal sarcoma (85-100%), transitional cell carcinoma of the genito-urinary tract (54%) 
and prostatic carcinoma (61%) (Avery et al, 2000;Chu & Arber, 2000;Chu et al, 
2001;Langner et al, 2004;McCluggage et al, 2001 ;Song et al, 2004;Toki et al, 2002;Zhu 
et al, 2004). It may also be expressed by pancreatic adenocarcinoma, malignant 
melanoma, rhabdomyosarcoma and schwannoma among others (Bilalovic et al, 
2004;Chu & Arber, 2000;Jongeneel et al, 1989). In lymphoid cells, CD 10 is restricted in 
its expression. In precursor lymphoid cells it is expressed by both precursor B- and T- 
cells, whereas in mature lymphoid cells its expression is limited to the follicle center 
compartment.
In the bone marrow, the CD 10 positive lymphoid cells include progenitors uncommitted 
to the B-or T-cell lineage, TdT positive, CD34 positive, CD 19 positive B-cell precursors 
(Hokland et al, 1984;LeBien et al, 1990;Loken et al, 1987) and also a significant
proportion o f T-cell precursors (Gore et al, 1991). The percentage o f CD 10 positive 
lymphoid cells in the marrow decreases with age, from 13 to 40% in the fetus (Delia et 
al, 1985;Gore et al, 1991;LeBien et al, 1990) to 1% in the elderly (Gore et al, 1991). In 
the fetus almost all bone marrow B-cells are CD 10 positive (Punnonen et al, 1992). The 
proportion o f CD 10 positive (also TdT positive) lymphoid cells in the marrow increases 
in a regenerating marrow and following transplantation (Kobayashi et al, 1991).
In the thymus, some normal CD34 expressing immature T-cells also express CD 10. The 
expression is strongest in immature T-cells that are CD3 negative/weakly positive and 
CD4- and CD8-, moderate in those that are CD4, CD8 double positive or CD4-, CD8 
positive and weak or absent in those that are CD4 positive, CD8- (Mari et al, 1994).
In peripheral lymphoid tissues, CD 10 expression is confined to the follicle center 
compartment and is a feature o f follicle center B-cells (Arber & Weiss, 1997;Barcus et 
al, 2000;Dogan et al, 2000) and a small subset o f follicle center T-cells, the 
characterization o f which, including their functional properties are yet to be studied 
(Cook et al, 2003).
In lymphomas, CD 10 is expressed in 90% o f precursor B-lymphoblastic lymphom a/ 
leukaemia and (27-40%) precursor T-lymphoblastic lymphoma/leukaemia (Arber & 
Weiss, 1997;Boucheix et al, 1994;Chu & Arber, 2000;Dowell et al, 1987;Pui et al,
1993). High levels o f CD 10 expression in precursor B- and T-lymphoblastic lymphoma / 
leukaemia is associated with a better prognosis (Basso et al, 1992;Boucheix et al, 
1994;Kersey et al, 1982). In peripheral lymphoid neoplasms CD 10 expression is 
confined to B-cell lymphomas (Arber & Weiss, 1997) and is a feature o f the majority 
(90%) of follicular lymphomas, and an almost consistent feature o f Burkitt lymphoma. 
(Dogan et al, 2000;Harris et al, 1994;Harris et al, 2000) It is also seen in approximately
30% of BLBCLs, many of which may represent transformed follicular lymphomas 
(Dogan et al, 2000;0hshim a et al, 2001). CD 10 is also expressed by a small number o f 
mantle cell lymphomas (Dong et al, 2003;Xu et al, 2002b) and 10 -  26% o f hairy cell 
leukaemias (Jasionowski et al, 2003;Robbins et al, 1993). It has also been reported in a 
small proportion o f plasma cell myelomas, a feature that is reported to determine a 
poorer outcome (Durie & Grogan, 1985). CD 10 expression is very unusual in other 
small B-cell neoplasms such as small lymphocytic lymphoma / chronic lymphocytic 
leukaemia, lympho-plasmacytic lymphoma, nodal marginal zone lymphoma and splenic 
marginal zone lymphoma (Arber & Weiss, 1997).
Except for a single report o f 2 cases o f peripheral T cell lymphomas (PTL) with a 
follicular growth pattern and CD 10 expression (de Leval et al, 2001), the latter has not 
been a feature o f mature T-cell and NK-cell neoplasms. In fact, these 2 CD 10 positive 
cases reported by de Leval, et al may represent “pattern 1” cases o f AITL, without 
significant FDC proliferation.
Due to its restricted expression in lymphoid neoplasms, CD 10 has been extensively used 
in the diagnosis o f precursor B-and T-cell neoplasms and mature B-cell neoplasms, 
especially follicular lymphoma (Arber & Weiss, 1997;Chu & Arber, 2000;Dogan et al,
2000).
CD 10 /NEP belongs to a family o f membrane peptidases that includes, among others, 
structurally related leukocyte-associated molecules: CD26 and CD 13 (Shipp & Look, 
1993). CD 10 is a monomeric 749-amino acid type II integral membrane peptide (Shipp 
et al, 1988). It contains a hydrophobic 24-amino acid transmembrane region that also 
functions as a signal peptide. The extracellular region contains a pentapeptide sequence 
that is associated with zinc binding and catalytic activity on cell surface, and zinc
dependant metalloproteases. CD 10 is phosphorylated by casein kinase II, a serine and 
threonine kinase that increases in activity following signaling (Shipp et al, 1988;Shipp & 
Look, 1993). Cell surface CD 10 acts to reduce cellular response to peptide hormones by 
regulating local peptide concentrations (Shipp et al, 1990;Shipp & Look, 1993). It 
hydrolyses peptide bonds on the amino side o f the hydrophobic amino acids, valine, 
phenyl-alanine, isoleucine or tyrosine thereby reducing the local peptide concentration 
available for receptor binding and signal transduction (Shipp & Look, 1993). CD 10 
hydrolyses many substances such as endothelins, enkephalin, angiotensin, atrial 
natriuretic factor and bombesin among others (Shipp & Look, 1993). In systems such as 
lung (Shipp et al, 1988) and prostate cancer (Papandreou et al, 1998), CD 10 has been 
shown to regulate tumour survival in vivo by decreasing extracellular neuropeptide 
concentrations and inhibiting certain signal transduction pathways (Sumitomo et al, 
2000;Sumitomo et al, 2001). Although several non-haematopoeitic tissues were known 
to express NEP, its presence on lymphoid cells was not established until CD 10 and NEP 
proved to be identical (Letarte et al, 1988). In haematopathology, CD 10 was used as a 
diagnostic marker long before its function was known. In a study by Guerin et al, they 
show that treatment o f fetal thymic organ cultures with specific CD 10 inhibitors results 
in the inhibition o f thymocyte differentiation, indicating that CD 10 plays a specific role 
in promoting early T-cell development (Guerin et al, 1997). The T-cell leukaemia cell 
line Jurkat that expresses low levels o f CD10/NEP has been used to show that 
CD10/NEP may function to regulate IL-2 production in certain T-cells. There are also in 
vivo and in vitro studies suggesting that CD10/NEP regulates B-cell development either 
by inactivating a peptide that stimulates B-cell proliferation and differentiation or by 
activating a pro-peptide that inhibits B-cell proliferation and differentiation (Salles et al,
1992). Despite its value as a diagnostic marker in B-cell lymphomas, there is very scant 
data on its physiological role in follicle center B-lymphocytes. This lack o f information 
is surprising since most follicle center derived B-cell lymphomas express CD 10 and 
there are proprietary pharmacological inhibitors o f CD 10 function (Weber, 2001).
3.3.3 Apoptosis and CD10 expression
In normal lymphoid tissues, the CD 10 expression is largely restricted to B-cell 
compartments with typically high rate o f apoptosis (Dogan et al, 2000). O f the B-cell 
neoplasms that express CD 10, follicular lymphoma is associated with inhibition o f 
apoptosis (Johnson et al, 1993) while Burkitt lymphoma is associated with a high rate of 
apoptosis (Blum et al, 2004;Mcgrath et al, 2001). In a recent study it was also shown 
that CD 10 positive acute lymphoblastic leukaemia cells were in cell cycle with elevated 
c-myc levels and a propensity to apoptosis (Cutrona et al, 2002). CD 10 expression is 
also induced in T-cells going through apoptosis (Bladon & Taylor, 2000;Cutrona et al, 
1999). Using in vitro and in vivo experiments, Cutrona et al have shown that both CD4 
positive and CD8 positive subsets o f  post thymic T-cells that do not normally express 
CD 10, become CD 10 positive when they undergo apoptosis induced by HIV infection 
and exposure to CD95 monoclonal antibody (Cutrona et al, 1999). This was only seen 
by flow-cytometric analysis but not by immunohistochemistry suggesting that the 
protein levels may be too low for detection on tissue sections. This close association 
with CD 10 expression and apoptosis suggests that CD 10 plays a role in regulation of 
lymphocyte survival. In fact, the relationship between CD 10 and apoptosis was recently 
demonstrated in HL-60 human promyelocytic leukaemia cell line, where CD10/NEP 
was induced by exposure to a pro-apoptotic agent jaspakinolide (Cioca & Kitano, 2002).
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Interestingly, CD10/NEP expression in turn, seemed to interfere with the apoptotic 
activity o f the agent, because inhibition o f CD 10, enhanced apoptosis. Also in this study, 
CD 10 expression was partially blocked by a broad-spectrum caspase inhibitor, further 
supporting the association o f CD 10 and apoptosis.
3.3.4 CD10 expression and regulation of apoptosis in AITL
It is possible that aberrant CD 10 expression in neoplastic T-cells in AITL may be an 
indicator o f disturbed apoptotic cell death. Previous studies (Feller, Namikawa, 
Willenbrock, Lee 2003) showed that the proliferating cells were CD4 positive, even in 
cases where CD8 positive cells predominated (Lee, 2003). Our findings showed that 
despite a high proliferation fraction, the CD 10 positive tumour cells, which are greatly 
outnumbered by reactive lymphoid cells and account for only a proportion o f the CD4 
positive lymphoid cells, have a low proliferation fraction. This is analogous to low grade 
B-cell lymphomas such as the follicular lymphoma where prevention o f cell death by 
over-expression o f anti-apoptotic BCL2 protein rather than acquisition of high 
proliferative activity is considered to be the critical molecular event (Harris & Ferry,
2001). An attractive hypothesis is, analogous to follicular lymphoma, AITL is a 
biologically indolent/low grade tumour causing and its development and progression are 
driven by immune deregulation rather than increased tumour load. This is supported by 
the clinical observations suggesting that some patients do respond to 
immunosuppressive treatment (Advani, et al 1997; Murayama, et al 1992; Takemori, et 
al 1999). Elevated serum levels o f Fas/CD95 were detected in AITL, but not in other 
NHL (Yufu et al, 1998). Following the publication o f the results included in this thesis 
(Attygalle et al, 2002), it has been shown that the FDCs and endothelial cells in AITL
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express Fas ligand (FasL) whereas the CD10 expressing tumour T-cells express Fas 
(CD95) and caspase 3, indicating Fas-FasL interaction between the neoplastic T-cell and 
the FDC and suggest that the follicular milieu is necessary for CD 10 expression by 
tumour cells, a feature that may play a functional role in regulating apoptosis (Kim et al, 
2002a).
3.3.5 Concluding remarks
The results o f this part o f the study show that CD 10 is a marker o f neoplastic T-cells in 
AITL. Identification o f a specific marker for the neoplastic T-cells in AITL, for the first 
time, gives us the opportunity to investigate the biology o f this disease with a view to 
devise novel therapeutic approaches.
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Chapter 4
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA 
VERSUS PERIPHERAL T-CELL LYMPHOMA, 
UNSPECIFIED:
DISTINGUISHING HISTOLOGICAL, IMMUNOPHENOTYPIC 
AND MOLECULAR GENETIC FEATURES
4.1 Introduction
Diagnosis and classification o f PTL in lymph nodes is challenging and important as 
different subtypes have different clinical outcomes and may require different treatment 
strategies. Nodal PTLs fall into the three broad categories o f AITL, PTLu and ALCL. 
Diagnosis o f ALCL is relatively easy and beyond the scope o f this study. Distinguishing 
between PTLu and AITL can be much more difficult and often rests on subtle 
morphological and phenotypical differences. As was briefly mentioned in chapter 1, 
section 1.9.3.7, typical cases o f AITL are characterised histologically, by a polymorphic 
infiltrate with or without clusters o f clear cells, a prominent arborising vascular network 
o f HEV, and more specifically by the FDC proliferation which shows a tendency to 
surround HEV (Jaffe & Ralfkiaer, 2001a). However, distinction from reactive conditions 
and PTLu, becomes quite difficult in cases with hyperplastic GCs (“pattern I histology” 
-described in chapter 3) and minimal FDC expansion and in cases with otherwise typical 
(“patterns II-III”) morphology that lack significant FDC proliferation. The evidence in 
support o f those with “pattern I” histology being AITL, comes mainly from the report by 
Ree and co-workers (1998), where 2 cases with hyperplastic GCs and molecular genetic
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evidence o f a monoclonal T-cell population progressed to more typical AITL on 
subsequent biopsy. This would also be consistent with the observations in the previous 
chapter (chapter 3), where the 3 overlapping histologic patterns (I-III) seemed to be 
consistent with a biologic continuum showing a progressive increase CD 10+ neoplastic 
T-cells from patterns I-III. Nevertheless, there appears to be a considerable overlap 
between the morphology o f less typical examples o f AITL and the heterogeneous group 
categorised as PTLu.
The aims in this study are two-fold. The first aim was to compare the histology and 
molecular genetic profiles o f AITL and PTLu.
The second aim was to assess the sensitivity and specificity o f CD 10 expression to 
AITL.
4.2 Results
4.2.1 Tissues used and categorization of subtypes
138 lymph node biopsies (from 138 patients) classified as PTL were retrieved from
departmental archives and the histology and available immunohistochemistry reviewed
and the diagnosis confirmed or revised in each case. The minimum
immunohistochemistry available for review included CD3, CD20 and in most cases,
CD4 CD8, and Ki67. In the cases o f ALCL, CD30, and ALK-1 were also examined. In
order to assess the FDC meshwork, immunohistochemistry was performed for CD21 in
all cases o f AITL and PTLu, and CD23 and CD35 in a limited number o f cases.
Categorisation o f cases were as follows: AITL (n=89), PTLu (n=22), ALCL (n=16; 12
ALK-1 positive and 4 ALK-negative) and nodal involvement by MF (n=l). The cases of
AITL were in turn subcategorized into those with pattern I (n=15), pattern II (n=17) and
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pattern III (n=57) according to the presence o f hyperplastic follicles, regressed follicles 
or absence o f identifiable follicles (refer chapter 3). O f the cases categorised as pattern I, 
the original diagnoses made at our institution were as follows: AITL (n=10); reactive, 
but suspicious for PTL (n=l); PTL, T-zone variant (n=l); PTLu (n=3). In addition to 
these cases o f PTL there were 10 cases that showed the typical morphology o f AITL 
(Figure IE) with effaced lymph node architecture by a polymorphous infiltrate and no 
identifiable residual follicular structures (pattern III histology described in chapter 3), a 
rich arborising vascular network, but only subtle expansion o f the FDC meshwork with a 
tendency to surround vessels (Figure IF). These cases were classified as “AITL/PTL- 
indeterminate”, for the purposes o f the study. The original diagnoses for these 10 cases 
included PTLu (n=6) and AITL (n=4).
4.2.2 Comparison of AITL, AITL/PTL - indeterminate and PTLu
4.2.2.1 Histology
In AITL, “AITL/PTL-indeterminate”, and PTLu, the following features were evaluated 
and compared. On histology, the features examined included, the nature o f the infiltrate 
(polymorphic vs monomorphic), degree o f vascularity (mild, moderate, prominent) and 
the presence or absence o f clusters o f clear cells, the results o f which are given in Tables
4.1 and 4.2. O f the 22 cases o f PTLu reviewed, 2 cases showed an interfollicular pattern 
o f growth (Figure IP) while 3 cases showed features o f the Lennert or lymphoepithelioid 
cell variant (Figure 10). Likewise in AITL, the 15 cases categorized as pattern I showed 
an interfollicular “T-zone” pattern (Figure 1C), while 3 cases with pattern III histology 
showed a prominence o f epithelioid cell histiocytes (Figure 1M)). The latter was also a 
feature in one o f the cases categorized as AITL/PTL-indeterminate (Figure IN). All
134
cases o f AITL and AITL/PTL-indeterminate showed a prominent arborising vascular 
network, while the cases o f PTLu showed a “mild” and occasionally “moderate” degree 
o f vascularity. Clear cells were a feature in 41/89 (46%) cases o f AITL, being more 
frequent in those with pattern III morphology (60%). They were a feature in 7/10 (70%) 
cases o f AITL/PTL-indeterminate, but were not identified in any o f the cases classified 
as PTLu.
Table 4.1. AITL and AITL/PTL-indeterminate: Histology and FDC evaluation
Histology Immunohistochemistry
Subtype 
(Number of 
biopsies
Pattern 
(Number of 
biopsies)
Infiltrate/
Pattern
Vascularity Number of 
biopsies with 
clear 
cells/total
CD21+ FDC meshwork
I (n= 15) Polymorphic/
Interfollicular
Prominent 1/15 (7%) Follicles +/- subtle 
expansion
AITL (n=90) II (n=17) Polymorphic Prominent 6/17(35%) Expanded meshworks 
surrounding vessels
III (n=57) Polymorphic Prominent 34/57 (60%) Expanded meshworks 
surrounding vessels
AITL/PTL- 
indeterminate 
(n=l 0)
III Polymorphic Prominent 7/10 (70%) Subtle expansion within 
close vicinity of and 
surrounding vessels
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; PTL, peripheral T-cell lymphoma; +, 
positive; FDC, follicular dendritic cell.
4.2.2.2 Immunohistochemistry
4.2.2.2.1 Evaluation o f the FDC meshwork
The FDC meshwork in all 3 categories was evaluated using immunohistochemistry 
(Tables 4.1 and 4.2). In AITL, patterns II and III histology, the FDC meshwork showed 
characteristic proliferation with a tendency to surround HEV (Figure IB). In the cases 
categorised as “pattern I” the FDCs was more or less confined to the follicles with subtle 
expansion in some of the follicles (Figure ID). In 4 o f the 10 cases categorized as
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Figure 4.1 Morphology, follicular dendritic cell (FDC) meshwork and CD10 expression 
in AITL, AITL/PTL indeterminate and PTLu.
Panels A and B show an example o f  AITL with typical morphology. (A) Haematoxylin and eosin (H&E) 
stained section o f  a typical (“Pattern 111”) AITL. (B) C D21 highlights the marked expansion o f  FDC.
Panels C and D show “Pattern I” AITL. (C) H&E stained section o f  “Pattern 1” AITL showing 
hyperplastic follicles. The inset shows a high power view o f  the paracortex with a prominence o f  vessels. 
(D) CD21 shows subtle (inset)/no significant expansion o f  FDC.
Panels E and F show an example o f  “AITL/PTL indeterminate”. (E) H&E stained section shows the 
typical morphology o f  AITL with a rich vascular network and a polymorphous infiltrate. (F) CD21 shows 
subtle expansion o f FDC with a tendency to encircle vessels.
Panels G and H show a case o f  PTLu. (G) H&E stained section o f PTLu showing a monomorphic 
infiltrate o f  atypical lymphoid cells. The inset shows a high power view o f  the same. (H) CD21 staining 
shows an example o f PTLu with residual follicles (H, upper panel) and an example with no residual 
follicles (H, lower panel).
(I, J, K and L) CD 10 immunostaining shows numerous CD 10 positive lymphoid cells in a case o f  typical 
AITL (I), “Pattern 1” AITL (J) and AITL/PTL indeterminate (K), and absence o f CD 10 positivity in PTLu 
(L).
Panels M -0 show examples o f  nodal PTL with a lympho-epithelioid/Lennert morphology. (M) H&E 
stained section o f  a case o f  AITL. (N) H&E stained section o f  a case o f  AITL/PTL indeterminate. (O) 
H&E stained section o f a case o f  PTLu.
Panel P shows an H&E stained section o f  a case o f PTLu that showed a monomorphic infiltrate in a 
interfollicular distribution.
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AITL/PTL-indeterminate (see above), CD23 and CD35 expression was also evaluated, 
but showed no expansion o f FDCs in excess of the subtle increase observed with CD21. 
In the 22 cases o f PTLu, the FDC was either absent or present in the form of residual or 
compressed follicles (Figure 1H).
Table 4.2. PTLu: histology and FDC evaluation by immunohistochemistry
Case
no
Histology Immunohistochemistry
Infiltrate/
Pattern
Vascularity Clear cells CD21+ FDC meshwork
1 Polymorphic Mild Absent Follicles
2 Polymorphic Mild Absent Follicles
3 Polymorpphic
(LEL)
Mild Absent Compressed follicles
4 Monomorphic Mild Absent Compressed follicles
5 Polymorphic Mild Present Compressed follicles
6 Monomorphic Mild Absent Follicles
7 Monomorphic Mild Absent Compressed follicles
8
Monomorphic/
interfollicular
Mild Absent Follicles
9 Polymorphic Mild Absent Compressed follicles
10 Polymorphic Mild Absent Follicles
11 Polymorphic Mild Absent Absent
12 Polymorphic Mild Absent Follicles
13 Polymorphic Mild Absent Compressed follicles
14 Monomorphic Mild Absent Follicles
15 Polymorphic Mild Absent Follicles
16 Polymorphic
(LEL)
Mild Absent Follicles
17 Polymorphic
(LEL)
Mild Absent Absent
18 Polymorphic/
Interfolliclular
Mild Absent Follicles
19 Monomorphic Mild Absent Follicles
20 Polymorphic/
Interfollicular
Mild Absent Follicles
21 Polymorphic Mild Absent Follicles
22 Monomorphic Moderate Absent Compressed follicles
Abbreviations: +, positive; FDC, follicular dendritic cell; LEL, lymphoepithelioid morphology.
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4.2.2.3 Molecular genetics
4.2.2.3.1 EBER-ISH and immunoglobulin heavy chain (IgH) gene PCR 
EBER-ISH was used to assess for the presence o f EBV-infected lymphoid cells. I f  only 
an occasional EBER-positive cell could be identified, this was interpreted as negative for 
expansion o f EBV-infected cells. The results are summarized in Figure 4.2 and Table 
4.3, and show that expansion o f  EBV infected B-cells was observed in AITL (81%) and 
AITL/PTL-indeterminate (57%) but not in PTLu. PCR for IgH gene rearrangement 
(Table 4.3) showed a monoclonal/oligoclonal pattern (1-2 dominant bands/3-4 dominant
Percentage of 
biopsies with EBV 
positive cells
AITL Indeterminate PTLu 
Figure 4.2 Percentage of biopsies with EBV-positive cells
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; Indeterminate, AITL/PTL indeterminate; 
PTLu, peripheral T-cell lymphoma, unspecified; EBER+, Epstein Barr virus encoded RNA positive 
bands) in 19% of AITL but no dominant band/bands were identified in the cases of
AITL/PTL-indeterminate or PTLu.
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Table 4.3. AITL, AITL/PTL-indeterminate and PTLu: EBER-ISH and PCR for IgH gene 
re-arrangement.
Nodal PTL 
subtype Pattern Number of EBER+ 
biopsies/ "Total (%)
PCR-IgH 
Mono-oligoclonal/ 
"Total (%)
I 7/10 (70%) 0/15
AITL
II 11/14(85%) 47/58 
(81%)
2/15 14/73 
(13%) (19%)
III 27/34 (80%) 12/43
(28%)
AITL/PTL-
indeterminate III 4/7 (57%) 0/9
PTL
unspecified 0/10 0/22
Abbreviations: PTL, peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EBER, Epstein Barr 
virus encoded RNA; +, positive; PCR, polymerase chain reaction; IgH, immunoglobulin heavy chain gene 
# Total number o f  cases that showed a conclusive result
4.2.2.3.2 PCR for T-cell receptor y  (TCRy) gene rearrangement
The PCR results are given in Figure 4.3 and Table 4.4. The presence o f 1-2 dominant 
bands and 3-4 dominant bands was interpreted as a monoclonal and oligoclonal result 
respectively. A monoclonal or oligoclonal result was obtained in 90% of the cases of 
AITL, 88% AITL/PTL-indeterminate and 59% o f the cases o f PTLu. This difference 
(between AITL and PTLu) was statistically significant (p=0.0006). There was no 
significant difference in the proportion o f cases with an oligoclonal result.
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Percentage of cases showing 
an oligoclonal/monoclonal PCR 
result for T-cell receptor y gene 
rearrangement
100
8 0
6 0
|  Monoclonal 
□  Oligoclonal
4 0
20
AITL Indeterminate PTLu
Figure 4.3 Percentage of cases showing an oligoclonal/monoclonal PCR result for T-cell 
receptor y gene rearrangement.
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; Indeterminate, “AITL/PTL indeterminate; 
PTLu, peripheral T-cell lymphoma, unspecified
Table 4.4: PCR for T-cell receptor y  gene rearrangement
Abbreviations: PTL, peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; PCR,
Nodal PTL 
subtype Pattern
TCRy gene 
PCR: mono­
clonal/ *Total 
(%)
TCRy oligo- 
clonal/T otal
(%)
PCR-TCRy gene PCR: mono- 
oligoclonal/ Total* (%)
11/14 3/14 14/14(100% )
I (79%) (21%)
AITL 14/16 66/87 0/16 12/87 14/16(88% ) 78/87(90% )
11 (88%) (76%) (14%)
41/57 9/57 50/57 (88%)
III (72%) (16%)
AITL/PTL- 7/8 0/8 7/8 (88%)
intermediate 111 (88%)
PTL 12/22 1/22 13/22 (59%)
unspecified (55%) (4%)
polymerase chain reaction; TCRy gene 
# Total number o f cases that showed a conclusive result
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4.2.3 CD10 expression in nodal peripheral T-cell lymphomas
To investigate for CD 10 expression by T-cells, single-layered immunohistochemistry 
was performed in 137 biopsies, supplemented by CD20/CD10 double-layered 
immunohistochemistry in selected biopsies, and evaluated independently by two 
Pathologists (A.D.A and A.D), without knowledge o f the sub-type o f the individual 
case/biopsy being assessed i.e. blind. Seventy-eight o f the 88 (89%) biopsies o f AITL 
had CD 10+ T-cells (Figure II and J). O f the 10 cases categorized as AITL/PTL- 
indeterminate, 6 had CD 10+ T-cells (Figure IK). The latter was not identified in any of 
the cases o f PTLu (0/22) (Figure 1L) or ALCL (0/16). The single case o f nodal 
involvement by MF contained many CD 10+ T-cells, consistent with the neoplastic 
population. In addition to the cases mentioned, 10 reactive lymph nodes were also 
double-stained with CD20/CD10, but no CD 10+ T-cells were identified.
Table 4.5 CD10 expression in nodal peripheral T-cell lymphomas
Nodal PTL subtype Pattern Number of biopsies with 
CD10+ T-cells / Total (%)
I 15/15 (100%)
AITL
II
78/88 (89%)
15/17(88%)
III 48/56 (86%)
AITL/PTL- indeterminate III 6/10(60%)
PTL unspecified 0/22
ALCL 0/16
Secondary node involvement by 
mycosis fungoides 1/1 (100%)
Abbreviations: PTL, peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; 
ALCL, anaplastic large cell lymphoma; +, positive
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4.3 Discussion
4.3.1 Frequency of AITL
PTLu includes a heterogenous group o f yet undefined entities, whereas AITL is believed 
to represent a distinct clinico-pathological entity that accounts for approximately 15- 
20% o f all nodal PTLs (1997). Although most cases in this study are from a referral 
practice and thus probably not entirely representative, AITL (patterns I, II and III) seems 
much more frequent than is reported in the literature, and accounts for approximately 
65% of nodal PTLs reviewed.
4.3.2 Histologic features of AITL versus PTLu
Clear cells, once considered to be an important feature o f AITL (Nathwani & Jaffe, 
1995), are no longer regarded as essential for diagnosis (Jaffe & Ralfkiaer, 2001a). In 
the present study, clear cells were observed in <50% o f cases o f AITL. They were 
present in the 7 o f 10 cases o f AITL/PTL-indeterminate but were not observed in any 
cases categorised as PTLu. Although the assessment in this study was subjective, the 
rich arborising-vascular network observed in cases o f AITL and AITL/PTL- 
indeterminate was not seen in any o f the cases o f PTLu.
4.3.3 AITL with hyperplastic follicles (pattern 1) versus T- zone 
variant of PTLu
Diagnosis of cases o f AITL that fulfill the defined criteria laid down by the WHO (Jaffe 
& Ralfkiaer, 2001a) is fairly straightforward. Although for many years, the presence of
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hyperplastic follicles was thought to exclude a diagnosis o f AITL, the cases described by 
Ree and co-workers (1998) showing hyperplastic follicles, have been included as AITL 
in the WHO classification (Jaffe & Ralfkiaer, 2001a). It is believed that such cases are 
rare and may show progression to typical AITL (Jaffe & Ralfkiaer, 2001a). In the 
current study these cases (pattern I) account for 15/89 (17%) cases o f AITL, suggesting 
that the “rarity” reported, may in part be due to difficulty in distinguishing it from 
reactive conditions and the T-zone variant o f PTLu. It is in fact impossible to 
distinguish “T-zone” PTLu - a histologic variant that is described as having an 
interfollicular growth pattern with preserved or hyperplastic follicles, a polymorphous 
infiltrate +/- clusters o f clear cells, scattered RS-like cells and prominent HEV (Ralfkiaer 
et al, 2001) - from AITL “pattern I”, and calls to question whether they are in fact the 
same entity -  i.e. early AITL. Clinically there is a clear overlap between AITL and T- 
zone variant o f PTLu, formerly known as T-zone lymphoma (Helbron et al, 1979) and at 
a cytogenetic level, trisomy 3, the most frequent abnormality described in AITL, has 
also been reported in “T-zone lymphoma” (Schlegelberger et al, 1994a). In the current 
study, CD 10+ T-cells were present in all 15 cases with “pattern I” histology, a 
phenomenon that was observed in almost 90% o f typical AITL, but not in a single case 
categorized as PTLu, again supporting the view that many o f these fall within the 
spectrum o f AITL.
4.3.4 AITL with a prominence of epithelioid cells versus 
lympho-epithelioid variant of PTLu
Lymphoepithelioid or Lennert lymphoma was initially described by Karl Lennert
(1968) prior to the concept o f immunophenotyping and thus included a heterogeneous
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group of entities characterised by a prominence o f epithelioid histiocytes (Kim et al, 
1980). It is now regarded as a histological variant o f PTLu, and not as a specific subtype. 
In the current study the presence o f numerous clusters o f epithelioid hisiocytes was 
noted in 3 cases o f AITL, in 1 case categorised as AITL/PTL-indeterminate and in 3 
cases o f PTLu, confirming the view that this histologic appearance is not specific to any 
given subtype (Kim et al, 1980;Patsouris et al, 1990). Gisselbrecht and co-workers 
(Gisselbrecht et al, 1998) show that there is an overlap in survival curves in patients 
with AITL and the lymphoepithelioid variant o f PTLu and comment on the difficulty in 
distinguishing the two entities morphologically, a problem that is also reported by 
Nakamura and Suchi (Nakamura & Suchi, 1991). The overlap is also reported at a 
genetic level, with the frequent occurrence o f trisomy 3 in both entities (Schlegelberger 
et al, 1994a).
4.3.5 EBV infection and dominant B-cell clones in AITL and PTLu
Although secondary EBV infection has been described in PTLu (Quintanilla-Martinez et 
al, 1999;Zettl et al, 2002), none o f the PTLu in the present study showed evidence of 
expansion o f EBV-infected lymphoid cells. However, 81% o f AITL and 67% of cases of 
AITL/PTL-indeterminate showed EBV-infected lymphoid cell. This frequency is not as 
high as that documented in some studies that report EBV-positivity in over 95% of the 
cases o f AITL (Anagnostopoulos et al, 1992;Weiss et al, 1992). The presence/absence 
of EBV infected B-cells in the present study correlates well with the outgrowth o f 
dominant B-cell clones in 19% o f AITL and its absence in PTLu.
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4.3.6 Detection of a dominant T-cell clone: AITL versus PTLu
T-cell clonality analysis enabled detection o f a monoclonal or oligo-clonal T-cell 
population in approximately 90% o f AITL whereas this was possible in approximately 
59% o f PTLu. Although the reason for this difference remains unknown, it may reflect 
the presence o f multiple dominant T-cell clones /oligo-clones in AITL, at least one of 
which would bind the primers used for clonality analysis and give rise to a dominant 
band. There was however no statistically significant difference in the frequency o f an 
oligoclonal result between the two groups. The identification o f a monoclonal T-cell 
population in all 14 “pattern I” cases that had a conclusive PCR result may reflect the 
fact distinction from reactive lymphoid hyperplasia and a definite diagnosis o f T-cell 
lymphoma in these cases is often difficult without the support o f a T-cell clonal 
molecular genetics result. Although at the time o f performing this work the BIOMED-2 
protocols (van Dongen et al, 2003) were not published, it would be useful to evaluate 
these cases using the BIOMED-2 TCRy, and (if the DNA quality is satisfactory) TCRp 
primer sets, to validate these results.
4.3.7 AITL/PTL- indeterminate or AITL?
The 10 cases categorised as AITL/PTL indeterminate showed morphologic similarity to 
AITL with a polymorphous infiltrate and pronounced vascularity. Clusters o f clear cells, 
a characteristic, but not universal feature o f AITL were also present in 7/10 cases. 
Although they lacked the florid FDC proliferation expected with “pattern III” histology, 
the FDCs present did show a tendency to surround vessels, yet another feature o f AITL.
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As in AITL, the expansion o f EBV-infected B-cells was a feature in most cases.
However, despite the evidence o f expanded EBV infected B-cells, there was no evidence 
of outgrowth o f a dominant B-cell clone in these cases. The pattern o f T-cell clonality in 
these cases was similar to AITL, with a dominant clone/clones being identified in a very 
high proportion (88%) o f cases. CD 10+ T-cells were also a feature in the 6/10 o f cases, a 
feature not observed in PTLu. Overall the features o f AITL/PTL-indeterminate suggest 
that they fall within the spectrum of AITL, rather than within the heterogeneous group of 
PTLu. The lower percentage o f CD 10 expression in these cases maybe due to the lack of 
the expected degree o f FDC proliferation seen in more typical cases with similar 
“pattern III” morphology.
4.3.8 CD10 expression in nodal T-cell lymphomas
CD 10 positive T-cells were observed in 86% o f typical AITL (patterns II and III) but not 
in PTLu or ALCL. This phenomenon seems to be a sensitive marker o f AITL. The 
specifity would depend on how the cases classified as AITL, pattern I histology and 
AITL/PTL-indeterminate are categorised. There is some recent evidence (Ree et al,
1998) that suggests that those cases with pattern I histology represent early AITL, and 
the evidence in this part o f the study suggests that the AITL/PTL-indeterminate cases 
fall within the spectrum o f AITL. If so, in the assessment o f nodal PTLs, CD 10 
expression is not only approximately 85% sensitive but also 100% specific to AITL.
CD 10 expression by the neoplastic cells in secondary nodal involvement by MF was an 
unexpected finding. Although there is a single report o f CD 10 expression in SS 
(Chubachi et al, 1994), this is not a recognized feature o f MF. Nevertheless, as the 
clinical scenario and histology is distinct from AITL, CD 10 expression in this case
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should not lead to a mistaken diagnosis o f AITL. The only mention o f CD 10 expression 
in nodal PTLs in the literature is the report by de Leval, et al (2001) describing a nodal 
PTL with a follicular growth pattern. These cases probably represent early AITL, rather 
than a distinct subtype o f PTL.
Although Cook and co-workers (2003) report the occurrence o f a small subset o f 
reactive CD 10+ T-cells in some reactive lymph nodes and B-cell lymphomas, we did not 
identify any CD 10+ lymphoid cells that could be interpreted as presumptive T-cells, in 
reactive lymph nodes. In their study Cook and co-workers use flow-cytometry and PAX- 
5/CD10 double-layered immunohistochemistry. The combination o f a nuclear stain 
(PAX-5) and a membrane stain (CD 10) may be superior to the method used in our study 
i.e. two membrane stains (CD20 and CD 10), when trying to identify small numbers o f 
CD 10+ T-cells.
4.3.9 Is AITL underdiagnosed?
If the cases o f AITL/PTL-indeterminate are included as AITL, the latter accounts for 
72% o f all nodal PTL reviewed, a figure far in excess o f that reported in the literature. 
Although as mentioned previously this may represent a sample bias, it may partly be due 
to the fact that many cases o f AITL that do not show “typical” morphology are probably 
categorised as PTLu or misdiagnosed as reactive. It is interesting to note that a case 
similar to that described by Macon and co-workers (Macon et al, 1995) as “paracortical 
nodular T-cell lymphoma”, believed at the time to be an unusual variant PTL, has 
recently (2004) been diagnosed as AITL by WR Macon and A Dogan (Figure 4.4 - 
personal communication). This example shows “pattern II” morphology, with, regressed 
follicles, increased vascularity and clusters o f clear cells (T-cells), and scattered RS-like
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B- cells amidst a polymorphic background (Figure 4.4). There is immunohistochemical 
evidence o f FDC expansion, but the T-cells are CD 10 negative. Rudiger and co-workers 
(Rudiger et al, 2000) describe 9 cases of PTL with a distinct perifollicular growth 
pattern showing a prominence o f HEV, regressed follicles and clusters of cells with pale 
to clear cytoplasm in a marginal zone distribution. In some of these cases, a close 
association between the HEV and clear cells was noted and in the majority, scattered 
Hodgkin-like cells were noted in the background. EBV-infected by-stander B-cells were 
however noted in only 1/8 cases. Dense FDC meshworks identified by CD23 staining, 
was present in the follicle centers o f all 9 cases described. Although CD23 highlights 
only a subset o f the FDCs, and there is no proof that CD21 or CD35 is superior in the 
assessment o f FDC expansion in AITL (Bagdi et al, 2001), it may be useful to assess the 
FDC meshworks in these cases with CD21 and may be CD35. The question remains 
whether at least some of these cases represent AITL.
Figure 4.4. Histology of case 
described as 
“paracortical 
nodular T-cell 
lymphoma”, with 
revised diagnosis 
of AITL.
Reproduced with permission
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4.3.10 Concluding remarks
In conclusion, CD 10 expression seems to be a sensitive and specific marker o f the 
disease and a useful adjunct to the diagnosis o f AITL. The findings in this study suggest 
that the diagnostic criteria for AITL need to be revised, as the existing pathological 
criteria apply only to the “typical” histology that probably accounts for approximately 
80% o f all cases.
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Chapter 5
CD10 EXPRESSION IN 
EXTRANODAL DISSEMINATION OF 
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
5.1 Introduction
AITL is a nodal PTL characterised by systemic disease and prominent constitutional 
symptoms (Frizzera et al, 1974;Siegert et al, 1992;Siegert et al, 1995). Although 
generalised lymphadenopathy is a prominent feature, clinical evidence o f extranodal 
involvement is often present at diagnosis. These include hepato-splenomegaly seen in 
50-70%, skin rash in 50%, pleuro-pulmonary involvement in 40% and bone marrow 
involvement in 60-80% o f patients (Frizzera et al, 1974;Ghani & Krause, 1985;Pautier 
et al, 1999;Siegert et al, 1992;Siegert et al, 1995;Starke et al, 1983;Weisenburger et al, 
1977). The almost universal occurrence o f lymphadenopathy permits a diagnosis based 
on examination o f a lymph node biopsy and extranodal sites, other than bone marrow are 
rarely subjected to histologic examination. However occasionally an extranodal site will 
be biopsied either as a diagnostic procedure or to examine the extent o f tumour 
involvement and rule out infectious or inflammatory conditions. In these situations 
diagnosis can be very challenging as the conventional criteria based on alterations in 
lymph node biopsies are not applicable. Histologically, involved lymph nodes show 
partial or total obliteration o f the normal architecture by a polymorphic infiltrate o f 
lymphocytes, plasma cells and eosinophils, prominent proliferation o f venules and 
expansion o f the FDC meshwork (Frizzera, 2001;Nathwani & Jaffe, 1995). Collections
of cells with pale to clear cytoplasm, described as being typical for AITL is not a 
consistent finding and in many instances cytological features o f malignancy are not 
readily identifiable (Jaffe & Ralfkiaer, 2001a). Therefore, despite histologic criteria, 
definite diagnosis is often difficult even on lymph node biopsy, leading to an error in 
initial diagnosis in over 50% o f the cases (refer chapter 3), further complicating 
histologic interpretation o f an extranodal biopsy.
In chapters 3 and 4, in the study o f  lymph nodes in AITL, we showed that the neoplastic 
T-cells in most cases can be identified by CD10 expression, a feature absent in other 
nodal PTLs. Early and accurate diagnosis o f AITL in lymph nodes can thus be achieved 
by immunostaining for CD 10. CD 10 expression if maintained at extranodal sites of 
involvement would serve as a phenotypic marker and a very useful diagnostic tool. The 
aim of the present study was to investigate whether the expression o f CD 10 by 
neoplastic T-cells is maintained in extranodal sites.
5.2 Results
5.2.1 Tissues used in this study
Seventy-eight cases o f AITL diagnosed on clinical, histologic, immunophenotypic and 
molecular genetic criteria on lymph node biopsy were retrieved from the archives o f the 
Department o f Histopathology, University College London Hospital. O f these, 10 
(referral) cases included biopsies o f involved extranodal sites and were selected for 
study.
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5.2.2 Clinical features
The clinical presentations and the initial diagnoses at referral are summarised in Table 
5.1. Among the 10 cases studied, there were 5 females and 5 males between the ages of 
33 and 82 years. In 5 o f the 7 cases where clinical history was available, systemic 
symptoms were prevalent at some time during the course o f the disease. Six cases had 
involved bone marrow trephines, 2 had pulmonary involvement, 1 had tonsillar and 
caecal involvement while 2 cases had involved nasopharyngeal biopsies. Lymph node 
biopsies were performed for initial diagnosis in 9 o f the 10 cases, while in 1 case (case 
2) a lung biopsy was followed 2 years later by a lymph node biopsy. An initial diagnosis 
o f AITL was made in only 5 o f  the 10 cases.
5.2.3 Histology
5.2.3.1 Lymph nodes
Lymph node biopsies in cases 1-8 and 10 conformed to that described as typical for 
AITL, with effacement o f architecture by a polymorphic infiltrate comprising, small 
lymphocytes and transformed blasts, plasma cells, histiocytes and eosinophils within a 
prominent vascular network (Figure 5.3A). A proportion o f the lymphoid blasts in cases
1,2 and 4 had pale to clear cytoplasm. Follicles were either not identifiable or regressed 
with concentrically arranged FDCs. The pattern o f involvement in case 9, was similar to 
that described by Ree and co-workers (1998), with preserved hyperplastic follicles, and 
a paracortical infiltrate similar to that seen in the other cases.
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Table 5. 1 Clinical features, site of biopsy and initial diagnosis
Case
no
Age/sex Clinical presentation Site of biopsy Initial diagnosis
1 33 F N o t av a ilab le L ym ph node 
T onsil
C aecum  (1 y ea r a fte r 
d iag n o sis)
A ITL
N o t ava ilab le
R ecurren t lym phom a or early 
in flam m atory  bow el d isease
2 75F S hortness  o f  b rea th  and  genera lised  
ly m phadenopathy . C h est X -ray  show ed  an  
ex p a n d in g  d isc re te  lesion  in  th e  righ t upper 
lobe
Lung
Ingu ina l lym ph  node (2 
years  a fte r lung  b iopsy)
R eactive lym phoid  hyperp lasia  
H odgk in  lym phom a
2-years la te r  she  re-p resen ted  w ith  m alaise , 
w eigh t loss, h epa to sp lenom ega ly  and 
lym phad en o p a th y
B one m arrow S tag ing  -?invo lved
3 82M B -sy m p to m s, an aem ia , genera lised  
ly m p h ad en o p a th y , sp lenom egaly .
Lym ph node 
B one m arrow
R eac tive -?connec tive  tissue 
d iso rder
S tag ing  - ? invo lved
4 43F L ym p h ad en o p a th y
2 yea rs  la ter, p resen ted  w ith  pneu m o n itis
L ym ph node 
L ung
A IT L
? invo lved  by A ITL
5 48M N o t av a ilab le L ym ph node 
B one m arrow
A ITL
S tag ing  - ? invo lved
6 63F P resen ted  w ith  pu lm o n ary  em b o lism  and 
su b seq u en tly  show n  to  have  sp lenom egaly  and 
ce rv ica l and  ab d o m in a l ly m phadenopathy
C erv ica l lym ph  node 
B one m arrow
A IT L  o r PT L  
S tag ing  - ? invo lved
7 67M B ila te ra l ax illa ry  and  ingu inal 
ly m phadenopa thy
Ingu ina l lym ph  node 
B one m arrow
H igh g rade N H L  
S tag ing  -?invo lved
8 58M G enera lised  lym p h ad en o p a th y  and  sk in  rash A xillary  lym ph node 
B one m arrow
A ITL
S tag ing  -in v o lv e d
9 81F N ot ava ilab le C erv ica l lym ph  node 
N asopharynx
N H L
N H L
10 59M L arge m ass  in  p o st-n asa l sp ace  and  m ultip le  
en larged  ce rv ica l lym ph  nodes
C erv ica l lym ph node 
N asopharynx
L ennert’s lym phom a 
L en n ert’s lym phom a
Abbreviations: F, female; M, male; AITL, angioimmunoblastic T-cell lymphoma; PTL, peripheral T-cell
lymphoma; NHL, non-Hodgkin’s lymphoma.
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5.2.3.2 Extranodal sites
The histologic features o f extranodal sites o f involvement o f each case are summarised 
in Table 5.2. The features ranged from a non-specific mixed infiltrate (bone marrow 
biopsies in cases 5,6 and 7) to a polymorphic infiltrate with clear cells in close proximity 
to a prominent arborizing vascular network (tonsillar and caecal biopsies in case 1) 
(Figure 5.1 A, B and G). All 6 involved bone marrow trephines showed focal 
involvement (paratrabecular in 4 cases). Two cases showed an increase in vascularity 
(Figure 5.2G). Three involved trephines (cases 5,6, and 7) showed a mixed infiltrate of 
small and large lymphoid cells. One case (case 3) had evidence o f regressed follicles in 
close association with the neoplastic infiltrate, while the 2 biopsies with increased 
vascularity (case 2 and 8) comprised foci with small and large lymphocytes, epithelioid 
histocytes, fibroblasts and eosinophils amidst the vessels imparting a “granulomatous” 
appearance (Figure 5.2G).
5.2.4 Immunohistochemistry
Single-layered immunohistochemistry for CD3, CD20, CD 10 and CD21 was performed 
in all cases and double-layered immunohistochemistry using CD20/CD10 in selected 
cases. In order to demonstrate CD 10 expression in neoplastic T-cells, CD 10 and 
CD20/CD10 sections were compared with sequential CD3 immunostained sections.
5.2.4.1 Lymph nodes
The infiltrate comprised a predominance o f CD3 positive T-cells (Figure 5.3C). In cases 
1-8 and 10, CD 21 highlighted the hyperplastic FDC meshwork that extended into the 
paracortex to surround HEV (Figure 5.3B). In case 9, CD21 immunostaining was more
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or less confined to the hyperplastic follicles identified on histology, with only subtle 
extensions into the paracortex. Single layered immunohistochemistry with CD 10 and 
double staining with CD20/CD10 highlighted a population o f CD 10 positive, CD20 
negative lymphoid cells in 8 cases (cases 3-10) (Figure 5.3D-F). Consistent with the 
results o f chapter 3, examination o f sequential sections immunostained for CD3 and 
CD20/CD10 showed that these CD 10 positive cells were the neoplastic T-cells. The 
distribution o f these cells was similar to that o f the expanded FDC meshwork. In case 9 
that had hyperplastic follicles, the CD 10 positive T-cells were situated at the outer rim of 
the follicle spilling into the paracortex. No CD 10 positive T-cells were identified in the 
lymph node biopsy in case 2. CD 10 expression could not be investigated in the lymph 
node biopsy in case 1 as no spare material was available.
§.2.4.2 Extranodal sites
CD3 immunostaining highlighted a marked T-cell infiltrate in all cases (Figure 5.1 D 
and I, Figure 5.2D and I and Figure 5.2H). The details o f CD21 expression and CD 10 
expressing T-cells are given in Table 5.2. At one end o f the spectrum, CD21 
immunostaining showed mild expansion o f the FDC meshwork as in the tonsillar and 
caecal biopsies o f case 1 (Figure 5.1C and H). Focally, the FDCs surrounded the venules 
in these biopsies. This feature was subtle but nevertheless present in the lung biopsy of 
case 2 (Figure 5.2C). At the other extreme there were no CD21 positive FDC 
meshworks in 5 o f the 6 bone marrow biopsies (Figure 5.2H). In all other biopsies the 
FDC meshwork highlighted either hyperplastic or regressed follicles but showed no 
expansion (Figure 5.3G). CD 10 immunostain and CD20/CD10 double immunostain 
highlighted CD 10 positive, CD20 negative lymphoid cells corresponding to T-cells in all
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sites except in the bone marrow (Figure 5 .IE, F, J and K, and Figure 5.2E and F). In the 
bone marrow, the presence o f non-neoplastic haematopoietic precursors and the subtle 
nature o f involvement made assessment o f CD 10 positivity o f the neoplastic cells a little 
more difficult (Figure 5.2K). Nevertheless after careful comparison with morphology 
and CD3 immunostain, CD 10 expression by neoplastic T-cells, could be identified only 
in one involved bone marrow trephine (Figure 5.31). CD 10 expression in all involved 
extranodal sites correlated well with the presence and distribution o f FDCs (Figures 5.2,
5.2 and 5.3). In those cases where the FDCs showed minimal expansion/sprouting (lung 
biopsies in cases 2 and 4, bone marrow biopsy in case 3 and nasopharyngeal biopsy in 
case 9), CD 10 positive T-cells were seen at the edge o f the follicle spilling into the 
adjacent interfollicular region (Figure 5.31).
5.2.5 In situ hybridisation for EBV-EBER
EBER-ISH was performed on lymph nodes in 2 -  10. Lymph nodes in cases 2-8 and 10 
showed hybridisation for EBV- EBER in a subset o f cells. Case 9 was EBER-ISH 
negative. EBER-ISH performed on the caecum in case 1 and the nasopharyngeal biopsy 
in case 9 was negative.
5.2.6 PCR for TCRy chain gene
The results o f PCR for TCRy chain gene are shown in table 5.2. All but one case with 
good quality DNA showed either a single or two distinct bands, consistent with 
monoclonal T-cell population. Case 1 showed 3 bands and was interpreted as being 
biclonal/oligoclonal.
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Table 5.2 Summary of histology, immunophenotypic profile and T-cell clonality
analysis of involved extranodal biopsies____________________________________ _
Case Extranodal Histology Immunohistochemistry TCR PCR
no site Follicles Vascularity Clear CD21+ FDC CD10+
cells meshwork T-cells
1 Tonsil Occasional
regressed
Rich
network
Present Expanded 
with sprouts 
encircling 
vessels
Numerous Not done
Caecum N o
identifiable
follicles
Rich
network
Present Expanded 
with sprouts 
encircling 
vessels
Numerous Oligoclonal
2 Lung Hyperplastic Inter-
follicular
increase
Absent Highlights 
follicles; one 
focus
expanded with 
sprouts
Many Monoclonal 
(same size 
band as lymph 
node)
Bone
marrow
No
identifiable
follicles
Increased Absent Absent Absent Monoclonal 
(same size 
band as lymph 
node and lung)
3 Bone
marrow
Regressed
follicles
N o increase Absent Highlights
regressed
follicles
Present Poor DNA
4 Lung No
identifiable
follicles
Increased Present Highlights 
follicles; no 
sprouts
Present Monoclonal 
(same size 
band as lymph 
node)
5 Bone
marrow
No
identifiable
follicles
N o increase Absent Absent Absent Poor DNA
6 Bone
marrow
No
identifiable
follicles
No increase Absent Absent Absent Monoclonal 
(same size 
band as lymph 
node)
7 Bone
marrow
No
identifiable
follicles
N o increase Absent Absent Absent Monoclonal 
(same size 
band as lymph 
node)
8 Bone
marrow
No
identifiable
follicles
Increased Absent Absent Absent Not done
9 Nasopharyn­
geal biopsy
Hyperplastic Inter-
follicular
increase
Absent Highlights
follicles
Present Inconclusive
10 Nasopharyn­
geal biopsy
No
identifiable
follicles
Increased Absent Expanded 
with sprouts 
encircling 
vessels
Present Monoclonal
Abbreviations: FDC, follicular dendritic cells; TCR, T-cell receptor y chain gene; PCR, polymerase chain
reaction
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Figure 5.1 Histology, follicular dendritic cell meshwork and CD10 expression in biopsies of 
caecum and tonsil in case 1.
Panels A-F show the sections o f  the caecum and panels G-K show sections o f  the tonsil.
(A and B) Haematoxylin and eosin (H&E) stained section o f caecum showing a polymorphous infiltrate 
with prominent vascularity and clear cells (A, inset and B). (C) C D21 highlights the follicular dendritic 
cell (FDC) meshwork which is mildly hyperplastic (D) CD3 stain shows numerous T-cells (E) CD 10 
highlights some lymphoid cells. (F) CD20/CD10 double stain shows many CD 10 (blue) positive cells that 
are negative for CD20 (brown) consistent with T-cells.
(G) H&E stained section o f  tonsil shows a similar appearance to that seen in the caecal biopsy. (H) C D 21 
shows subtle FDC expansion. (I) CD3 highlights numerous T-cells. (J) CD 10 shows many CD 10 positive 
lymphoid cells. (K) CD20/CD10 double stain shows numerous CD 10 positive (blue) cells, similar to the 
caecal biopsy and consistent with T-cells.
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Figure 5.2. Histology, follicular dendritic cell (FDC) meshworks, CD10 positive T-cells and 
gel image of T-cell receptor gene rearrangement PCR of biopsies of lung and 
bone marrow of case 2.
Panels A-F shows lung biopsy, panels G-K show sections o f  bone marrow and panel L shows gel image o f  
T-cell receptor y gene PCR.
(A and B) Haematoxylin and eosin (H&E) stained section shows a focus with a dense infiltrate which on 
high power (B) is seen to have a rich vascular network amidst a polymorphous infiltrate that includes 
eosinophils. (C) CD21 stain o f  the same focus shows subtle FDC hyperplasia. (D) CD3 shows numerous 
lymphoid cells in this area. (E, F G) CD 10 highlights many lymphoid cells (E), and CD20/CD10 double 
stain shows numerous CD 10 positive (blue) cells, similar to the caecal biopsy and consistent with T-cells. 
(G)H&E stained section showing involved focus in bone marrow. (H) CD21 stain showing a complete 
absence o f  FDC. (1) CD3 higlights numerous T-cells in involved area (J and K) CD 10 stain showing the 
same area highlights neutrophils and stroma, but the lymphoid cells are negative (K).
(L) Gel image o f T-cell receptor y gene PCR o f lymph node (left lane), bone marrow (middle) and lung 
(right) biopsies, each showing 2 dominant bands o f  identical size.
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Figure 5.3. Histology, follicular dendritic cell (FDC) meshwork and CD10 positive T-cells 
in biopsies of lymph node and bone marrow of case 3.
Panels A-F show sections o f  the lymph node and panels G-l show sections o f  the bone marrow.
(A) Haematoxylin and eosin stained section shows features o f  AITL. (B) CD21 highlights the markedly 
expanded FDC meshwork. (C) CD3 shows numerous T-cells. (D) CD 10 highlights many lymphoid cells. 
(E and F) CD20/CD10 double staining shows many CD 10 positive (blue) lymphoid cells that are CD20 
(brown) negative, consistent with T-cells.
(G)CD21 highlights a follicle (H) CD3 shows many T-cells. (1) CD 10 stain shows many CD 10 positive 
lymphoid cells. I, inset, shows these cells at high power.
; > : y £ v  ‘
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5.3 Discussion
5.3.1 Diagnosis of AITL in extranodal sites
The diagnosis o f  AITL is based on histological examination o f  a lymph node and 
requires demonstration o f architectural, cytological and immunophenotypic changes 
often combined with molecular genetic analysis (Frizzera, 2001;Jaffe & Ralfkiaer, 
2001a). O f the morphologic features described as being typical for AITL, a polymorphic 
infiltrate and prominent HEV are rather non-specific, and shared by reactive conditions 
and other lymphomas. Clear cells, considered characteristic, are present in less than half 
the cases (see chapter 4). In practice, it is the proliferation o f FDCs, best appreciated by 
immunohistochemistry, and its association with vessels, that is most specific, and 
ultimately helps to distinguish AITL from PTLu (Jaffe & Ralfkiaer, 2001a;Leung et al, 
1993). However, this pattern o f FDC hyperplasia may be subtle if present at all, and 
follicular hyperplasia, once thought to exclude AITL, could be a prominent feature 
(Kojima et al, 2001;Ree et al, 1998). Thus, except when changes are florid, specific 
histologic diagnosis can be quite difficult, even on lymph node biopsy, requiring 
correlation with immunohistochemistry, molecular genetics and importantly the clinical 
presentation (see chapter 3). This difficulty also questions the diagnostic accuracy o f 
early reports o f extranodal involvement, when AITL was believed to be an atypical 
reactive process, rather than a lymphoma, and diagnosis was purely on morphologic 
grounds, with no resort to immunohistochemistry or molecular genetic evidence o f T- 
cell clonality. Nevertheless, in both early and more recent reports o f visceral 
involvement by AITL, the histologic features are essentially that o f a polymorphous 
infiltate with prominent vascularity and interstitial periodic acid -Schiff-positive 
material to follicular hyperplasia with an interfollicular polymorphous infiltrate, similar
to that observed in early lymph node involvement (Ghani & Krause, 1985;Moreb et al, 
1983;Myers et al, 1978;Rosenstein et al, 1988;Starke et al, 1983;Tobinai et al, 
1988;Weisenburger et al, 1977).
5.3.2 CD10 as a phenotypic marker
In our study, the histology in involved extranodal sites such as lung, nasopharynx, 
caecum and tonsil showed a similar spectrum of histologic changes, ranging from those 
that may be mistaken for a reactive lymphoid proliferation to features suggestive of 
lymphoma, but not specifically AITL. A specific phenotypic or molecular marker would 
thus be the only means o f definite diagnosis o f AITL at these sites, in the absence o f an 
accompanying lymph node biopsy. In our study, expression o f CD 10, a feature shown to 
be a sensitive and specific marker o f  neoplastic T-cells in affected lymph nodes, was 
consistently seen in all involved extranodal sites, except 5/6 involved bone marrow 
trephines. Its value is especially highlighted in case 2 where the misdiagnosis o f reactive 
(follicular) hyperplasia on lung biopsy may have been averted if CD 10 expression had 
been assessed.
5.3.3 Bone marrow involvement in AITL
Bone marrow is biopsied as a part o f staging procedure and is often involved at 
diagnosis (Dogan & Morice, 2004;Ghani & Krause, 1985). In their series o f 8 cases 
Ghani and Krause (1985) describe focal infiltrates with prominent epithelioid cells 
imparting a “granulomatoid appearance” as the predominant pattern o f involvement. In 
the same study, paratrabecular involvement described as typical for AITL by Pangalis 
and co-workers (Pangalis et al, 1978) was a rare feature and an increase in vascularity, 
prominent in involved lymph nodes was seen in only 3 o f their cases. In our study
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although focal involvement was seen in all involved bone marrow biopsies two thirds 
(4/6 cases) o f which showed a paratrabecular distribution, a “granulomatoid” appearance 
was seen only in a third o f the cases (2/6 cases). An increase in vascularity was also 
observed only in the latter 2 cases. FDCs, a prominent feature in involved lymph nodes 
was observed only in case 3 in the form o f regressed follicles. In all 6 cases, the 
morphologic, immunophenotypic and molecular genetic features on bone marrow 
trephine enabled a diagnosis o f PTL, but were not sufficient to subtype further as AITL. 
CD 10 expression, a useful feature in this situation, was however present only in one case 
(case 3).
5.3.3 Skin involvement
Skin rash is a common symptom at presentation (Siegert et al, 1995). It is thought that 
some of these lesions are immunologically mediated secondary manifestations of 
systemic disease, perhaps mediated by immunological abnormalities characteristic o f 
AITL rather than direct tumour involvement (Seehafer et al, 1980). However, with the 
advent o f molecular methods, it has become apparent that a significant subset o f the skin 
lesions represents direct tumour involvement (Brown et al, 2001;Murakami et al, 2001). 
Unfortunately, due to the lack o f involved skin biopsies in this series, we were unable to 
assess the usefulness o f CD 10 expression at this site.
5.3.4 CD10 expression correlates with the presence of follicular 
dendritic cell meshwork
CD 10, a transmembrane protein with neutral endopeptidase activity is expressed in
follicle centre B-cells and is a marker o f follicular lymphoma (Dogan et al, 2000). In the
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latter, CD 10, although strongly expressed within the neoplastic follicles, is down 
regulated in clonally identical interfollicular neoplastic cells (Dogan et al, 1998). The 
expression o f CD 10 in follicular lymphoma cells may thus be dependent on a signal 
from the FDC. In vitro studies have shown that highly purified FDCs are able to induce 
the proliferation o f allogeneic T-cells or T-cell lines (Butch et a l, 1994). There is 
however no direct evidence for ongoing interactions between the neoplastic cells of T- 
cell lymphomas and FDCs. Nevertheless, AITL is characterised by an expansion o f FDC 
meshwork (Jaffe & Ralfkiaer, 2001a). In lymph nodes and extranodal sites, CD 10 
expression correlates well with the presence and distribution o f FDCs. This correlation is 
especially well highlighted in the cases with bone marrow involvement in our study, 
where CD 10 expression in the marrow is confined to the only case associated with 
FDCs, while in cases 2, 5-8, the neoplastic cells are CD 10 negative in the marrow when 
devoid o f associated FDCs, but CD 10 positive in other involved sites that harboured 
FDCs. This suggests an analogy with follicular lymphoma where despite clonal identity, 
there is down regulation o f CD 10 in neoplastic cells that lack association with FDCs and 
indicate a possible role o f FDCs in this phenomenon. In support o f this theory, in a 
recent study, Kim et al, have shown that FDCs and endothelial cells in AITL express 
FasL whereas the CD 10 expressing tumour T-cells express Fas (CD95) and caspase 3, 
indicating Fas-FasL interaction between the neoplastic T-cell and the FDC and suggest 
that the follicular milieu is necessary for CD 10 expression by tumour cells, a feature that 
may play a functional role in regulating apoptosis (Kim et al, 2002a).
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5.3.5 Concluding remarks
In AITL, expression o f CD 10 by neoplastic T-cells is maintained in most involved 
extranodal sites and shows good correlation with the presence/distribution o f FDCs. This 
immunophenotypic feature may thus be used to make a diagnosis o f AITL in an 
extranodal site, even in the absence o f accompanying lymph node histology.
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Chapter 6
HISTOLOGIC PROGRESSION OF 
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
6.1 Introduction
As was discussed in chapter 1, AITL was initially believed to be an atypical reactive 
process, “AILD” (Frizzera et al, 1974;Lennert, 1979;Lukes & Tindle, 1975) a concept 
that was refuted by m olecular genetic evidence o f a monoclonal T-cell proliferation in 
most cases (Feller et al, 1988;Lipford et al, 1987;Weiss et al, 1986). Although it is now 
universally accepted as a subtype o f PTL (Harris et al, 2000), there is still a debate as to 
whether the T-cell lymphoma arises de novo, or in the background o f an oligo-clonal 
pre-neoplastic state. The clonal expansion o f by-stander EBV infected B-cells and the 
occurrence o f an EBV-associated B-cell lympho-proliferation in some cases causes 
confusion with regard to lineage assignment, diagnosis, and prognostication (Smith et al, 
2000). The prognosis in AITL is dismal, with a median survival o f less than 3-years 
following diagnosis (Pautier et al, 1999;Pellatt et al, 2002;Siegert et al, 1992). Despite 
this aggressive course, the cause o f death in many cases is due to the consequences o f 
secondary immune-deficiency, rather than tumour bulk (Siegert et al, 1995). As the 
disease is uncommon, and the biology poorly understood, there are no uniform treatment 
protocols and treatment remains empirical. There are a few clinical trials that are being 
set up, each targeting different aspects o f the disease - immune-modulation with 
cyclosporine A in relapsed AITL (Eastern Coorporative Oncology Group, 2003) and 
Rituximab with CHOP in cases o f AITL with a prominent B-cell component (Joly et al,
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2004). Histologic progression o f the disease is poorly studied and documentation is 
limited to a few isolated case reports and small case series (Abruzzo et al, 1993;Bauer et 
al, 1982;Joly et al, 2004;Knecht et al, 1995;Matsue et al, 1998;Nathwani et al, 
1978;Park et al, 2002;Pirker et al, 1986;Zettl et al, 2002).
The aim o f this part o f  the study was to evaluate the histology in sequential biopsies in a 
large series o f patients in order to correlate histology with the evolution o f the disease.
6.2 Results
6.2.1 Tissues used in this study
Twenty-nine cases o f AITL where sequential biopsies were available were reviewed and 
the diagnosis confirmed on clinical, histological, immunophenotypic and genetic 
criteria, the data are summarized in Table 6.1.
6.2.2 Clinical features
There were 17 males and 12 females who were between the ages o f  26 and 80 years at 
presentation. In most cases (where staging information was available) they presented 
with disseminated disease (Table 6.1). In 28 o f the 29 cases, a lymph node was biopsied 
at presentation while in one case a lung biopsy was obtained for diagnosis. In all 29 
cases however, the initial diagnosis o f AITL was made on lymph node biopsy (Table 
6 . 1).
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Table 6.1. Summary of clinical details, histology, molecular genetics, therapy and 
outcome.
Case Age/Sex Month Biopsy Histology TCR Ig H Stage Treatment Outcome
No site
1 42/M 0 LN AJTL-1 MC PC IVB None N/A
2 AITL-3 MC* PC IVB N/Av N/Av
N/Av
2 69/M 0 LN AITL-1 MC PC IIA None N/A
23 LN AITL-3 MC* PC nro Et+P NR
26 SK AITL MC* PC IVB
DOD, 26
months
3 74/F 0 LU AITL-1 MC PC ND None
18 LN AITL-3 MC* PC IVB N/Av
N/Av
4 28/M 0 LN AITL-3 N/Amp N/Amp IIA CHOP CR
20 LN AITL-3 MC PC IIIA ESHAP
A-BMT PR
22 BM AITL N/Amp N/Amp IVB ESHAP NR
G PR
24 BM EBV- N/Amp N/Amp IVB G NR
DLBCL
Died, 27
months
5 60/F 0 LN AITL-3 MC PC IVA CHOP CR
8 LN AITL-3 MC* MC IVB CHOP, Et NR
&EBV-
DLBCL Died, 11
months
6 60/M 0 LN AITL-3 MC PC IIIB CHOP CR
13 LN AITL-3 MC* MC IA Et, SCT CR
37 SA AITL MC* PC IIA N/Av NR
37 BM AITL ND ND IV N/Av NR
Died 38
months
7 79/F 0 LN AITL-3 MC PC N/Av N/Av
63 LN EBV- PC PC N/Av N/Av
CHL N/Av
8 67/F 0 LN AITL-3 MC ND IVB CHOP CR
60 LN EBV- PC PC N/Av ABVD CR
CHL
A&W 72
months
9 62/M 0 LN AITL-3 MC PC IIIB CEOP CR
28 LN AITL-3 MC* PC IIIB Et+N CR
36 SK AITL MC* ND IVB M +If+E t NR
Died, 36
months
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Table 6.1 continued from previous page
Case Age/Sex Month Biopsy Histology TCR Ig H Stage 
No rite
Treatment Outcome
10
11
33/F
78/F
0 LN AITL** N/Av N/Av N/Av N/Av
11 CAE AITL* OC PC IVB N/Av
11 TON AITL-3 N/Av N/Av IVB N/Av
N/Av
0 LN AITL-3
&EBV-
DLBCL
MC MC IIIA Thai PR
3 LN AITL2 MC* PC niA None
PR
AWD, 12 
months
12 58/F 0 LN AITL-3 OC PC IIIB CHOP CR
58 LN AITL-3 MC** PC IVB ESHAP NR
Died, 60
months
13 80/F 0 LN AITL-2 MC N/Amp N/Av Palliative N/A
24 GA PTL Indet PC N/Av Palliative N/A
N/Av
14 26/M 0 LN AITL-2 N/Amp PC IVB CHOP PR
6 LN AITL-2 N/Amp PC IVB ABVD, CR
A- BMT
Died 26
months
15 33/M 0 LN AITL-3 OC PC IVB CHOP CR
12 LN AITL-3 OC* PC IVB CHOP PR
Died 12
months
16 73/M 0 LN AITL-3 MC PC N/Av N/Av N/Av
22 LN AITL-3 MC PC N/Av N/Av N/Av
N/Av
17 49/F 0 LN AITL-3 PC PC N/Av N/Av N/Av
17 LN AITL-3 Indet Indet N/Av N/Av
17 SK AITL* Indet Indet N/Av N/Av
Died 21
months
18 69/M 0 LN AITL-3 N/Av N/Av IIIB P PR
8 LN EBV- MC MC IA Multi-CT CR
DLBCL
15 LN AITL-3 me* PC IIIA Multi-CT PR
AWD 68
Months
19 32/M 0 LN AITL-1/2 N/Av N/Av IIIA None N/A
7 LN AITL-2 MC PC IIIB CVP PR
23 LN AITL-3 MC PC IIIB ACVBP.BMT CR
98 LN AITL-1 N/Av N/Av IIIB P PR
AWD, 119 
months
169
Table 6.1 continued from previous page
Case Age/Sex Month Biopsy Histology TCR IgH Stage Treatment
No site
20 76/M 0 LN AITL-3 MC me IIIB P
3 LN AITL-3 MC* me* IIIB N/Av
3 SK AITL* MC* me* IIIB N/Av
21 64/M 0 LN AITL-1 PC PC IVA None
5 LN AITL-2 MC PC IVA None
37 LN N-DX N/Av N/Av IVB N/Av
22 55/F 0 LN AITL-3 MC PC IVA Multi-CT,
A-BMT
10 SK AITL* MC N/Av IVA P
23 49/M 0 LN AITL-3 N/Av N/Av IVB Multi-CT,
0 SK AITL5 N/Av N/Av A-BMT
12 OR AITL5 N/Av. N/Av IVB P
24 67/F 0 LN AITL-3 MC N/Av IIIA Multi-CT
42 LN AITL-2 MC MC IA CT
25 43/F 0 LN AITL-3 N/Av N/Av N/Av P
228 SK AITL5 MC PC IVA C + P
228 WAL AITL5 MC PC
228 BLD AITL5 MC* PC
CHOP-R
26 72/M 0 LN AITL-3 MC MC* IIIB N/Av
84 LN EBV-DLBCL PC MC** IA N/Av
27 N/Av/M 0 LN AITL-1 N/Av N/Av IIIA P
168 LN AITL-3 MC PC IIIB N/Av
28 52/M 0 LN AITL-3 N/Av N/Av IIIB Multi-CT
8 LN EBVneg N/Av N/Av N/Av Multi-CT-R
DLBCL
29 54/F 0 LN AITL-3 MC PC IB P
22 LN AITL-2 MC* PC IB None
Outcome
PR
N/Av
N/Av
N/Av
N/A
N/A
N/Av
PR
NR
Died, 13 
months
PR
NR
Died, 17 
months
CR
N/Av
N/Av
CR
PR
Relapse ly  
following 
Rx, AWD, 
247 months
CR
N/Av
N/Av
CR
N/Av
N/Av
CR
CR
A&W 24 
months 
CR 
N/A
AWD 25 
months
s Not assigned a “pattern” because site of involvement is extranodal
* Same size band as previous biopsies
** Different size band/bands to previous biopsies
* Weak band
** Biopsy diagnosed elsewhere; not available for review
Abbreviations: F, female; M, male; LN, lymph node; SK, skin, LU, lung; BM, bone marrow; SA, salivary gland;
CAE, caecum; TON, tonsil; GA, gastric, OR, oral; WAL, waldeyer’s ring; BLD, blood; AITL, angioimmunoblastic T- 
cell lymphoma; AITL-1, angioimmunoblastic T-cell lymphoma, pattern 1; AITL-2, angioimmunoblastic T-cell 
lymphoma, pattern 2; AITL, pattern 3, angioimmunoblastic T-cell lymphoma, pattern 3; EBV, Epstein Barr virus; 
DLBCL, diffuse large B-cell lymphoma; neg, negative; CHL, classical Hodgkin lymphoma; MC, monoclonal; PC, 
polyclonal; me, oligoclonal with a weak dominant band; OC, oligoclonal;NDx, not diagnostic; ND, not done; N/Amp, 
not amplifiable; indet, indeterminate; N/A, not applicable; N/Av, not available; E (in CEOP regimen), epirubicin; Et, 
etoposide; G, gemcitabine; P, prednisolone; C, cyclophosphamide; H, doxorubicin; O, vincristine, R, Rituximab; A, 
adriamycin; B, bleomycin; V, vinblastine; D, dacarbazine; ESHAP, Etoposide, methyl prednisolone, cytarabin (ara-C) 
and cisplatin; N, novantrone; M, methotrexate; If, ifosphamide; Thai, thalidomide; B, bleomycin; CT, chemotherapy, 
details not available; multi-CT, multi-agent chemotherapy, details not available; SCT-stem cell transplant; BMT, bone 
marrow transplant; A-BMT, autologous bone marrow transplant; CR, complete remission; PR, partial response; NR, 
no response; A&W, alive and well; AWD, alive with disease; y, year; Rx, treatment
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6.2.3 Histology, immunohistochemistry and EBER-ISH
The histological diagnosis for each biopsy is given in Table 6.1 and the summary of 
EBER-ISH results are given in Table 6.2.
6.2.3.1 “Pattern I” on initial biopsy to more typical AITL (patterns II/III) on 
follow up
In 6 cases (cases 1-3, 13, 21 and 27) the initial histology showed a predominantly 
“pattern I” morphology (Figure 6.1), with hyperplastic follicles (see chapter 3) while the 
histology on follow up biopsy showed a “pattern II” or “pattern III” appearance with 
effaced architecture and either regressed follicles (pattern II) or no identifiable follicles 
(pattern III) (Figure 6.2). The FDC meshworks, highlighted by CD21 
immunohistochemistry was as described for patterns I, II and III in chapter 3. The time 
interval between the 2 biopsies ranged from 2 to 23 months in 5 o f these 6 cases, but was 
168 months in one o f the cases (case 27). In one case (case 19), the histology showed a 
“pattern I” appearance on initial biopsy and “typical” AITL with patterns II and III 
respectively at 1st and 2nd relapse, but the biopsy at 3rd relapse, 98 months after initial
biopsy showed “pattern I” morphology with hyperplastic follicles.
6.2.3.2 “Typical” AITL on initial biopsy and follow up lymph node biopsies
In 10 cases (cases 4, 5, 6, 9, 12, 14, 15, 17 and 20), the initial and follow up biopsies 
showed the same appearance o f “typical” AITL. Nine o f these 10 cases showed pattern 
III histology and 1 case (case 14) showed a pattern II appearance on initial and follow up
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biopsies. In 3 other cases (cases 11, 24 and 29) the histology showed a pattern III 
appearance on initial biopsy and pattern II in the second biopsy. In case 11, the 
vascularity was less pronounced in the second biopsy (a feature demonstrated better by 
CD34 immunohistochemistry -  see Figure 6.41 and J)
6.2.3.3 Relapse of AITL (and biopsy) involving extranodal site
In 12 cases, the follow up biopsies o f involved extranodal sites showed features of 
involvement by a T-cell lymphoma. In some sites (e.g. caecum and tonsil in case 10) the 
histology showed prominent vascularity and clear cells suggestive o f AITL, but in others 
(e.g. skin biopsies in cases 2, 9, 17, 20, 22, 23 and 25), the features were non-specific.
In one case (case 13) the patient relapsed 24 months following initial biopsy with gastric 
involvement, and the gastric biopsy showed a diffuse monomorphic infiltrate o f highly 
atypical CD3+ T-cells, not present in the initial biopsy, and the diagnosis o f PTL (rather 
than AITL) was made (Figure 6.3).
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Figure 6.1 Case 1, biopsy at presentation 
showing a predominantly 
“Pattern I” histology.
(A) Haematoxylin and eosin stained section 
showing many hyperplastic and an occasional 
regressed follicles. (B) High-power view of 
regressed follicle. (C and D) increased vascularity 
o f the paracortex. (E and F) CD3 shows numerous 
T-cells. (G and H) highlights B-cells (I and J) 
CD21 showing no/subtle expansion o f  the 
follicular dendritic cell meshwork. (K and L)
CD 10 staining shows lighter staining germinal center B-cells and darker, crisply staining neoplastic T- 
cells. (M and N) CD79a/CD10 double staining shows CD 10 positive (blue) lymphoid cells that are 
CD79a (brown) negative, consistent with T-cells.
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meshwork which surrounds vessels (H). (1)
Figure 6.2 Case 1, follow up biopsy (2 
months later) showing 
“Pattern 111” histology.
(A) Haematoxylin and eosin stained section 
showing effaced architecture with no 
identifiable follicles. (B-D) High power view  
showing clear cells and a rich vascular 
network.(E) CD3 shows numerous T-cells. (F) 
CD20 highlights B-cells. (G and H) CD21 
shows marked expansion o f  the follicular cell
CD 10 stain highlights many lymphoid cells (J) 
CD79a/CD10 double stain shows many CD 10 positive (blue) lymphoid cells that are CD79a (brown) 
negative, consistent with T-cells
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Figure 6.3. Initial and follow up biopsies from case 13, showing AITL (panels A-D) and 
Peripheral T-cell lymphoma (panels E-H), respectively.
(A) Haematoxylin and eosin (H&E) stained section o f initial biopsy showing AITL “Pattern 111”. (B) 
High power view o f  initial biopsy showing clusters o f  clear cells. (C) CD3 highlights T-cells (D, left 
panel) high power view o f  CD3 stain showing T-cells, (D, right panel) high power view o f  CD 10 staining 
highlights neoplastic T-cells. (E and F) H&E stained section o f  follow up biopsy showing a monomorphic 
infiltrate o f  large atypical lymphoid cells (G and H) CD3 highlights the neoplastic T-cells in the follow up 
biopsy.
6.2.3.4 EBV-associated B-cell proliferations
The results o f EBER-ISH are summarized in Table 6.2. Seven of the 29 cases (24%) in 
this series showed evidence o f EBV-associated B-cell “lymphomas” (5, DLBCL; 2 
CHL) and 3 cases had a dominant B-cell clone in the presence o f prominent EBV- 
infected B-cells.
6.2.3.4.1 EBV-associated DLBCL
One case (case 11) showed histological features o f AITL and co-existent numerous 
EBV-associated large B-cells amounting to DLBCL at initial presentation (Figure 6.4, 
left panels, A, C, E, G, I, K). The DLBCL in this case had regressed with a complete
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absence o f EBER-ISH (in situ hybridization) positive cells in the follow up biopsy 
(Figure 6.4L). Four cases (cases 4, 5, 18 and 26) that showed only AITL on initial 
biopsy, showed DLBCL on follow up biopsy (Figure 6.5). In 2 o f  these cases (cases 4 
and 5) where EBER-ISH was performed on the biopsy pre-dating the development of 
DLBCL [3rd biopsy (bone marrow) in case 4 and initial biopsy in case 5] the latter 
showed a prominence o f EBER-ISH positive cells. Cases 5 and 18 had co-existent AITL 
and EBV-associated DLBCL in the same biopsy (Figure 6.5F-H). The time interval 
between biopsies (the preceding biopsy and the biopsy showing EBV-associated 
DLBCL) ranged from 2-8 months in 3 cases but was 84 months in one case (case 26). In 
one o f the cases (case 18), following multi-agent chemotherapy and complete remission, 
the patient relapsed again 7 months later with AITL and no evidence o f DLBCL.
6.2.3.4.2 EBV- associated Classical Hodgkin lymphoma (CHL)
Two cases (cases 7 and 8) developed EBV-associated CHL 5-years after complete
remission was achieved following initial diagnosis and treatment (Figure 6.6). The
Reed-Stemberg cells in these cases were LMP-1 (immunohistochemistry) and EBER (in
situ hybridization) positive (Figure 5.6K). Although the presence o f a polymophous
reactive background in
CHL made interpretation a little difficult, there were no histological, immunophenotypic 
or molecular genetic evidence o f AITL in these follow up biopsies.
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Figure 6.4 Biopsies from case 11 
showing AITL 
“Pattern III” histology 
and co-existent EBV 
positive diffuse large B- 
cell lymphoma in the 
initial biopsy and 
“Pattern II” with 
regression of the EBV- 
positive lympho- 
proliferation in the 
follow up biopsy, 10 
weeks of Thalidomide 
treatment.
Left panels (A,C,E,G,1 and K) show the 
biopsy before treatment and the right 
panels (B,D,F,H,J and L) show the biopsy 
after treatment. (A  and B) Haematoxylin 
and eosin stained section, low power view  
o f  excised lymph nodes; C and D) high 
power view highlighting subtle changes in 
vascular architecture and cellular 
morphology; E and F) CD3 
immunostaining and G and H) CD10 
immunostaining showing the differences in 
distribution o f  neoplastic T-cells after 
treatment; 1 and J) CD34 immunostaining 
highlighting the changes in vascular 
architecture after treatment; K and L) 
EBER in-situ hybridisation showing 
disappearance o f  EBV infected B-cell 
proliferation after treatment. The positive 
cells show dark blue/purple nuclear 
staining.
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Figure 6.5 Case 5, the initial (Panels A-E) biopsy showing AITL, “pattern III and follow 
up (F-H) biopsies showing AITL pattern III in the initial biopsy and AITL 
pattern III with EBV-associated DLBCL in the follow up biopsy.
(A-C) Haematoxylin and eosin (H&E) section showing “pattern 111” morphology with prominent 
vascularity and clear cells (high power, panel C). (D) double EBER-in situ hybridization (EBER-ISH) and 
CD79a immunohistochemistry highlighting EBER-positive B-cells. (E) CD21 highlights the expanded 
follicular dendritic cell meshwork which surrounds vessels (inset)/ (F) H&E stained section o f  follow up 
biopsy with many large atypical cells, some o f  which have a Reed-Stemberg-like morphology (inset). (G 
and H). Double EBER-ISH, CD79a immunohistochemistry showing numerous EBER-positive B-cells 
consistent with diffuse large B-cell lymphoma
6.2.3.S EBV-negative DLBCL on follow up
One case (case 28) showed features o f DLBCL (EBV-negative) on follow up biopsy 8 
months after the initial diagnosis and after complete remission was achieved with multi­
agent chemotherapy.
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Figure 6.6 Cases 7 and 8 showing progression from AITL (initial biopsy) to classical 
Hodgkin lymphoma (follow up biopsy 5-years later).
Panels A-L show the biopsies from case 7; panels A-G, show the initial biopsy and panels H-L show the 
follow up biopsy. Panels M-P show the biopsies from case 8; panels M -0 show the initial biopsy and 
panel P shows the follow up biopsy.
(A and B) Haematoxylin and eosin (H&E) stained sections o f  the initial biopsy o f  case 7 showing AITL, 
“Pattern 111”. Panel B shows a high power view  with clusters o f  clear cells amidst a rich vascular network. 
(C and D) CD21 staining highlights the marked expansion o f  the follicular dendritic cell (FDC) 
meshwork, and shows that it surrounds vessels (D). (E) CD 10 highlights neoplastic T-cells. (F) 
CD20/CD10 double staining shows CD 10 positive lymphoid cells, negative for CD20 and consistent with 
T-cells. (G) EBER in situ hybridisation (EBER-ISH) highlights scattered EBV-infected cells. (H) CD21 
staining o f  the follow up biopsy o f  case 8 shows absence o f  FDC. (1 and J) H&E stained sections o f  the 
same biopsy shows features consistent with classical Hodgkin lymphoma (CHL), with mummified and 
Reed-Stemberg (RS) cells (J). (K, upper panel) LMP-1 and (K, lower panel) EBER-ISH highlight EBV- 
infected RS cells. (L, upper panel) CD30 and (L, lower panel) CD 15 positive RS cells. (M) H&E stained 
section o f  the initial biopsy o f  case 8 showing “Pattern 111” AITL. (N) CD21 highlights the expanded FDC 
meshwork that encircles vessels (inset). (O) CD 10 highlights the neoplastic T-cells. (P) H&E stained 
section showing CHL with typical RS cells in a polymorphous background.
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6.2.3.6 CD10 expression by neoplastic T-cells
The results o f CD 10 immunostaining are given in Table 6.2. The neoplastic T-cells 
expressed CD 10 in 21 o f 24 cases that were immunostained for CD 10. If involved by 
AITL, CD 10 expression was maintained in the initial biopsy and follow up lymph node 
biopsies in all but 2 cases (cases 3 and 27) where material was available for assessment. 
In cases 3 and 27, although the initial biopsies expressed CD 10, the follow up lymph 
node biopsies were CD 10 negative.
6.2.3.6.1 “Pattern I ” on initial biopsy to more typical AITL (patterns II/III) on
follow up
The initial as well as follow up biopsies in 5 cases (cases 1, 2, 3, 19 and 27) showing 
pattern I histology on the initial biopsy and more typical AITL on follow up were 
investigated for CD 10 expression. In 3 cases (cases 1, 2 and 19), CD 10 expressing 
neoplastic T-cells were concentrated in the vicinity o f the hyperplastic follicles on initial 
biopsy, and increased in number, were more diffusely distributed, but concentrated 
around the expanded FDC meshwork in the later biopsies showing patterns II and III 
morphology. In case 19 where the biopsy at 3rd relapse showed a pattern I appearance, 
the CD 10 positive neoplastic cells were present predominantly in the vicinity o f the 
follicles. In 2 cases (cases 3 and 27), although the initial biopsy was CD 10 positive, the 
follow up biopsy was CD10 negative. In case 3, the initial (lung) biopsy, which was 
misdiagnosed as reactive showed CD 10 expression by the neoplastic T-cells, but the 
subsequent poorly fixed diagnostic lymph node biopsy showing pattern III histology was 
CD 10 negative. In case 27, although the neoplastic T-cells in the initial lymph node
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biopsy were CD 10 positive, the lymph node biopsy at relapse 168 months later was 
CD 10 negative.
In one o f the cases (case 21) although the neoplastic T-cells expressed CD 10 in the 
initial biopsy, due to unavailability o f spare material, immunohistochemistry for CD 10 
was not performed in the follow up biopsy.
6.2.3.6.2. “Typical” AITL on initial biopsy and follow up lymph node biopsies
Ten cases (cases 4-6, 9, 11, 12, 14, 15, 20, and 24) that showed “typical” AITL on initial 
and follow up biopsies were investigated for CD 10 expression.
CD 10 expression by the neoplastic T-cells was maintained in both initial and follow up 
biopsies in 7 o f the 10 cases (cases 4, 6, 9, 11, 12, 14, and 15) investigated. In 6 o f the 7 
cases the distribution and proportion o f CD 10 positive T-cells were similar in initial and 
follow up biopsies, while in one case (case 9) the follow up biopsy which was poorly 
fixed showed a marked reduction in the number o f CD 10 expressing tumour cells. In one 
case (case 11), although there was no sizeable reduction in the number, the tumour cells 
which were more diffusely distributed in the initial biopsy (pattern III histology), were 
more confined to the vicinity o f the follicles in the post-treatment biopsy (pattern II 
histology) (Figure 6.4H).
In case 20, although CD 10 expression was present in the follow up biopsy, this could not 
be assessed in the initial biopsy due to lack o f access to spare material.
In 2 o f the cases (case 5 and 24), the neoplastic T-cells failed to express CD 10 in both 
initial and follow up biopsies.
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6.2.3.6.3. Relapse o f AITL (and biopsy) involving extranodal site
In case 9, CD 10 expression was observed in both tonsil and caecum at relapse. Due to
technical reasons, it was not possible to demonstrate CD 10 expression in skin biopsies 
(cases 3 and 9) showing involvement by AITL. In case 25, CD 10 expression was 
observed in the initial lymph node biopsy, but was not investigated for in the W aldeyer’s 
ring biopsy involved at relapse 228 months later. Nevertheless at this time the presence 
o f CD 10 positive T-cells in the peripheral blood was detected on flow cytometry in this 
case. In one o f the cases (case 13), the neoplastic T-cells in the initial biopsy (showing 
AITL) were CD 10 positive, but in the follow up gastric biopsy showing a monomorphic 
proliferation o f large atypical T-cells (Figure 6.3E and F), the latter were CD10 
negative.
6.2.4 PCR for T-cell receptor y chain (TCR-y) gene rearrangement 
and immunoglobulin heavy chain (IgH) gene rearrangement
6.2.4.1 PCR for TCR-y gene rearrangement
The results o f PCR for TCR-y gene rearrangement are summarized in Table 6.1. In 25 
cases, T-cell receptor y chain gene PCR gave a monoclonal/oligoclonal pattern in at least 
one o f the biopsies (Table 1). One case (case 17) gave a polyclonal pattern on initial 
biopsy and an indeterminate result on follow up biopsies, while one case (case 14) failed 
to amplify due to poor quality o f DNA. In two further cases (cases 23 and 28), the 
molecular genetics results were not available. In 12 o f the 18 cases, where PCR was 
successful and AITL was present in both initial and follow up biopsies, the band/bands
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in the initial and follow up biopsies were identical in size. In 4 cases the PCR products 
o f both initial and follow up biopsies could not be compared. In one case (case 12) the 
initial biopsy had showed an oligoclonal pattern, while the biopsy at relapse showed a 
monoclonal pattern, with a band size that did not correspond to any o f the bands o f the 
previous biopsy. In case 21 the initial biopsy showed a polyclonal pattern while the 
follow up biopsy showed a monoclonal pattern.
6.2.4.2 PCR for IgH gene rearrangement
The results o f PCR for IgH gene rearrangement are summarized in Table 7.1
6.2.4.2.1 EBV-associated DLBCL
In case 11, the initial biopsy showed features o f AITL and a numerous EBV-infected 
(EBER-positive) B-cell cells with molecular genetic evidence o f a dominant B-cell clone 
i.e. AITL with EBV-associated DLBCL. The post-treatment biopsy, with features o f 
AITL and a complete absence o f EBER-ISH positive cells, showed a polyclonal Ig 
heavy chain gene PCR result.
In 3 o f the 4 cases (cases 5, 18 and 26) that were complicated by EBV-associated 
DLBCL on follow up biopsies, a monoclonal B-cell population was detected by PCR in 
the biopsy showing DLBCL. In one o f these cases (case 26) the preceding biopsy that 
had no features o f DLBCL gave rise to a weak monoclonal band, differing in size to that 
o f the subsequent biopsy. In one case (case 5), although the biopsy showing DLBCL had 
a dominant B-cell clone, the preceding biopsy, which showed many scattered EBV- 
infected cells (EBER-ISH positive), showed a polyclonal pattern by PCR.
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Table 6.2 CD 10 expression and EBER in situ hybridization
Biopsy Diagnosis CD10 positve T-cells EBER-ISH
Case 1 1 *  b iopsy  (lym ph  node) A IT L -1 Positive + ++
2 nd b iopsy  (ly m p h  n ode) A ITL-3 P ositive ++
Case 2 1” b iopsy  (ly m p h  n ode) AITL-1 P ositive ++
2 nJ b iopsy  (ly m p h  no d e) A ITL-3 Positive N egative
3 ,d b iopsy  (sk in ) A ITL* N ot in terp re tab le N ot done
Case 3 I ” b iopsy  (lu n g ) AITL-1 P ositive N ot done
2 nd b iopsy  (ly m p h  n ode) A ITL-3 N egative N ot done
Case 4 I* b iopsy  (ly m p h  n ode) A ITL-3 P ositive N o t done
2 nd b iopsy  (ly m p h  n o d e) A ITL-3 P ositive N ot done
3 ,d b iopsy  (b o n e  m arrow ) A ITL* N ot done +
4 th b iopsy  (b o n e  m arrow ) E B V -D L B C L N egative D iffuse  sheets  o f  positive 
ce lls
Case 5 1" b iopsy  (ly m p h  n ode) A ITL-3 N egative ++
2 nd b iopsy  (ly m p h  no d e) A IT L  &  E B V -D L B C L N egative + + + +
Case 6 1* b iopsy  (ly m p h  no d e) A ITL-3 P ositive + +
2 nd b io p sy  (ly m p h  n o d e ) A ITL-3 P ositive ++
3 rd b iopsy  (p a ro tid ) A ITL* N egative +
4 th b iopsy  (b o n e  m a rro w ) A ITL* N ot done N o t done
Case 7 151 b iopsy  (ly m p h  n o d e ) A ITL-3 Positive +
2 nd b iopsy  (lym ph  n o d e) E B V -C H L N egative + + + #  (R eed  S ternberg  ce lls)
Case 8 1“ b iopsy  (ly m p h  n ode) A ITL-3 Positive +
2 nd b iopsy  (lym ph  n ode) E B V -C H L N egative + + + #  (R eed  S ternberg  ce lls)
Case 9 r ‘ b iopsy  (lym ph  node) A ITL-3 P ositive ++
2 nd b iopsy  (lym ph  n o d e) A ITL-3 Positive (p o o r f ixa tion ) + + +
3rd b iopsy  (sk in ) A ITL* N ot in terp re tab le N ot done
Case 10 I*1 b iopsy  (lym ph  n ode) A IT L  (no t rev iew ed) N ot done N /A
2nd b iopsy  (cae cu m ) A ITL* P ositive N ot done
3 rd b iopsy  (to n s il) AITL* Positive N o t done
Case 11 1 ” b iopsy  (lym ph  n ode) A ITL-3 & E B V -D L B C L P ositive + ++
2nd b iopsy  (lym ph  n ode) A ITL-2 Positive N egative
Case 12 1” b iopsy  (lym ph  n ode) A ITL-3 P ositive +
2nd b iopsy  (lym ph  n o d e) A ITL-3 Positive + ++
Case 13 C  biopsy  (lym ph  n ode) A ITL-3 P ositive ++
2nd b iopsy  (g as tric ) P T L N egative N o t done
Case 14 1,1 b iopsy  (lym ph  n ode) A ITL-2 Positive N egative
2nd b iopsy  (lym ph  node) A ITL-2 P ositive N egative
Case 15 l sl b iopsy  (lym ph  n ode) A ITL-3 Positive ++
2nd b iopsy  (lym ph  node) A ITL-3 P ositive ++
Abbreviations: AITL-1,2,3, angioimmunoblastic T-cell lymphoma patterns I, II and III; *not assigned a 
“pattern” as involved site is extranodal; EBV, Epstein Barr virus; DLBCL, diffuse large B-cell lymphoma; 
PTL, peripheral T-cell lymphoma; EBER-ISH, Epstein Barr virus encoded RNA -  in situ hybridization; N/A, 
not available, + to ++++, number o f  EBER positive cells ranging from a few scattered cells to a large number 
o f  positive cells. # LMP-1 positive; N /A, not available
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Table 6.2 CD10 expression and EBER in situ hybridization
(continued from previous page)
Biopsy Diagnosis CD 10 positive T-cells EBER-ISH
Case 16 1st b iopsy  (lym ph  n ode) A ITL-3 N o t d one N o t done
2nd b iopsy  (ly m p h  n o d e) A ITL-3 N o t done N egative
1 * b iopsy  (ly m p h  no d e) A ITL-3 N o t done N ot done
Case 17 2 nd b iopsy  (lym ph  n ode) A ITL-3 N ot done +++
3rd b iop ;sy  (sk in ) A ITL* N ot done N egative
1" b iopsy  (ly m p h  no d e) A ITL-3 N ot done N /A
Case 18 2nd b iopsy  (lym ph  no d e) E B V -D L B C L
N o t done
D iffuse  sheets  o f  positive 
ce lls
3 rd b iop ;sy  (ly m p h  n o d e) A ITL-3 N o t done N /A
1“ b iopsy  (ly m p h  n ode) A IT L -1/2 P ositive N /A
2 nd b iopsy  (ly m p h  no d e) A ITL-2 P ositive N /A
Case 19 3 rd b iopsy  (lym ph  n o d e) A ITL-3 P ositive N /A
4 th b iopsy  (lym ph  no d e) AITL-1 P ositive N /A
1* b io p sy  (ly m p h  n o d e) A ITL-3 N o t done N /A
Case 20 2 nd b iopsy  (lym ph  n o d e) A ITL-3 P ositive N /A
3rd b iopsy  (sk in ) A ITL* N o t done N /A
Case 21 I s1 b iopsy  (lym ph  n o d e) AITL-1 P ositiv e N /A
2 nd b iopsy  (lym ph  n o d e) A ITL-2 N o t done N /A
3 rd b iopsy  (lym ph  n o d e) N o t d iagnostic N o t done N /A
Case 22 1" b iopsy  (lym ph  no d e) A ITL-3 P ositive N /A
2 nd b iopsy  (sk in ) A ITL -3- N o t done N /A
1st b iopsy  (lym ph  n ode) A ITL-3 N o t done N /A
2 nd b iopsy  (sk in ) A ITL* N ot done N /A
Case 23 3 'd b iopsy  (o ra l) A ITL* N ot done N /A
Case 24 P ' b iopsy  (lym ph  node) A ITL-3 N egative N /A
2 nd b iopsy  (lym ph  n ode) A ITL-2 N egative N /A
1 *  b iopsy  (lym ph  n ode) A ITL-3 P ositive N /A
2 nd b iopsy  (sk in ) A ITL* N ot done N /A
Case 25 3 rd b iopsy  (W ald ey e r’s ring ) A ITL* N o t done N /A
4 Ul b iopsy  (b lood ) A ITL* P ositive N /A
Case 26 P 1 b iopsy  (lym ph  n ode) A ITL-3 N o t done N /A
2 nd b iopsy  (lym ph  n ode) E B V -D L B C L N egative D iffuse  sheets  o f  positive 
ce lls
Case 27 1“ b iopsy  (lym ph  n o d e) AITL-1 P ositive +
2 nd b iopsy  (lym ph  n ode) A ITL-3 N egative ++
Case 28 1“ b iopsy  (lym ph  n ode) A ITL-3 N egative N /A
2 nd b iopsy  (lym ph  n ode) E B V  n ega tive  D L B C L N egative N egative
Case 29 P 1 b iopsy  (lym ph  n ode) A ITL-3 N o t done N ot done
2 nd b iopsy  (lym ph  n ode) A ITL-2 N ot done N ot done
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In case 18, a dominant B-cell clone could not be detected in the biopsy (showing AITL) 
that followed complete remission o f the EBV-associated (monoclonal) DLBCL. In the 
same case however, the PCR results o f the biopsy (showing AITL) that preceded the 
development o f DLBCL were not available.
In one case (case 4) with EBV-associated DLBCL with involvement o f the bone 
marrow, PCR was unsuccessful due to technical reasons.
6.2.4.2.2 EB V-associated CHL
A dominant B-cell clone could not be detected in both biopsies (cases 7 and 8) 
complicated by EBV-associated CHL.
6.2.4.2.3 EB V-negative DLBCL
The molecular genetics results were not available in case 28, where the biopsy at relapse 
showed features o f an EBV-negative DLBCL
6.2.4.2.4. A dominant B-cell clone in AITL, in the absence o f features amounting 
to DLBCL on histology
A dominant B-cell clone was detected in 3 cases (cases 6, 20 and 24) showing features
o f AITL, but no histological evidence o f DLBCL. In one case (case 6), there were many
scattered EBV-infected B-cells in the biopsy that harboured a detectable dominant clone
and in the preceding (initial) biopsy where a dominant B-cell clone was not detected. In
case 20, a dominant B-cell clone was detected in the initial biopsy and in the subsequent
biopsies there were weak dominant bands, but size comparison o f the bands was not
possible in this case. In the 3rd case (case 24), a PCR result was available only on follow
up where a dominant B-cell clone was detected.
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6.2.5 Treatment given and survival data
These are summarized in Table 6.1. A variety o f treatment regimens have been used to 
which there does not appear to be a predictable response. In the 18 patients where follow 
up clinical data was available, 11 patients died (duration o f  survival from initial 
diagnosis ranged from 11- 60 months [mean survival 26 months]), 5 were alive with 
disease (follow up, 12-247 months) and 2 cases (cases 8 and 28) were alive and well 
(follow up, 72 and 24 months respectively).
6.3 Discussion
6.3.1 Progression from pattern I (with hyperplastic follicles) to 
pattern Il/III (typical AITL)
As 5 o f the 6 cases showing pattern I histology on initial biopsy were misdiagnosed as 
reactive on initial biopsy, the histology in the consecutive biopsy represents natural 
histologic progression with no influence o f treatment. O f these 5 cases, in the 3 cases 
that were investigated for CD 10 expression, the neoplastic T-cells highlighted by CD 10, 
not only increased in number, correlating well with the marked increase in FDC 
meshwork, but their distribution also changed from being in the vicinity o f hyperplastic 
follicles in pattern 1 (figure 6.1K-N) to a more diffuse distribution with concentration 
around the expanded FDC meshworks (Figure 6.21 and J). The histologic progression 
from patterns I to III in consecutive biopsies is thus confirmation o f the findings o f Ree 
and co-workers (Ree et al, 1998), that those cases with pattern I histology, should be 
classified as AITL. The time interval between biopsies showing patterns I and II/III 
showed marked variation (2 -  168 months) which indicates that this may represent a
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varied rate progression o f the disease in different patients. When the interval is as short 
as 2 months (case 1) however, the possibility that this may represent varying degrees o f 
involvement o f  different lymph nodes at one time in a particular patient also needs to be 
considered -  i.e. limited involvement a lymph node in pattern I versus more extensive 
involvement in patterns II/III.
In case 19, the histology progressed from patterns I to II, and then to pattern III at 1st and 
2nd relapse respectively. In this case, complete remission was achieved following 
treatment o f each relapse (Table 6.1). However, at 3rd relapse, the histology showed 
“pattern I” histology on biopsy, indicating that this appearance may also be seen in 
relapse following successful treatment.
6.3.2 “Typical” AITL on initial biopsy and follow up lymph node 
biopsies
In 13 cases, the initial and follow up biopsies showed features o f “typical AITL” which 
probably indicates extensive involvement o f biopsied nodes at diagnosis and follow up. 
A lack o f change in numbers or distribution o f CD 10 positive neoplastic T-cells in many 
o f these cases, also suggests similar extent o f lymph node involvement at diagnosis and 
follow up. In case 11 however, although there was no significant reduction in number, 
the CD 10 positive tumour cells which showed a diffuse distribution in an effaced node 
(pattern III) at diagnosis, was more confined to a follicular distribution (pattern II) 
following treatment and probably indicates a favourable response to the latter.
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6.3.3 “High grade” transformation
Prior to the era o f immunohistochemistry, there are reports o f progression o f “AILD” to 
“immunoblastic lymphoma”, with no reference to the lineage o f the latter (Pangalis, et al 
1983). Following the advent o f immunohistochemistry, enabling lineage assignment, the 
reports o f high-grade transformation have mainly been to B-cell “ immunoblastic 
lymphoma” or DLBCL, many associated with EBV (Abruzzo et al, 1993;Bauer et al, 
1982;Joly et al, 2004;Knecht et al, 1995;Matsue et al, 1998;Nathwani et al, 1978;Park et 
al, 2002;Pirker et al, 1986;Zettl et al, 2002).
The findings in our study confirm that in most instances o f “high-grade” histologic 
“transformation” in AITL, the large cell lymphoma is EBV-associated and o f B-cell 
rather than T-cell lineage. In the current study, in 3 cases (the initial biopsy in case 11 
and the follow up biopsies in cases 6 and 18), the EBV-associated DLBCL comprised 
numerous EBV-infected large B-cells that co-existed with AITL in the same biopsy.
Two other cases cases developed EBV-associated DLBCL with no evidence o f AITL. 
One case (case 28) developed an EBV-negative DLBCL, an unusual feature to occur 
following complete remission o f AITL diagnosed only 8 months previously. However, 
expansion o f EBV-negative B-cell clones, although uncommon has been previously 
described (Brauninger et al, 2001). A single case (case 13) in the present study the 
follow-up biopsy showed a large cell lymphoma o f T-cell lineage with no hint o f any 
defining features o f AITL. Although the latter could be clonally related to the preceding 
AITL, this was not proved by molecular genetics studies.
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6.3.4 EBV-associated B-cell proliferations
EBV-infected lymphocytes have been reported in over 95% o f cases in some 
studies.(W eiss et al, 1992) A variety o f EBV-associated B-cell proliferations, have been 
reported in AITL. These are thought to occur due to the associated immune deficiency 
and include a prominent population o f EBV-infected lymphoid cells, sometimes forming 
a confluent population in the background o f AITL, while in others it has occurred as an 
EBV-associated DLBCL in patients with a previous history o f  AITL (Abruzzo et al, 
1993;Knecht et al, 1995;Matsue et al, 1998;Park et al, 2002;Zettl et al, 2002). There are 
also few reports o f the occurrence o f CHL in a patient with a history o f AITL (D'Arrigo 
et al, 1985;Melato et al, 1983;Nakamura et al, 1995). In the current study o f 29 cases, 10 
cases (34%) showed either an EBV-associated B-cell lymphoma or a dominant B-cell 
clone. Five cases were complicated by EBV-associated DLBCL and molecular genetics 
evidence o f a dominant B-cell clone, while 2 cases developed EBV-associated CHL. In 
3 other cases there was a dominant B-cell clone associated with a prominence o f EBV- 
infected B-cells that did not amount to DLBCL.
6.3.4.1 DLBCL
The prognosis o f AITL once complicated by EBV-associated DLBCL is not well 
known. In the study by Zettl and co-workers (2002), they report 2 cases o f AITL that 
were complicated by EBV-associated DLBCL and 1 case complicated by EBV- 
associated plasmacytoma, 34-96 months from initial diagnosis. In the cases in the 
current study, the time taken to develop EBV-associated DLBCL varied from being 
present at initial diagnosis (case 11) to its development 84 months following initial 
diagnosis (case 26) suggesting varied susceptibility. In the 2 cases o f EBV-associated
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DLBCL reported in the study by Zettl, et al (2002) the clinical course varied, with one 
case dying from infection in 4 months, while the other patient had a complete remission 
o f the DLBCL, but only to relapse with DLBCL 10 months later and die o f infection 3 
months later. The case in their series that was complicated by EBV-associated 
plasmacytoma was alive with disease 24 months after diagnosis o f plasmacytoma. In our 
study, 2 o f the cases (cases 5 and 6), the patients died within 3 months o f diagnosis of 
EBV-associated DLBCL. However, in 2 other cases (cases 11 and 18) complete 
regression o f the DLBCL was achieved. In case 11, the complete regression o f EBV- 
infected B-cells was achieved following treatment with thalidomide. In case 18, the 
patient received multi-agent chemotherapy. This suggests that the prognosis following 
development o f EBV-associated DLBCL is quite varied and may also depend on what 
treatment the patients receive. Recently, GELA (France) has recognized the need to 
combat the B-cell component in AITL and has commenced a phase II trial using 
Rituximab with CHOP for AITL with a prominent B-cell component. Similarly, in the 
UK, a trial is being launched using Fludarabine and cyclophosphamide with the addition 
o f thalidomide which has been included not only for its anti-angiogenic properties but 
also in order to investigate its value in controlling the expansion o f EBV-infected B-cells 
(Dogan et al, 2005); personal communication).
6.3.4.2 Classical Hodgkin lymphoma (CHL)
Nakamura, et al (1995) reported the occurrence o f EBV-associated CHL with no 
evidence o f T-cell lymphoma, 16-years following AITL that had no EBER positivity at 
initial diagnosis. In our series we have 2 cases that developed EBV-associated CHL 5- 
years following AITL. As EBV-infected Reed-Sternberg-like cells and a polymorphous
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background are regular features o f AITL, the diagnosis o f CHL in a patient with a 
history o f AITL is a difficult one. This is especially so, as the CD30 positive Reed- 
Stemberg-like cells in AITL may also be CD15 positive (Quintanilla-M artinez et al, 
1999). In fact a diagnosis o f CHL can be made with any degree o f confidence only in the 
absence o f AITL. The latter is difficult to prove on morphology alone as the absence o f 
cytological features o f  malignancy does not rule out AITL, but the absence o f FDC and 
vascular proliferation and lack o f molecular genetics evidence o f a T-cell lymphoma 
helps to exclude it.
6.3.5 Concluding remarks
AITL with hyperplastic follicles represents an early form o f AITL, an appearance that 
may also on occasion be seen at relapse following complete remission. When AITL is 
complicated by the occurrence o f a “ large cell lymphoma” it is most often an EBV- 
associated DLBCL. However a PTL with large cell morphology or EBV-negative 
DLBCL may also occur. EBV-associated B-cell lymphomas such as DLBCL and less 
commonly CHL may occur in up to 25% o f cases o f AITL.
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Chapter 7
CELL OF ORIGIN OF 
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
7.1 Introduction
In B-cell lymphomas, characterization o f normal cell counter part o f specific neoplasms 
has greatly enhanced our ability to classify and risk stratify. In contrast in T-cell 
lymphomas no such scheme is in place. If present it would help better classification and 
risk stratification.
In AITL, FDC proliferation is one o f the defining histological features (Jaffe & 
Ralfkiaer, 2001a). In chapter 3, we showed that the CD3+, CD4+, CD8- neoplastic T- 
cells in AITL also express CD 10 and show a distribution closely associated with that o f 
the expanded FDC meshwork. It was also shown that in early cases with hyperplastic 
follicles and minimal FDC expansion, the CD 10+ neoplastic cells are seen in the outer 
rim and vicinity o f hyperplastic follicles. In peripheral lymphoid tissues, CD 10 
expression appears to be associated with the GC microenvironment, and is restricted to 
GC B-cells (Arber & Weiss, 1997) and the more recently documented, minor subset o f 
benign CD 10+ T-cells located mainly within GCs (Cook et al, 2003). All these features 
raise the possibility that the neoplastic T-cells in AITL may be derived from GC T-cells. 
The latter form a distinct subset o f T-cells that are confined to the GC and express CD4 
and CD57. A small proportion o f these cells also express BCL-6. In a recent study 
production o f B-cell chemokine (BLC), also known as B-cell chemo-attractant (BCA) or
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CXCL13 has been shown to be a feature unique to GC T-cells, setting it apart from other 
T-cells (Kim et al, 2004).
The investigation o f the exact phenotype and cytokine secretion profile o f the neoplastic 
T-cell in AITL, a pre-requisite to identifying the cell o f  origin, is complicated by the fact 
that the neoplastic T-cells are invariably outnumbered by a prominent reactive 
component that also includes numerous reactive T-cells and a varied number o f 
“atypical” EBV-infected bystander B-cells (Anagnostopoulos et al, 1992;Khan et al, 
1993;Willenbrock et al, 2005).
Therefore, the aim o f  this study was to use CD 10 as a marker o f the neoplastic T-cell in 
AITL and investigate whether the latter expresses the GC- T-cell antigens, CD57 and 
BCL-6, and the chemokine CXCL13.
7.2 Results
7.2.1 Tissues used in this part of the project
Forty five paraffin embedded lymph node biopsies from 45 cases o f AITL, diagnosed 
on clinical, histologic, immunophenotypic and molecular genetic criteria were reviewed 
and the diagnosis confirmed in each case. These forty-five (biopsies) cases, all o f which 
showed CD 10 expression by the neoplastic T-cells, were selected to evaluate whether 
the CD 10+ neoplastic T-cells expressed CD57 (26 cases) and BCL-6 (20 cases) and 
CXCL13 (22 cases).
7.2.2 Histology
The architecture o f all lymph nodes examined was either partially or completely effaced
by a polymorphic infiltrate comprising, small lymphocytes and transformed blasts,
plasma cells, histiocytes and eosinophils within a prominent vascular network.
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Depending on the presence o f hyperplastic or regressed follicles or the absence of 
follicles, the histology could be categorized into the previously described patterns I, II 
and III.
Table 7.1: Histology and percentages of CD57+ T-cells and CD10+ T-cells, and BCL-6 
expression CD10+ tumour cells.
Case
no
Pattern Clear cells CD57+ T-cells/ 
CD3+ T-cells
CD 10+ T-cells/ 
CD3+ T-cells
BCL-6 expression by 
tumour cells
1 3 Present 10% 20% Variably positive
2 3 Absent 10% 50% Variably positive
3 3 Present 10% 40% N ot done
4 3 Absent <5% 50% Variably positive
5 3 Present <5% 40% Variably positive
6 3 Absent 30%* 30%** Variably positive
7 3 Present 20% 50% Variably positive
8 3 Present 30% 50% N ot done
9 3 Absent 10% 20% Variably positive
10 3 Present 10% 60% Variably positive
11 3 Absent 20% 50% Variably positive
12 3 Absent <5% 15% Variably positive
13 3 Present 20%* 30%** Variably positive
14 3 Absent 20% 40% Variably positive
15 3 Absent 30% 20% Variably positive
16 3 Absent 50%* 80%** Variably positive
17 2 Present 10% 30% Variably positive
18 2 Absent 10% 20% Not done
19 2 Present <5% 20-30% Variably positive
20 2 Absent <5% 40% Variably positive
21 2 Absent 10% 15-20% Variably positive
22 2 Absent <5% 15-20% Not done
23 1 Present <5% 20% Not done
24 1 Absent 10% 20% Variably positive
25 1 Absent 10% 20% Not done
26 1 Absent 20% 15-20% Variably positive
*Medium or medium to large CD57+ T-cells 
** A subpopulation o f  CD 10+ T-cells appear to co-express CD 10 and CD57
Abbreviations: +, positive
7.2.3 Immunohistochemistry
7.2.3.1 CD57 is not expressed by the neoplastic T-cell in most cases of AITL
Serial sections stained with CD57, CD3, CD10, CD20 and CD21 were examined to 
estimate the approximate ratio o f CD57 positive cells, and CD 10 positive neoplastic T-
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cells, to all (CD3 positive) T-cells, and assess the distribution o f CD57 positive cells in 
relation to CD 10 positive neoplastic T-cells, and CD21 FDC meshworks. In selected 
cases, the distribution o f CD57 positive cells was also assessed using CD10/CD57 and 
CD57/CD21 double-layered immunohistochemistry. These results are given in Table 
7.1. In 23 o f 26 cases, CD57 staining highlighted small cells, distinct from the CD 10+ 
neoplastic T-cell population (Figure 7.1 A-F). O f these cases, in those with typical 
morphology (18 cases), the distribution o f CD57+ cells showed no definite association 
with the FDCs. In those showing “pattern 1” histology with hyperplastic GCs (5 cases), 
the CD57+ T-cells showed a diffuse, interfollicular distribution with concentration 
within some follicles. In the remaining 3 cases (with typical morphology) the CD57 cells 
were mainly medium-sized or medium to large, somewhat atypical lymphoid cells and 
showed a diffuse distribution with concentration around expanded FDCs (Figure 7.1J 
and L). In these latter 3 cases, the distribution o f CD57+ cells showed an overlap with 
CD 10+ cells and double staining showed a subpopulation that appeared to co-express 
CD 10 and CD57 (Figure 7 .IK)
7.2.3.2 BCL-6 is expressed by the neoplastic T-cell in AITL
In all cases examined BCL-6 was expressed although in varied intensity, by cells that 
showed a similar distribution to CD10+ T-cells (Table 7.1M). When assessing the latter, 
residual CD 10+ (GC) B-cells were excluded by comparing sequential sections stained 
with CD20 and CD 10 and by double-layered CD20/CD10 immunohistochemistry. In 
cases where assessment was difficult owing to varied staining intensity o f BCL-6 
expression in individual cells, the pattern o f expression was clarified by CD10/BCL-6 
double-staining (Figure 7 .IN and O). In the 7 cases that showed clear cells, a variable 
pattern o f BCL-6 expression was observed in the clusters o f pale to clear tumour cells.
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Figure 7.1 CD57 and BCL-6 expression in AITL
Panels A-F show biopsy from case 23. (A and B) Haematoxylin and eosin (H&E) stained section showing 
clusters o f clear cells. (C) CD3 stain confirms that the clear cells are T-cells. (D) CD21 showing mild 
expansion o f the follicular dendritic cell (FDC) meshwork. (E) CD 10 stain highlights clusters o f  clear 
cells. (F) CD57 stain shows small CD57 positive T-cells but the clear cells are CD57 negative. Panels G- 
M show biopsy from case 13. (G) H&E stained section showing a “pattern 111” histology with clear cells 
in a polymorphous background (inset). (H) CD3 stain highlights numerous T-cells. (I) CD 10 stain shows 
many CD10 positive neoplastic T-cells. (J) CD57 highlights many CD57 positive cells. (K, left panel) 
CD10/CD57 double stain and (K, right panel) CD57/CD10 shows many lymphoid cells that appear to co­
express CD10 and CD57. (L) CD21/CD57 double stain shows that the CD57 positive cells are 
concentrated around the CD21 positive expanded FDC (M) BCL-6 stain highlights many positive cells. 
Panels N and O show CD10/BCL6 double staining in another case (case 2) shows many CD 10 (brown) 
positive cells show variable co-expression o f  BCL6.
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Figure 7.2 CXCL-13 expression by the neoplastic T-cells in AITL.
(A) Haematoxylin and eosin stained section showing clusters o f  clear cells. (B) CD3 highlights these 
clusters o f  clear cells. (C) CD 10 stain shows that the neoplastic T-cells (clear cells) are CD 10 positive. 
(D) CXCL-13 stain shows positive staining in the clear cells (neoplastic T-cells).
7.2.3.3 CXCL13 is expressed by the neoplastic cell in AITL
Similarly, CXCL13 expression by tumour cells was assessed by single-layered 
immunohistochemistry. All 22 cases o f  AITL (where the neoplastic cells were CD 10 
positive) showed CXCL13 positivity. In all cases examined, the distribution o f CXCL13 
positivity was identical to the distribution o f  CD 10+ tumour cells (Figure 7.2).
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7.2.4 Microdissection and PCR for TCRy gene reararrangement: 
in a subset of cases, part of the neoplastic T-cell population 
expresses CD57
As 3 cases showed a rather large subpopulation that appeared to co-express CD 10 and 
CD57, in one such case (case 16 -  Table 7.1), CD57+ cells were microdissected by laser 
capture (Figure 7.3) and subject to PCR for TCRy gene reararrangement. PCR products 
from microdissected cells gave a band identical in size to the dominant band observed 
for the PCR performed on whole sections (Figure 7.4), suggesting that in these cases, at 
least part o f the neoplastic population expressed CD57.
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Figure 7.3. Laser capture microdissection of CD57 positive lymphoid cells in AITL.
(A) CD57 stained section before microdissection; the cells targeted for microdissection are indicated 
within the black arrows. (B) Same area after microdissection; the black arrows show the spaces left after 
cells have been removed. (C) High-power view o f  a cluster o f  CD57 positive cells after microdissection. 
These are the cells/spaces indicated by the arrows in panels A and B. Original magnification A, B, 3 200; 
C 3 400.
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Figure 7.4. Case 16: analysis of PCR products for TCR-y chain gene (from whole section 
and microdissected samples) on a 10% polyacrylamide gel.
Lane 1 (M), molecular weight markers; lane 2, negative control; lane 3, positive control; 
lane 4and 5 whole section PCR products from case 16; lanes 6-9 (16a-e) microdissected 
PCR products from case 16.
7.3 Discussion
7.3.1 Germinal centre (GC) T-cells
GC T-cells comprise a distinct subset o f CD4+ effector T-cells that is localized to GCs 
and efficient at inducing B-cell antibody production. In addition to CD4, these 
lymphocytes also express CD2, CD3 and more specifically CD57 (Kim et al, 2001b).
GC T-cells also express the activation marker CD69 (Schaerli et al, 2000) and a subset 
has been shown to express BCL-6 (Falini et al, 1996;Flenghi et al, 1995). Recently 
Cook, and co-workers (2003) reported the presence o f a minor population o f benign 
CD10 positive T-cells that are located mainly within GCs. GC-T-cells proliferate poorly 
in response to T-cell activation (Johansson-Lindbom et al, 2003), and are CD45RA- and 
CD45RO+ (Kim et al, 2001b), features that would be consistent with terminal 
differentiation. On activation, GC-T-cells express inducible antigens CD 134 (0X 40) and 
CD40L (Kim et al, 2001b), which enable interaction with GC-B-cells (Calderhead et al,
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1993;Stuber et al, 1995), and also express high levels o f interleukin-10 (IL-10) (Kim et 
al, 2001b), a cytokine important for antibody class switching and B-cell differentiation 
into plasma cells (Liu & Banchereau, 1997). Furthermore, inducible co-stimulator 
(ICOS) and cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4), members o f the 
CD28 family o f  co-stim ulatory molecules are highly expressed on GC-T-cells (Breitfeld 
et al, 2000;Vandenborre et al, 1998). ICOS, when activated, superinduces the synthesis 
o f IL-10 (H utloff et al, 1999). Although it was believed that GC-T-cells were unable to 
secrete IL-2, T N F -a  and IFNy (Bowen et al, 1991;Velardi et al, 1986), more recent 
reports (Kim et al, 2001b), show that they are able to produce IL-2, IL-4, IFNy and 
TN F-a. Their chemokine receptor phenotype o f expressing CXCR5 (the receptor for 
BCA/CXCL13), but not CCR7 [the receptor for E B 11-ligand chemokine (ELC)] 
correlates well with their localization to G C ’s, as they chemotax to B-cell chemo- 
attractant - CXCL13, but not T-cell zone chemokine -  ELC) (Breitfeld et al, 2000;Kim 
et al, 2001b;Schaerli et al, 2000).
More recently, gene expression profiling has shown that CXCL13 is one o f the most 
highly up-regulated genes in GC-T-cells. The latter, but not other T-cells, secrete large 
amounts o f functional CXCL13 upon T-cell receptor activation (Kim et al, 2004).
7.3.2 CD57 and its expression in AITL
The CD57 antigen is a 110-kd glycoprotein that is encoded by a gene on chromosome 11 
(Schroder et al, 1983). In peripheral blood it is expressed by NK-cells and a subset o f T- 
cells that is predominantly o f  the CD8+ cytotoxic phenotype (Abo & Balch, 1981 ;Arber 
& Weiss, 1995;Phillips & Lanier, 1986). In lymphoid tissues CD57+ T-cells are CD3+, 
CD4-t-, CD8-, located primarily in the GCs and are referred to as GC-T-cells (Poppema
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et al, 1983;Si & W hiteside, 1983;Swerdlow & Murray, 1984;Velardi et al, 1986). The 
structure and function o f  CD57, associated molecules and its relevance to disease is not 
known. The most common CD57+ lympho-proliferative disorder is T-cell large granular 
lymphocytic leukaemia (T-LGL) (WHO, 2001). CD57 is not usually expressed by 
extranodal NK/T-cell lymphoma, nasal type or aggressive NK-cell leukaemia (Chan et 
al, 2001a;Chan et al, 2001b). Although most haematopoietic neoplasms do not express 
CD57, it may be expressed by a wide range o f non-haematopoietic neoplasms such as 
prostatic adenocarcinomas, thyroid carcinomas and oligodendrogliomas, among others 
(Ghali et al, 1992;Liu et al, 2004;Loy et al, 1994;Motoi et al, 1985). Following most 
bone marrow and some solid organ transplantation and in HIV infection, there is a well- 
documented increase in CD8+, CD57+ T-cells (Leroy et al, 1986;Mizuno et al, 
1986;Reipert et al, 1992) and a few reports o f an increase in CD4+, CD57+ T-cells 
(Legendre et al, 1989;Velardi et al, 1988) in the peripheral blood. Non-neoplastic 
reactive CD57+ GC-T-cells are often increased in number in nodular lymphocyte 
predominant Hodgkin lymphoma (NLPHL), where they form rosettes around the 
neoplastic L&H cells (Kamel et al, 1993;Poppema, 1989).
With regard to AITL, Ree and co-workers (1999) reported that in “AITL with GCs” (3 
cases), many GCs were devoid o f CD57+ cells while others were loosely populated with 
CD57+ cells and scattered CD57+ cells were also seen in the interfollicular areas, 
suggesting outward migration o f intra-follicular T-cells. Their results with double 
staining for CD57 and BCL-6 showed that approximately 90% o f CD57+ cells were 
BCL-6 negative, the staining being equivocal in the remaining 10% suggesting that they 
are 2 distinct populations. Although Ree and co-workers (1999) describe the 
distribution o f CD57+ T-cells in early AITL, the status o f the neoplastic T-cell with
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regard to CD57 expression is not entirely clear from their study. In the present study, all 
cases showed a varied number o f CD57+ T-cells (<5%-50%). With the aid o f CD 10 as a 
marker o f neoplastic T-cells and the use o f both single and double layered 
immunohistochemistry, our results show that in most cases, the CD57 T-cell population 
represents small T-cells, forming a distinct population from CD 10 positive T-cells 
including atypical “clear” cells when present, suggesting that the former are probably 
reactive in nature (Figure 6.1A-F.). These findings are consistent with those inferred in 
the study by Ree and co-workers/ (1999). However in 3 o f 26 cases, the CD57+ cells, 
were diffusely distributed but with some concentration around the expanded FDC 
meshwork, and included medium sized or medium to large and sometimes clearly 
atypical cells. In these cases double staining showed that a subpopulation o f the CD 10+ 
neoplastic T-cells appeared to co-express CD57 (Figure 6 .IK). Preliminary molecular 
genetics analysis o f  TCRy gene rearrangement in one o f the latter cases showed that the 
size o f the PCR product obtained from micro-dissected samples was identical to that 
obtained from the whole section. These results suggest that the CD57+ population in this 
case form at least part o f the neoplastic clone. However, as interpretation (and 
comparison) o f band size on a 10% polyacrylamide gel is not entirely accurate and an 
identical band size does not always mean identical sequence, because the difference in 
DNA sequence may result from a difference in (N-region) composition, rather than 
number o f base pairs, confirmation o f these findings would require DNA sequence 
analysis. Overall, in most cases o f AITL, CD57+ T-cells are probably reactive but in a 
minority o f cases, a subset o f the neoplastic population appears to co-express CD57.
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7.3.3 BCL-6 and its expression in AITL
BCL-6, a nuclear phosphoprotein, with transcriptional repressor activities, is expressed 
by GC-B-cells and critical for GC development. It is induced in B-cells during GC 
induction and down-regulated on GC cell differentiation. BCL-6 is also expressed by a 
small subset o f  CD57+ GC-T-cells (Falini et al, 1996), and a small fraction o f 
interfollicular CD4+ T-cells (Flenghi et al, 1995). On expression profiling, Kim and co­
workers (2004) and Chtanova and co-workers (2004) have shown that BCL-6 is up- 
regulated in GC-T-cells. The function o f BCL-6 in T-cells is not yet known. Kraus and 
Haley (Kraus & Haley, 2000) showed that the reactive CD57+ T-cells that rosette the 
neoplastic L&H cells in NLPHL, also co-express BCL-6.
The results o f the present study show that the tumour cells in AITL express BCL-6 in 
varying intensity, a feature confirmed by the use o f double-layered 
immunohistochemistry in selected cases demonstrating co-expression o f CD 10 
(membrane stain) and BCL-6 (nuclear stain) in T-cells, including clusters o f “atypical 
clear cells” . These findings are in concordance with those o f Ree and co-workers (1999) 
who reported a similar pattern o f BCL-6 expression in “atypical tumour cells” in 10 
cases o f AITL.
7.3.4 CXCL-13 and its expression in AITL
CXCL-13, the ligand for CXCR5 plays a crucial role in attracting B-cells to follicles 
containing FDCs (Ansel et al, 2000). CXCL13 is believed to be expressed by FDCs, and 
as mentioned above has been shown to be a characteristic o f  GC-T-cells, setting them 
apart from other T-cells (Kim et al, 2004). It has also been shown to be expressed by 
dendritic cells and endothelial cells o f HEV (Ebisuno et al, 2003;Vissers et al, 2001).
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Many o f the CXCL13+ GC-T-cells are in direct contact with antigen presenting 
CD11C+ cells and GC-B-cells (Kim et al, 2004). Freshly isolated GC-T-cells secrete 
low levels o f CXCL13, in the absence o f stimulation. T-cell activation, similar to T-cell 
receptor activation increases CXCL13 expression by 20-40 fold (Kim et al, 2004). Anti- 
CD3 in combination with anti-CD28, and also interaction with GC-B-cells stimulate 
CXCL13 production by GC-T-cells (Kim et al, 2004). In-vitro studies have shown that 
CXCL13 in GC-T-cells efficiently attracts CD4+ memory T-cells, GC-T-cells and IgD+ 
naive B-cells (Kim et al, 2004).
Ohshima and co-workers (Ohshima et al, 2004) reported CXCL13 expression in AITL. 
Using CD 10 as a marker o f  the neoplastic T-cell we showed that the latter co-expresses 
CXCL13, consistent with the chemokine secretion profile o f GC-T-cells. One o f the 
downstream effects o f CXCL13 expression is induction and proliferation o f FDCs 
probably via stimulation o f lymphotoxin alpha production by B-cells (Ansel et al, 2000). 
In this light, it would be interesting to investigate whether CXCL13 plays a role in the 
FDC proliferation in AITL, a feature considered to be a morphological hallmark o f the 
disease
7.3.5 Cell of origin in AITL -  Concluding remarks
The neoplastic T-cell in AITL is known to be o f the CD3+, CD4+ phenotype and in 
chapter 3 we showed that it also expresses CD 10. In the present study using CD 10 as a 
marker for the neoplastic T-cell we show that it expresses BCL-6, and in a minority o f 
cases, CD57. As chemokine receptors have been used as markers o f functional subsets 
o f T-cells, the CXCR3+, CD 134+ (0X 40), CD69+ and T-box transcription factor (T-
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bet)+ profile in AITL has hitherto been interpreted as evidence o f Thl differentiation 
(Dorfman & Shahsafaei, 2002;Dorfman et al, 2003;Ishida et al, 2004;Jones et al, 
1999;Jones et al, 2000;0hshim a et al, 2004;Tsuchiya et al, 2004). However, GC-T-cells, 
which have only recently been identified as a subset that is distinct from Thl and Th2 
effector subtypes, are also known to express CD 134 (0X 40) and the activation marker 
CD69 (Kim et al, 2004). Furthermore, the results o f our study have shown that the 
neoplastic T-cells express CXCL13, a marker that sets GC-T-cells apart from other T- 
cells. Despite the lack o f CD57 expression in most cases, overall, the features favour a 
GC-T-cell origin for the neoplastic T-cell in AITL. W hether they arise from a specific 
subset o f GC-T-cells is however, yet to be determined.
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Chapter 8
CORRELATION BETWEEN EBV LOAD AND 
HISTOLOGY, AND THE ROLE OF HHV-8 IN 
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
8.1 Introduction
AITL is characterised by prominent systemic symptoms and has been shown to be 
associated with a state o f  immune dysregulation and the production o f a variety o f 
cytokines (Foss et al, 1995;Pautier et al, 1999;Pizzolo et al, 1990;Siegert et al, 
1992;Siegert et al, 1995;Takeshita et al, 1993;Tobinai et al, 1988). These features are 
similar to those o f  conditions such as multicentric Castleman disease that have a proven 
viral (HHV-8) aetiology in many cases (Dupin et al, 2000).
Although it is widely accepted that AITL is indeed a T-cell lymphoma, there is an 
ongoing debate as to whether an oligoclonal process precedes the emergence o f 
lymphoma. (Jaffe & Ralfkiaer, 2001a) This suggests that the disease may be associated 
with the effects o f an agent that induces T-cell proliferation, which in turn would give 
rise to a dominant clone possessing genetic changes that confer growth advantage. A 
possible viral aetiology has been entertained and EBV has been the most extensively 
investigated as a potential causative agent. Although some studies (Anagnostopoulos et 
al, 1992;Anagnostopoulos et al, 1995) have suggested that T-cells may also be infected, 
the overall consensus is that the EBV infection does not involve T-cells but t an 
expansion o f EBV infected B-cells may be present in up to 95% of cases (Brauninger et
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al, 2001;0hshim a et al, 1994;Weiss et al, 1992). The latter is believed to be a secondary 
phenomenon due to the immune dysregulation present.
Other viruses such as HHV-6, (Daibata et al, 1997;Luppi et al, 1993) HHV-8 (Luppi et 
al, 1996) and hepatitis C virus (Luppi & Torelli, 1996), have also been reported in 
AITL. HHV-6 although identified by PCR, (Luppi et al, 1993) was localized to scattered 
by-stander plasma cells (Luppi et al, 1998) by immunohistochemistry. There have also 
been conflicting reports regarding the presence o f HHV-8 infection in AITL (Chadburn 
et al, 1997;Luppi et al, 1996).
In chapter 3 we showed that histological pattern I represents limited lymph node 
involvement, while pattern III shows extensive lymph node involvement by the disease. 
Furthermore in chapter 6 we showed histological progression from pattern I to patterns 
II/III in sequential biopsies.
The aim o f this part o f the project was two-fold. The first was to characterise and 
immunophenotype the cell-type o f EBV-associated cell proliferations in AITL and to 
correlate the EBV load with the histological patterns (I-III) previously described.
In the second part o f this study we investigated for the presence o f HHV-8 virus in 
AITL.
8.2 Results
8.2.1 Tissues used in this part of the study
Paraffin embedded biopsies from 63 diagnosed cases o f AITL were reviewed and the
histology confirmed in each case. Paraffin embedded tissue was available in all cases,
and frozen material was available on 5 cases.
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8.2.1.1 Characterisation of EBV-infected cells
Four cases (Cases 1, 2, 40 and 41) selected for this part o f the study showed numerous 
EBV-positive cells on EBER in situ hybridisation and had histological features o f  
DLBCL (lymph node biopsy at relapse in case 1, and bone marrow biopsy in case 41) 
and/or evidence o f  a dominant B-cell clone on Ig heavy chain gene PCR (lymph node 
biopsies in cases 2 and 40).
8.2.1.2 EBV quantification by real time PCR
Paraffin embedded tissues from 49 biopsies (39 cases [Cases 1-39]) were used for this 
part o f the study. Frozen material available in 5 o f the cases was also utilised.
8.2.1.3 HHV-8 screening by conventional PCR
Paraffin embedded tissues from 28 cases o f AITL (Cases 1, 11, 12, 19, 29, 36 and 42- 
63), were used for this part o f the study.
8.2.2 Characterisation of EBV-infected cells in AITL
8.2.2.1 Double layered immunohistochemistry and EBER in situ hybridisation: 
EBER positive cells are CD79a positive
Four biopsies from 3 cases (with many EBER positive cells) were selected for double 
layered immunohistochemistry and EBER in situ hybridisation. One case (case 1) had 
consecutive biopsies (case 5 in chapter 6) the first o f  which had many EBER positive 
cells but no evidence o f a dominant B-cell clone on IgH PCR, and the second which had 
numerous confluent sheets o f EBER positive cells and a dominant B-cell clone,
210
amounting to DLBCL. The other 2 cases (cases 2 and 40) had many scattered EBER 
positive cells and a dominant B-cell clone. The combinations o f double layered 
immunohistochemistry and EBER-ISH were as follows: CD3/EBER, CD20/EBER, 
CD79a/EBER and CD10/EBER. The EBER positive population was distinct from the 
CD3 and CD 10 positive populations in all 4 biopsies (Figures 8.1). On CD20/EBER, 
although some EBER positive cells were CD20 positive, there were many cells that were 
CD20 negative (Figure 8.2). However, CD79a highlighted all EBER positive cells 
(Figure 8.2).
Figure 8.1. EBER positive cells are CD3 negative
EBER-in situ hybridization/CD3 staining in case 2 (panel A), case 1 (panel B) and 
case 40 (panels C and D) show that the EBER positive population (blue) is distinct 
from the CD3 positive T-cells (brown)
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Figure 8.2 EBER positive cells are CD20 +/-, CD79 positive and CD 10 
negative.
(A) EBER/CD20 in case 2 shows that only some o f  the EBER positive cells express 
CD20. (B) EBER/CD79a in case 2 highlights all EBER positive cells. (C and D) 
EBER/CD10 in case 2 (C) and case 40 (D) shows that the EBER positive 
population is distinct from the CD 10 positive cells.
8.2.2.2 Further im m unophenotypic characterisation o f EBER positive B-cells: 
EBV-infected B-cells in AITL show an immunoblastic / plasm acytoid  
phenotype
For further immunophenotypic characterisation, sections stained using single layered 
immunohistochemistry were compared with consecutive sections on which EBER-ISH
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was performed. When examining sections, areas where EBER positive cells were 
present in sheets were selected for comparison.
BCL-6 performed on cases 1 and 41 showed that the EBER-ISH positive cells were 
BCL-6 negative (Figure 8.3). MUM -1/IR4 and CD 138 immunostaining performed on 
case 41, showed that the EBER-ISH positive cells were M UM-1/IR4 positive (Figure 
8.3), but CD138 negative. Immunoglobulin light chain staining in case 40 showed 
specific staining with abundant cytoplasmic Ig and and kappa light chain restriction in 
the EBV positive B-cell population (Figure 8.4)
8.2.2.3 Microdissection of EBER positive cells and IgH PCR: EBV-infected B- 
cells comprise the dominant B-cell clone (when present) in AITL
EBER-ISH positive cells from case 40 were microdissected by laser capture and IgH 
PCR was performed on single microdissected cells. The band size in 2 o f the 4- 
microdissected samples was identical to the dominant band on whole section PCR 
(Figure 8.4) confirming (the immunohistochemical observation o f light chain restriction) 
that EBV-infected cells comprise the dominant clone.
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Figure 8.3. EBER positive cells in EBV-associated diffuse large B- 
cell lymphoma in bone marrow of case 41, are CD79a 
positive, BCL6 negative and MUM-1 positive.
(A) CD79a highlights numerous B-cells. (B) EBER-in situ hybridization shows 
numerous EBV infected cells in same area. (C and D) Deeper section showing 
same area, with cells that are negative for BCL-6, but positive for MUM-1.
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Figure 8.4 Light chain immunostaining and immunoglobulin heavy chain gene PCR of 
whole section and microdissected EBER-positive cells in case 40 show that 
EBER positive cells comprise dominant clone.
(A  and B) Kappa (A) and lambda (B) immunostaining shows kappa light chain restriction. Lambda 
staining highlights a few scattered plasma cells only.
(C) PCR products o f  whole section (lane 1) and microdissected EBER positive cells (lanes 2-5) show that 
the product size o f  the microdissected samples in lanes 3 and 4 are identical in size to that o f  the whole 
section dominant band.
8.2.3 Virus specific EBV quantitative real-time PCR
Forty-nine biopsies from 39 cases (Table 8.1) were selected for quantitative PCR using 
EBV-specific primer pairs designed from EBNA region for EBV (106bp), the results of 
which are shown in Table 8.1 and Figure 8.4. For details o f method o f quantification see 
Chapter 2, section 2.5.9.3.
215
8.2.3.1 A high EBV load, a feature predominantly of pattern III histology
Real-time, quantitative PCR using EBV virus-specific primers was successful in 48 
biopsies (39 cases) (Table 8.1). O f these, 24/27 biopsies (22/25 cases), showing pattern 
III histology were EBV positive (Tables 8.1). O f the 27 “pattern III” biopsies, 15 
biopsies had a high EBV load o f >50 copies/1000 cells (Table 8.1 and Figure 8.4). O f 
the 13 biopsies showing pattern II histology, 10 were EBV positive by PCR, but only 2 
biopsies showed an EBV load o f >50 copies/1000 cells (Table 8.1 and Figure 8.4). Three 
o f the 4 biopsies showing pattern I histology were EBV positive, but none o f them had a 
high EBV load (>50 copies/1000 cells) (Table 8.1 and Figure 8.1).
8.2.3.2 Cases with consecutive biopsies
The results o f EBV-virus specific quantitative PCR, in cases where consecutive biopsies 
were available for study, are summarised in Table 8.1
8.2.3.2.1 Progression from “Pattern I ” to “Pattern III” associated with marked rise
in EBV load
In the 2 cases which showed histologic progression from patterns I to III (cases 32 and 
33), the initial biopsies with pattern I histology was either negative or had a low EBV 
load, whereas the consecutive biopsies had a high EBV load (> 50 copies/1000 cells).
8.2.3.2.2 Consecutive biopsies with “Pattern III” histology show a decrease or 
mild ncrease in EBV load in follow up biopsy
O f the 3 cases where consecutive biopsies showed “pattern III” histology (cases 34-36),
one case (case 34) had a high EBV load in both biopsies, but the first biopsy had a much
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higher load than the second biopsy. The involved parotid biopsy that followed was also 
EBV-positive, but with a lower viral load than in previous lymph node biopsies. In case 
35, only the follow up biopsy had a successful result and was negative for EBV, while in 
case 36, both biopsies were EBV positive, with a viral load o f <50 copies/1000 cells.
8.2.3.2.3 Regression o f EB V-associated lympho-proliferation in AITL Pattern III 
and DLBCL treated with Thalidomide
In case 37 (case 11 in chapter 6, treated with Thalidomide between biopsies), the initial
biopsy which showed AITL and co-existent EBV-DLBCL had a very high EBV load, a 
feature that had regressed in the follow up, post-treatment biopsy.
8.2.3.2.4 Absence o f EB V in PTL that followed EB V positive AITL
In case 38 although EBV was present in the first biopsy showing AITL, this was not the
case in the consecutive biopsy showing diffuse sheets o f large atypical T-cells, classified 
as PTL, unspecified.
8.2.3.2.5 High EBV load in a case o f AITL, that developed CHL 5-years later
In case 39, where the patient developed EBV-associated CHL 5-years following AITL, a
high EBV load was detected in the initial biopsy showing AITL.
8.2.4 HHV-8, virus specific PCR: HHV-8 infection is not a feature 
of AITL
All 28 cases investigated were negative for HHV-8, virus-specific PCR
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Table 8.1 Summary of results of real-time EBV -specific PCR
Site of biopsy Diagnosis Pattern
EBV copies/1000 cells 
(triplicate, mean)
1 Lymph node AITL 3 71.3
2 Lymph node AITL 3 53.4
3 Lymph node AITL 3 7.5
4 Lymph node AITL 3 18.4
5 Lymph node AITL 3 156.1
6 Lymph node AITL 3 10.4
7 Lymph node AITL 3 3.5
8 Lymph node AITL 3 54.2
9 Lymph node AITL 3 3462.6
10 Lymph node AITL 3 359.1
11 Lymph node AITL 3 86.4
12 Lymph node AITL 3 232.3
13 Lymph node AITL 3 499.1
14 Lymph node AITL 3 0
15 Lymph node AITL 3 21.8
16 Lymph node AITL 3 0
17 Lymph node AITL 3 14.4
18 Lymph node AITL 2 0
19 Lymph node AITL 2 94.9
20 Lymph node AITL 2 25.2
21 Lymph node AITL 2 0.9
22 Lymph node AITL 2 0
23 Lymph node AITL 2 47.6
24 Lymph node AITL 2 7.7
25 Lymph node AITL 2 8.9
26 Lymph node AITL 2 36.4
27 Lymph node AITL 2 0
28 Lymph node AITL 2 6.5
29 Lymph node AITL 2 512.6
30 Lymph node AITL 1 12.4
31 Lymph node AITL 1 3.4
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Table 8.1 Summary of results of real-time EBV -specific PCR (continued from previous
page)
Site of biopsy Diagnosis Pattern
EBV copies/1 OOOcells 
(triplicate, mean)
32 Lymph node AITL 1 14.7
Lymph node AITL 3 55.7
33 Lung AITL 1 0
Lymph node AITL 3 1124.4
34 Lymph node AITL 3 418.5
Lymph node AITL 3 65.3
Parotid gland AITL 19
35 Lymph node AITL 3 failed
Lymph node AITL 3 negative
36 Lymph node AITL 3 15.4
Lymph node AITL 3 35.4
37 Lymph node AITL
+EBV -
DLBCL 3 3697.9
Lymph node AITL 2 2.4
38 Lymph node AITL 3 33.9
Lymph node PTL,
unspecified N/A 0
39 Lymph node AITL 3 291.3
Lymph node EBV-CHL N/A 13.6
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Figure 8.5: Correlation between EBV load and histological pattern o f AITL in tumour 
tissues
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8.3 Discussion
8.3.1 EBV infection in B-cells and its occurrence in AITL
EBV, a y herpes virus with a double stranded DNA genome, infects mainly B-cells, but 
may also infect T-cells and epithelial cells (Kuppers, 2003). EBV infection usually 
occurs in childhood or adolescence when it results in an asymptomatic or mild illness 
(Cohen, 2003;Kuppers, 2003), following which the virus remains in a latent state for life 
(Yao et al, 1985). In individuals with impaired cellular immunity, virus reactivation 
occurs (Babcock et al, 1999), while in the immunosuppressed, an uncontrolled EBV- 
driven B-cell proliferation may occur (Ho et al, 1988;Shapiro et al, 1988).
In healthy virus carriers EBV infects naive B-cells, which proliferate and undergo clonal 
expansion. Some o f these B-cells then undergo the GC reaction and differentiate into 
memory B-cells (Thorley-Lawson, 2001). EBV remains latent in these memory cells, 
but if the latter differentiate into plasma cells, the virus may switch to a lytic cycle 
(Laichalk & Thorley-Lawson, 2005) and infect new naive B-cells, thus maintaining the 
pool o f virus-infected cells (Babcock et al, 2000;Joseph et al, 2000a;Joseph et al, 
2000b;Thorley-Lawson & Babcock, 1999;Thorley-Lawson, 2001). Although many 
studies support this model for infection in healthy carriers, in vitro experiments suggest 
that EBV may not just target naive B-cells, but may also infect memory B-cells (Ehlin- 
Henriksson et al, 2003). There is also some speculation as to whether the GC 
characteristics acquired by EBV-infected B-cells occurs in “extrafollicular” regions 
(Thorley-Lawson, 2001).
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In infectious mononucleosis, EBV infects GC/memory B-cells and also naive B-cells 
(Kurth et al, 2000). Kurth, et al showed that clonal expansion in infectious 
mononucleosis occurs mainly in B-cells with mutated Ig genes that show no intraclonal 
diversity.
EBV-associated post-transplant lympho-proliferative disorder (PTLD) which in most 
instances is o f  B-cell origin, may be polyclonal, oligoclonal or monoclonal (Harris et al, 
2001b). The majority however is monoclonal and most clones have mutated Ig genes, a 
fraction o f which show on-going somatic hypermutations (Brauninger et al, 2003). The 
occurrence o f “crippling m utations” in Ig genes and survival without selection for 
expression o f a functional antigen receptor have also been reported, suggesting that EBV 
may interfere with normal B cell differentiation and selection processes in PTLD 
(Brauninger, et al 2003).
In AITL, EBV-infection has been reported mainly in bystander B-cells, but a few studies 
report infection in T-cells. Reports in the literature (Anagnostopoulos et al, 
1992;Anagnostopoulos et al, 1995) demonstrating EBV infection o f  T-cells in AITL 
used CD45RO to identify T-cells. However as transformed B-cells and pre-plasma cells 
may also be reactive with anti-CD45RO (Hathcock et al, 1992;Jensen et al, 1989), 
reactivity to the latter is not proof o f T-cell lineage. Most studies (Brauninger et al,
2001 ;Ohshima et al, 1994;Weiss et al, 1992) including the present study, have shown 
that EBV infection is confined to B-cells. As in PTLD, expansion o f EBV-infected B- 
cell clone in AITL is thought to be a result o f  immune deregulation.
Brauninger and co-workders (2001) showed that most EBV infected B-cells in AITL 
carry mutated Ig genes, indicating a memory or GC-like genotype. They also showed 
that the subset o f EBV infected B-cells resembling memory B-cells showed little
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tendency for clonal expansion, whereas the proliferating EBV infected B-cells 
undergoing clonal expansion showed evidence o f  on-going somatic hypermutations, 
indicating a GC-like genotype. They go on to postulate that in AITL, the large 
aggregates o f FDCs, in association with the CD4 positive T-cells, may simulate their 
role in normal GCs and provide the required microenvironment to induce or maintain 
somatic hypermutations in some o f these cells. Furthermore as described for PTLD 
(Brauninger et al, 2003), Brauninger, et al (2001) demonstrated that many o f the 
expanding B-cell clones had acquired destructive mutations in originally functional V 
gene rearrangements, over repeated rounds o f mutation and division, showing that 
somatic mutations are acquired without selection for expression o f a functional antigen 
receptor. Although seen mainly as a feature o f EBV infected B-cells, it was also 
occasionally observed in EBV negative B-cells in AITL (Brauninger et al, 2001).
8.3.2 EBV-infected B-cells in AITL have an immunoblastic / 
plasmacytoid immunophenotype
Several studies (Brauninger et al, 2001 ;Ohshima et al, 1994;Weiss et al, 1992) used 
double labelled immunohistochemistry / in situ hybridisation and showed that most 
EBER positive cells co-expressed CD20. In our study double labelling showed that some 
EBER positive cells express CD20 but all seem to be highlighted by CD79a. In contrast, 
the EBER positive cells were distinct from the CD3 and CD 10 positive lymphoid 
populations (Figure 8.3). The MUM-1 positive, CD 10 negative, BCL-6 negative,
CD79a positive, CD138 negative, CD20 +/- immunophenotype together with the 
presence o f abundant cytoplasmic light chain Ig, point to an
immunoblastic/plasmacytoid phenotype. This phenotype is similar to that observed in
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EBV-driven PTLD with a “post-GC” phenotype (Capello et al, 2003). In the light o f the 
findings by Brauninger, et al (2001), the “post-GC”, rather than a “GC” phenotype (in 
EBV-infected cells) is unexpected, as all examples selected to investigate the EBV- 
infected B-cell phenotype in the present study had numerous EBER-ISH positive cells 
amounting to DLBCL and/or a dominant B-cell clone on IgH PCR, indicative o f clonal 
expansion. W hether some o f the genotypic characteristics such as acquisition o f GC-like 
features with ongoing somatic mutations, and survival despite “crippling” mutations are 
the result o f the viral infection and the association with the tumour/FDC environment is 
yet to be determined.
8.3.3 Histologic progression from patterns I to III, and its 
correlation with EBV load
In chapter 3, 3 overlapping histologic patterns (“patterns I-III”) were described in AITL. 
They showed increasing destruction o f the normal lymph node architecture from patterns 
I through to III, and were defined by the presence o f hyperplastic follicles (pattern I), 
regressed follicles (pattern II) or absence o f  identifiable follicles (pattern III). The 
appearance described as “pattern I” histology has also been described by Ree, et al 
(1998) as “AITL with hyperplastic follicles”, and shown (in 2 cases) to progress to more 
“typical AITL” suggesting that “pattern I” may represent the histological appearance in 
“early” AITL. This was confirmed in the results presented in chapter 6 where 4 cases 
showing “pattern I” morphology progressed to more typical AITL (“patterns 11/111”) on 
subsequent biopsy. Furthermore, in chapter 3, it was shown that the number and 
distribution o f CD 10 positive neoplastic T-cells in patterns I, II and III, were consistent 
with histologic progression, as they increased in number from patterns I-III and
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progressed from being confined to the region o f the follicles (pattern I) to a more diffuse 
distribution correlating with the increasing expansion o f  FDCs (pattern III). AITL is 
characterised by immune deregulation resulting in susceptibility to opportunistic 
pathogens, which would result in re-activation o f latent viral infections. A high EBV- 
load was mainly a feature in biopsies with “pattern III” histology. Furthermore, in the 
two cases where sequential biopsies showed progression from “Pattern I to “Pattern III”, 
there was a dramatic rise in EBV load at second biopsy. The correlation o f EBV load 
with the histological pattern, being more prevalent in cases with pattern III histology, 
may be related to the increasing immune-deficiency in more advanced disease. As AITL 
is characterised by a prominent reactive infiltrate, these may contribute the histology 
observed as “pattern III” . However, the occurrence o f this pattern in the absence o f a 
high EBV load indicates that these are not essential or do not play a significant role in 
defining the pathology o f “pattern III” .
8.3.4 HHV-8 infection in AITL
HHV8 or Kaposi sarcoma herpesvirus (KSHV), a y herpes virus, the aetiological agent 
in Kaposi sarcoma, is also causatively linked with lympho-proliferative conditions such 
as multicentric Castleman disease and the plasmablastic lymphoma that it may give rise 
to, HHV-8 and EBV associated germinotropic lymphoproliferative disorder and primary 
effusion lymphoma, the latter most often found in the setting o f HIV infection.
On morphology, the prominence o f regressed follicles in some cases o f AITL shows an 
overlap with the histology o f HHV-8 associated Castleman disease (Frizzera, 2001). 
AITL, like multicentric Castleman disease is associated with immune dysregulation and 
is characterized by prominent systemic symptoms, which are attributed to cytokine
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production. Thus the clear overlap between clinical and pathological features o f the two 
conditions warrants investigation o f HHV8 as a possible aetiological agent in AITL. In 
support o f this, Luppi, et al (1996) reported detection o f HHV8 sequences in 3 cases of 
AITL by PCR. However, Chadbum et al, (1997) failed to observe any evidence o f 
HHV8 infection by PCR or immunohistochemistry. In the present study, using virus- 
specific PCR we were unable to detect evidence o f  HHV8 in 28 cases o f AITL 
excluding the likelihood o f a causative role.
There are a few reports in older literature showing an association o f “AILD” with 
Kaposi sarcoma (Friedman-Birnbaum et al, 1985;Kluin-Nelemans et al, 1984;Suster et 
al, 1987). Considering the morphologic overlap between the two conditions, and 
paucity o f  adjuncts such as immunohistochemistry and molecular diagnostics available 
for diagnosis at the time o f  these studies, these cases probably represent examples o f 
HHV-8 related Castleman disease rather than AITL.
8.3.5 Concluding remarks
In AITL, EBV infected B-cells in AITL show an immunoblastic/plasmacytoid 
immunophenotype.
EBV load correlates well with histological patterns I-III described in chapter 3. A high 
EBV load is mainly a feature o f “pattern III” histology, and probably parallels the 
increasing immunosuppression in these patients.
HHV8 infection is not a feature o f AITL.
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Chapter 9
OVERVIEW
9.1 CD10 is expressed by the neoplastic T-cells in AITL and is a 
sensitive and specific marker of the disease.
In chapter 3, CD 10 was investigated as a possible phenotypic marker o f AITL. As the 
neoplastic cells comprise the minority and are vastly outnumbered by reactive cells, it 
was necessary to m icrodissect individual CD 10 positive lymphoid cells for molecular 
genetic analysis. The results showed that the neoplastic T-cells in AITL expressed 
CD 10, thus providing a marker to identify the neoplastic T-cell. In chapter 4, it was 
shown that in the assessment o f nodal PTLs, CD 10 expression appears to be specific to 
AITL. CD 10 was thus shown to be a sensitive (85%) and specific (100%) marker o f the 
disease. As CD 10 immunostaining can be performed in any histopathology laboratory, 
this provides a very useful diagnostic marker and a useful adjunct to diagnosis. 
Furthermore, identification o f  a specific marker for the neoplastic T-cells in AITL, for 
the first time provides the opportunity to investigate the biology o f the disease and may 
be in the future, devise novel therapeutic approaches.
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9.2 The (CD10 positive) neoplastic T-cells in AITL account for a 
minority o f total T-cells in most cases, and only a small 
proportion o f them are in cycle
In chapter 3 it was shown that CD 10 positive tumour cells accounted for only 10-30% of 
T-cells in most cases, confirming the studies o f others that the neoplastic cells are in the 
minority. Although the overall proliferation fraction as assessed by single layered Ki 67 
immunostaining, was high, double-layered immunohistochemistry showed that the 
majority o f CD 10 positive T-cells were Ki 67 negative. This raised the question whether 
CD 10 expression in neoplastic T-cells in AITL may be an indicator o f disturbed 
apoptotic cell death analogous to follicular lymphoma, and whether AITL is a 
biologically indolent/low grade tum our causing disease and death by immune 
deregulation rather than increased tumour load?
9.3 CD10 expression is maintained at most extranodal sites and 
correlates with the presence of FDCs
In chapter 5, we studied CD 10 expression in extranodal sites involved by AITL. CD 10 
expression was maintained in most extranodal sites o f involvement, except bone 
marrow. CD 10 expression at extranodal sites correlated well with the presence o f FDCs, 
suggesting an analogy with follicular lymphoma, where CD 10 expression is down 
regulated in bone marrow and interfollicular areas lacking FDCs.
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9.4 AITL has 3 overlapping histologic patterns
In chapter 3 it was also shown, that based on histology, 3 overlapping histological 
patterns could be identified, depending on the presence o f hyperplastic (pattern I) or 
regressed (pattern II) follicles or the complete absence o f identifiable follicles (pattern 
III). The FDC meshwork showed minimal/ no expansion in pattern I, but was 
hyperplastic in patterns II and III, with marked expansion in pattern III. An increase in 
CD 10 positive T-cells was observed from patterns I to III. Furthermore, the distribution 
o f the CD 10 expressing neoplastic T-cells was perifollicular in pattern I and diffuse in 
pattern III, but concentrated around the markedly hyperplastic FDC meshwork.
9.4.1 Pattern I represents an early phase of AITL
In chapters 3,4 and 6 it was shown why AITL, pattern I should be classified as AITL, 
rather than PTLu. In chapter 6 we showed histological progression from pattern I to III, 
confirming earlier reports that that the appearance we describe as pattern I represents 
early lymph node involvement by AITL.
9.4.2 Partial phenotype is more consistent with AITL
In chapter 4 it was shown that the category described as AITL/PTL indeterminate had 
morphologic features o f  pattern III AITL such as a polymorphous infiltrate with or 
without clear cells and prominent vascularity but lacked the prominent FDC hyperplasia 
characteristic o f AITL. However there was subtle FDC expansion with a tendency to 
encircle vessels. CD 10 was also expressed by neoplastic T-cells in the majority. 
AITL/PTL indeterminate cases, also showed evidence o f EBV infection in a high 
percentage o f cases, a feature seen in AITL but not observed in any PTLu studied.
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Furthermore, on m olecular genetic analysis, the pattern o f T-cell clonality in these cases 
was similar to AITL, with a dominant clone/clones being identified in a very high 
proportion (88%) o f cases. Overall the evidence suggests that these cases are best 
regarded as AITL rather than PTLu.
9.4.3 Do we need to revise existing diagnostic criteria?
The findings in chapter 4 showed that the existing pathological criteria apply only to the 
“typical” histology that probably accounts for approximately 80% o f all cases. This calls 
to question whether AITL is underdiagnosed and whether we need to revise existing 
criteria.
9.5 EBV-associated B-cell proliferation is a frequent complication of 
AITL
In chapter 6 we studied the histology o f sequential biopsies. It was noted that when 
AITL is complicated by the occurrence o f a “large cell lymphoma” it is most often an 
EBV-associated DLBCL. However a PTL with large cell morphology or EBV-negative 
DLBCL may also occur. EBV-associated B-cell lymphomas such as DLBCL and less 
commonly CHL may occur in up to 25% o f cases o f AITL. Evidence in one case showed 
that Thalidomide maybe useful in treating EBV-associated B-cell proliferations in AITL.
9.6 AITL originates from germinal center T-cells
In chapter 7 we used CD10 as a phenotypic marker and show that the neoplastic T-cells
in AITL express BCL-6 and CXCL13. Although the neoplastic T-cells in most cases
were CD57 negative this phenotypic profile favours a GC T-cell origin.
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9.7 EBV infected B-cells have an immunoblastic/plasmacytoid 
phenotype
In chapter 8 we showed that the immunophenotype o f EBV infected B-cells (in cases 
showing a dom inant B-cell clone) were CD79a positive, CD20 +/-, BCL6 negative, 
CD 10 negative and MUM-1 positive with abundant cytoplasmic Ig, consistent with an 
immunoblastic/plasmacytoid phenotype.
9.8 EBV-load correlates well with histological pattern of AITL
In chapter 8 we showed that a high EBV load is mainly a feature o f “pattern III” 
histology, possibly due to increasing levels o f immunosuppression that parallel 
histologic progression.
9.9 HHV-8 infection is not a feature of AITL
Finally in chapter 8, by PCR, we show that HHV-8 infection is not associated with 
AITL.
9.10 Diagnostic applications, research investigations derived from 
this study and the direction of future research activity
Following the publication o f results included in this thesis (Attygalle et al,
2002;Attygalle et al, 2004). Lee and colleagues (Lee et al, 2003a) and Bassegio and co­
workers (Baseggio et al, 2004) confirmed our findings by using flow cytometry, and 
showed CD 10 expression in AITL in involved lymph nodes, extranodal sites and blood.
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As CD 10 immunostaining can be performed in any histopathology laboratory and flow 
cytometry performed in many haematology/haematopathology laboratories, CD 10 
expression by the neoplastic T-cells in AITL, provides a very useful phenotypic marker 
and a valuable adjunct to diagnosis, even at an early stage o f evolution o f the disease. 
Furthermore, the presence o f such a marker provides an opportunity to establish more 
objective criteria for diagnosis than those currently in use.
As the neoplastic T-cell in AITL are in the minority, CD 10 expression provides a means 
o f identifying the tumour cells for phenotypic, genetic and functional studies:
Cytokine profile: Immunohistochemistry, in situ hybridisation and gene expression 
profiling may be used to investigate the cytokine secretion profile o f the neoplastic T- 
cells.
Chrom osom al and  cytogenetic changes: Previous studies describing cytogenetic (clonal 
and clonally unrelated) abnormalities used whole tissue that contained not only 
neoplastic T- cells, but also include varying numbers o f EBV-infected B-cells/ 
proliferations (Schlegelberger et al, 1994b). Microdissection o f CD 10 positive tumour 
cells would limit the investigation to tumour cells alone. CGH and the more recently 
described comparative expressed sequence hybridisation (CESH) could be performed on 
microdissected material and double labelled fluorescence studies (CD 10/FISH) 
performed to investigate chromosomal and cytogenetic abnormalities in the neoplastic 
T-cells.
Apoptosis and  A IT L :  The possible correlation between CD 10 expression and apoptosis 
has been discussed in chapter 3, sections 3.3.3 and 3.3.4. Following the publication of 
our results (Attygalle et al, 2002), Kim, et al showed that the FDCs and endothelial cells 
in AITL express Fas ligand (FasL) whereas the CD 10 expressing tumour T-cells express
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Fas (CD95) and caspase 3, indicating Fas-FasL interaction between the neoplastic T-cell 
and the FDC and suggest that the follicular milieu is necessary for CD 10 expression by 
tumour cells, a feature that may play a functional role in regulating apoptosis (Kim et al, 
2002a).
Functional studies: Establishment o f CD10 positive lymphoma cell lines and the study 
o f the effects o f pharmacological inhibitors o f CD 10 (neutral endopeptidase) activity, 
which may provide an opportunity to investigate the biology o f the disease and in the 
future, to devise novel therapeutic approaches in the management o f AITL.
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O r i g i n a l  A r t i c l e
CD10 Expression in Extranodal Dissemination of 
Angioimmunoblastic T-cell Lymphoma
Ayoma D. Attygalle, MB, BS, MD, Timothy C. Diss, PhD, Philippa Munson, MSc, 
Peter G. Isaacson, MB, ChB, FRCPath, DSc, M ing Q. Du, MB, PhD, and  
Ahm et Dogan, MD, MRCPath, PhD
Abstract: Angioimmunoblastic T-cell lymphoma (AITL) is a sys­
temic disease that often has evidence o f extranodal involvement at 
presentation. In a recent study o f lymph nodes in AITL, we showed 
that the neoplastic T cells in most cases can be identified by aberrant 
expression o f CD 10. The aim o f  this study was to investigate whether 
CD 10 expression by the neoplastic T cells is maintained in extranodal 
sites. Ten cases o f  AITL with histologic and immunophenotypic evi­
dence o f  extranodal dissemination were studied. Seven cases o f  pe­
ripheral T-cell lymphoma unspecified (PTLu), that included biopsies 
o f  involved extranodal sites, two cases o f  enteropathy type T-cell 
lymphoma (ETTL), and one case o f  extranodal NK/T lymphoma, na­
sal type were selected as controls. Diagnostic lymph node biopsies 
and biopsies o f  extranodal sites were reviewed. PCR for T-cell clonal- 
ity and single layer imm unostaining for CD3, CD20, CD 10, and 
CD21 and double layer immunostaining for CD20/CD10 were per­
formed. All 10 cases o f  AITL had characteristic histologic features 
and m olecular evidence o f  the disease in lymph node biopsies. In 
these cases, aberrant CD 10 expression was maintained in the lung, 
cecum, tonsil, nasopharynx, and one o f  six involved bone marrow 
trephines. In these extranodal biopsies, the distribution o f  CD 10- 
positive tum or cells correlated with that o f  the follicular dendritic cell 
m eshwork (FDC). The five bone marrow trephines that lacked aber­
rant CD 10 expression were devoid o f morphologic and immunohis- 
tochemical evidence o f  FDC. In these five cases, there was evidence 
o f  aberrant CD 10 expression in other involved sites that had FDC. 
The neoplastic cells in PTLu, ETTL, and extranodal NK/T lym­
phoma, nasal type were CD 10 negative. Our data show that aberrant 
CD 10 expression is a useful phenotypic marker for diagnosis o f AITL 
in most involved extranodal sites, except bone marrow, and suggest a 
possible role o f  FDC in the pathogenesis o f  AITL.
Key W ords: angioimmunoblastic, peripheral T-cell lymphoma, ex­
tranodal, CD 10
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Angioimmunoblastic T-cell lymphoma (AITL) is a nodalperipheral T-cell lymphoma characterized by systemic 
disease and prominent constitutional sym ptom s.1 9 21,22 A l­
though generalized lymphadenopathy is a prominent feature, 
clinical evidence o f  extranodal involvement is often present at 
diagnosis. This includes hepatosplenomegaly seen in 50% to 
70%, skin rash in 50%, pleuropulmonary involvement in 40%, 
and bone marrow in vo lvem en t in 60% to 80% o f  pa­
tients3'9, l0’18'21'22,25 The alm ost universal occurrence o f  
lymphadenopathy permits a diagnosis based on examination o f  
a lymph node biopsy and extranodal sites, other than bone mar­
row are rarely subjected to histologic examination. Occasion­
ally, an extranodal site is biopsied either as a diagnostic pro­
cedure or to examine the extent o f  tumor involvement and rule 
out infectious or inflammatory conditions. In these situations, 
diagnosis can be very challenging as the conventional criteria 
based on alterations in lymph node biopsies are not applicable. 
Histologically, involved lymph nodes show partial or total 
obliteration o f  the normal architecture by a polymorphic infil­
trate o f  lymphocytes, plasma cells and eosinophils, prominent 
proliferation o f  venules, and expansion o f  the follicular den­
dritic cell (FDC) meshwork.4,8,11 Collections o f  cells with pale 
to clear cytoplasm, described as being typical for AITL, is not 
a consistent finding and in many instances cytologic features 
o f malignancy are not readily identifiable.1 Therefore, despite 
histologic criteria, definite diagnosis is often difficult even on 
lymph node biopsy, leading to an error in initial diagnosis in 
>50% o f  the cases, further complicating histologic interpreta­
tion o f  an extranodal biopsy.1
In a recent study o f  lymph nodes in AITL, w e showed  
that the neoplastic T cells in most cases can be identified by 
aberrant expression o f  CD10, a feature absent in reactive lym ­
phoid proliferations and other peripheral T-cell lym phom as.1 
Early and accurate diagnosis o f  AITL in lymph nodes can thus 
be achieved by immunostaining for CD 10. Aberrant CD10 ex ­
pression, i f  maintained at extranodal sites o f  involvem ent, 
would serve as a phenotypic marker and a very useful diagnos­
tic tool. The aim o f  the present study was to investigate wheth­
er the expression o f  CD 10 by neoplastic T cells is maintained 
in extranodal sites.
Am J Surg Pathol • Volume 28, Number 1, January 2004
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MATERIALS AND METHODS
Tissues
Seventy-eight cases o f  AITL, diagnosed on lymph node 
biopsy, on clinical, histologic, immunophenotypic and m o­
lecular genetic criteria, were retrieved from the archives o f  the 
Department o f  Histopathology, University C ollege London 
Hospital. O f these, 10 cases that included biopsies o f  involved 
extranodal sites were selected for study. A ll had been re­
ferred from other institutes. Seven cases o f  nodal peripheral 
T-cell lymphoma, unspecified (PTLu), diagnosed on lymph 
node biopsy, that included biopsies o f  involved extranodal 
sites [bone marrow (5), tonsil (1), and stomach (1)], 2 cases 
o f  enteropathy-type T-cell lymphoma (ETTL), and 1 case o f  
extranodal NK/T lymphoma, nasal type were included as 
controls.
Imm unohistochemistry
Paraffin sections (3 pm) were immunostained by the 
streptavidin immunoperoxidase method (ChemMate Strepta­
vidin Peroxidase kit, Dako, Cambridge, United Kingdom) and 
DAB chromogen (Dako) following heat-mediated antigen re­
trieval as previously described.5 Primary antibodies included 
CD3 (polyclonal anti-CD3; Dako), CD 10 (56C6, Novocastra 
Labs, Newcastle, United Kingdom), CD20 (L26; Dako), and 
CD21 (1F 8; D ako). Sequ en tia l dou b le sta in in g  using  
CD20/CD10 was done on selected cases, in each case the first 
antibody being revealed with peroxidase and the second with 
alkaline phosphatase with a fast blue chrom ogen in each  
case.13 N o counterstain was used. To demonstrate CD10 ex­
pression in neoplastic T cells, CD 10, and C D 20/C D 10 sections 
were compared with sequential CD3 immunostained sections 
as described previously.1
TABLE 1. Clinical Features, Site of Biopsy, and Initial Diagnosis
Case
No. Age (yr)/Sex
Clinical
Presentation Site of Biopsy
Initial
Diagnosis
1 33/F Not available Lymph node 
Tonsil
Cecum (1 year after diagnosis)
AITL
Not available
Recurrent lymphoma or early 
inflammatory bowel disease
2 75/F Shortness o f  breath and generalized 
lymphadenopathy; chest X-ray 
showed an expanding discrete 
lesion in the right upper lobe;
2 years later she re-presented with 
malaise, weight loss, 
hepatosplenomegaly, and 
lymphadenopathy
Lung
Inguinal lymph node (2 years after 
lung biopsy)
Bone marrow
Reactive lymphoid hyperplasia 
Hodgkin lymphoma 
Staging-?involved
3 82/M B-symptoms, anemia, generalized 
lymphadenopathy, splenomegaly.
Lymph node 
Bone marrow
Reactive-‘/connective tissue disorder 
Staging-? involved
4 43/F Lymphadenopathy 2 years later, 
presented with pneumonitis
Lymph node 
Lung
AITL
? involved by AITL
5 48/M Not available Lymph node 
Bone marrow
AITL
Staging-? involved
6 63/F Presented with pulmonary 
embolism and subsequently 
shown to have splenomegaly and 
cervical and abdominal 
lymphadenopathy
Cervical lymph node 
Bone marrow
AITL or PTL 
Staging-? involved
7 67/M Bilateral axillary and inguinal 
lymphadenopathy
Inguinal lymph node 
Bone marrow
High-grade NHL 
Staging-? involved
8 58/M Generalized lymphadenopathy and 
skin rash
Axillary lymph node 
Bone marrow
AITL
Staging-involved
9 81/F Not available Cervical lymph node 
Nasopharynx
NHL
NHL
10 59/M Large mass in postnasal space and 
multiple enlarged cervical lymph 
nodes
Cervical lymph node 
Nasopharynx
Lennert’s lymphoma 
Lennert’s lymphoma
AITL, angioinununoblastic T-cell lymphoma; PTL, peripheral T-cell lymphoma; NHL, non-Hodgkin’s lymphoma.
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TABLE Z Summary of Histology, Immunophenotypic Profile, and T-Cell Clonality Analysis of Involved Extranodal Biopsies
Histology Inununohistochemistry
Case Extranodal Clear CD21+ FDC CD10+ TCR
No. Site Follicles Vascularity Cells Meshwork T Cells PCR
1 Tonsil Occasional regressed Rich network Present Expanded with Numerous Not done
sprouts
encircling
vessels
Cecum No identifiable Rich network Present Expanded with Numerous Oligoclonal
follicles sprouts
encircling
vessels
2 Lung Hyperplastic Interfollicular increase Absent Highlights Many Monoclonal
follicles; one (same size
focus expanded band as
with sprouts lymph node)
Bone marrow No identifiable Increased Absent Absent Absent Monoclonal
follicles (same size
band as
lymph node
and lung)
3 Bone marrow Regressed follicles No increase Absent Highlights Present Poor DNA
regressed
follicles
4 Lung No identifiable Increased Present Highlights Present Monoclonal
follicles follicles; no (same size
sprouts band as
lymph node)
5 Bone marrow No identifiable No increase Absent Absent Absent Poor DNA
follicles
6 Bone marrow No identifiable No increase Absent Absent Absent Monoclonal
follicles (same size
band as
lymph node)
7 Bone marrow No identifiable No increase Absent Absent Absent Monoclonal
follicles (same size
band as
lymph node)
8 Bone marrow No identifiable Increased Absent Absent Absent Not done
follicles
9 Nasopharyngeal Hyperplastic Interfollicular increase Absent Highlights Present Inconclusive
biopsy follicles
10 Nasopharyngeal No identifiable Increased Absent Expanded with Present Monoclonal
biopsy follicles sprouts
encircling
vessels
FDC, follicular dendritic cells; TCR, T-cell receptor-^ chain gene; PCR, polymerase chain reaction.
In Situ Hybridization for Epstein Barr Virus 
(EBV)-Epstein Barr Early Region (EBER)
In situ hybridization (ISH) was carried out with a poly­
merase chain reaction (PCRegenerated EBV DNA probe la­
beled with digoxigenin, followed by incubation with antidi- 
goxigenin-AP (Boehringer Mannheim, Germany) and visual-
56
ization w ith 5-brom o-4-ch loro-3-indoly l phosphate and 
nitroblue tetrazolium as previously described.7
PCR for T-cell Receptor-y (TCR-y) Chain Gene
PCR was performed to analyze clonal expansion o f  T 
cells. D NA  was extracted from paraffin sections using protein-
©  2003 Lippincott Williams & Wilkins
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ase K digestion without subsequent organic extraction as pre­
viously described.13 T-cell clonal expansion was detected by 
analysis o f  TCR-y chain gene rearrangement. Duplicate ali­
quots o f  each sample were analyzed for rearrangement using 
two sets o f  primers as previously described.1 DNA extracted 
from a paraffin block o f  a T -cell lymphoma was used as a posi­
tive control, and a reaction without template DNA was run as a 
negative control in all experiments. PCR products were ana­
lyzed on 10% polyacrylamide minigels, stained with ethidium 
bromide, and viewed under UV light.
RESULTS 
Clinical Features
The clinical presentations and the initial diagnoses at re­
ferral are summarized in Table 1. Among the 10 cases studied, 
there were 5 females and 5 males between the ages o f  33 and 
82 years. In 5 o f  the 7 cases for whom clinical history was 
available, systemic symptoms were prevalent at some time 
during the course o f  the disease. Six cases had involved bone 
marrow trephines, 2 had pulmonary involvement, 1 had tonsil­
lar and cecal involvement, while 2 cases had involved naso­
pharyngeal biopsies. Lymph node biopsies were performed for 
initial diagnosis in 9 o f  the 10 cases, while in 1 case (case no. 2) 
a lung biopsy was follow ed 2 years later by a lymph node bi­
opsy. An initial diagnosis o f  AITL was made in only 5 o f  the 10 
cases.
Histology 
Lymph Nodes
Angioimmunoblastic T-cell Lymphoma
Lymph node biopsies in cases nos. 1-8 and 10 con­
formed to that described as typical for AITL, with efface- 
ment o f  architecture by a polymorphic infiltrate comprising 
sm all lym phocytes and transformed blasts, plasma cells , 
histiocytes, and eosinophils within a prominent vascular net­
work. A proportion o f  the lymphoid blasts in case nos. 1, 2, 
and 4 had pale to clear cytoplasm. Follicles were either not 
identifiable or regressed with concentrically arranged FDC. 
The pattern o f  involvement in case no. 9 was similar to that 
described in early AITL,1 with preserved hyperplastic fo l­
licles, and a paracortical infiltrate similar to that seen in the 
other cases.
Extranodal Sites
Angioimmunoblastic T-cell Lymphoma
The histologic features o f  extranodal sites o f  involve­
ment o f  each case are summarized in Table 2. The features 
ranged from a nonspecific mixed infiltrate (bone marrow bi­
opsies in case nos. 5, 6, and 7) to a polymorphic infiltrate with 
clear cells in close proximity to a prominent arborizing vascu­
lar network (tonsillar and cecal biopsies in case no. 1; Fig.
O 2003 Lippincott Williams A  Wilkins
1 A,D,G , J). A ll 6 involved bone marrow trephines showed fo­
cal involvement, which was para trabecular in 4 cases. Two 
cases showed an increase in vascularity (Fig. 1J). Three in­
volved trephines (case nos. 5, 6, and 7) showed a mixed infil­
trate o f  small and large lymphoid cells. One case (case no. 3) 
had evidence o f  regressed follicles in close association with the 
neoplastic infiltrate, while the 2 biopsies with increased vas­
cularity (case nos. 2 and 8) comprised foci with small and large 
lymphocytes, epithelioid histocytes, fibroblasts, and eosino­
phils amid the vessels imparting a “granulomatous” appear­
ance (Fig. 1 J).
Immunohistochemistry 
Lymph Nodes
Angioimmunoblastic T-cell Lymphoma
The infiltrate com prised a predom inance o f  C D 3- 
positive T cells. In case nos. 1-8 and 10, CD21 highlighted 
the hyperplastic FDC meshwork that extended into the para­
cortex to surround high endothelial venules. In case no. 9 , 
C D 21 immunostaining was more or less confined to the hyper­
plastic fo llic les identified on h istology, w ith on ly  subtle 
extensions into the paracortex, consistent with early ArTL.' 
Single layered immunohistochemistry with CD 10 and double 
staining with CD20/CD10 highlighted a population o f  CD 10- 
positive, CD20-negative lymphoid cells in 8 cases (case nos. 
3-10). Examination o f  sequential sections im munostained  
for CD3 and CD20/CD10 showed that these CD 10-positive 
cells were the neoplastic T cells, as previously reported. The 
distribution o f  these cells was similar to that o f  the expanded 
FDC m eshw ork. In case no. 9, w hich  had hyperplastic  
follicles, the CD 10-positive T cells were situated at the outer 
rim o f  the fo llicle spilling into the paracortex. N o CD 10- 
positive T cells were identified in the lymph node biopsy in 
case no. 2. CD 10 expression could not be investigated in the 
lymph node biopsy in case no. 1 as insufficient material was 
available.
Peripheral T-cell Lymphoma, Unspecified
N o CD 10-positive lymphoid cells were present in any o f  
the cases o f  PTLu.
Extranodal Sites
Angioimmunoblastic T-cell Lymphoma
CD3 immunostaining highlighted a marked T-cell infil­
trate in all cases. The details o f  CD21 expression and CD 10 
expressing T cells are given in Table 2. At one end o f  the spec­
trum, CD21 immunostaining showed mild expansion o f  the 
FDC meshwork as in the tonsillar and cecal biopsies o f  case  
no. 1 (Fig. IB, E). Focally, the FDC surrounded the venules in 
these biopsies. FDC expansion was subtle but nevertheless 
present focally, in the lung biopsy o f  case no. 2 (Fig. 1H). At 
the other extreme, there were no CD21-positive FDC m esh-
57
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works in 5 o f  the 6 bone marrow biopsies (Fig. 1K). In all other 
biopsies, the FDC meshwork highlighted either hyperplastic or 
regressed follicles but showed no expansion (Fig. IN). CD 10 
and CD20/CD10 double immunostaining highlighted CD 10- 
positive, CD20-negative lymphoid cells corresponding to T 
cells in all sites except in the bone marrow (Fig. 1C, F, I). In the 
bone marrow, the presence o f  non-neoplastic hematopoietic 
precursors and the subtle nature o f  involvement made assess­
ment o f  CD 10 positivity o f  the neoplastic cells more difficult. 
Nevertheless, after careful comparison with morphology and 
CD3 immunostaining, aberrant CD 10 expression by neoplas­
tic T cells could be identified only in one involved bone mar­
row trephine (Fig. 1L, O). Aberrant CD 10 expression in all 
involved extranodal sites correlated w ell with the presence and 
distribution o f  FDC (Fig. 1). In those cases in which the FDC 
showed minimal expansion or sprouting (lung biopsies in case 
nos. 2 and 4, bone marrow biopsy in case no. 3, and nasopha­
ryngeal biopsy in case no. 9), CD 10-positive T cells were seen 
at the edge o f  the follicle spilling into the adjacent interfollicu­
lar region (Fig. 10).
Other Peripheral T-cell Lymphomas
N o CD 10-positive lymphoid cells were present in any o f  
the cases o f  PTLu. The neoplastic cells in both cases o f  ETTL 
and in the case o f  extranodal NK/T lymphoma, nasal type were 
CD 10 negative.
In Situ Hybridization for EBV-EBER
EBER-ISH was performed on lymph nodes in case nos. 
2-10. Lymph nodes in case nos. 2-8 and 10 showed hybridiza­
tion for EBV-EBER in a subset o f  cells that appeared to cor­
respond to C D20-positive B-blasts. Case no. 9 was EBER-ISH  
negative. EBER-ISH performed on the cecum in case no. 1 and 
the nasopharyngeal biopsy in case no. 9 was negative.
PCR for TCR-y Chain Gene
The results o f  PCR for TCR-y chain gene in the 10 cases 
o f  AITL are shown in Table 2. A ll but one case with good 
quality DNA showed either a single or two distinct bands, con­
sistent with monoclonal T-cell expansion. Case no. 1 showed 3 
bands and was interpreted as being biclonal/oligoclonal.
DISCUSSION
The diagnosis o f  AITL is based on histologic examina­
tion o f  a lymph node and requires demonstration o f  architec­
tural, cytologic, and immunophenotypic changes often com ­
bined with molecular genetic analysis.8,11 O f the morphologic 
features described as being typical for AITL, a polymorphic 
infiltrate and prominent high endothelial venules are rather 
nonspecific, and shared by reactive conditions and other lym­
phomas. Clear cells, considered characteristic, are present in 
less than half the cases.1 In practice, it is the proliferation o f  
FDC, best appreciated by immunohistochemistry, and its as­
sociation with vessels, that is most specific, and ultimately 
helps to distinguish AITL from PTLu.11,14 However, it is now  
known that, in early cases, this pattern o f  FDC hyperplasia may 
be subtle if  present at all, and follicular hyperplasia, once 
thought to exclude AITL, is a prominent feature.1,19 Thus, ex ­
cept when changes are florid, specific histologic diagnosis can 
be difficult, even on lymph node biopsy, requiring correlation 
with immunohistochemistry, molecular genetics, and impor­
tantly, the clinical presentation.1,4 This difficulty also ques­
tions the diagnostic accuracy o f  early reports o f  extranodal in­
volvement, when AITL was thought to be an atypical reactive 
process, rather than a lymphoma, and diagnosis was purely on 
morphologic grounds, with no resort to immunohistochemis­
try or molecular genetic evidence o f  T-cell clonality. N ever­
theless, in both early and more recent reports o f  visceral in­
volvem ent by AITL, the histologic features range from a poly­
morphous infiltrate with prominent vascularity and interstitial 
periodic acid-Schiff positive material to follicular hyperplasia 
with an interfollicular polymorphous infiltrate, similar to that 
observed in early lymph node involvem ent.10,15,16,20,23 25 In 
our study, the histology in involved extranodal sites such as 
lung, nasopharynx, cecum, and tonsil showed a similar spec­
trum o f  histologic changes, ranging from those that may be 
mistaken for a reactive lymphoid proliferation to features sug-
FIGURE 1. Histology, follicular dendritic cell meshwork, and CD10 expression in extranodal biopsies of case nos. 1-3. A-F: The 
cecal (panels A-Q and tonsillar biopsies (panels D-F) from case no. 1, panels G-L, the lung (panels G-l) and bone marrow biopsies 
(panels J-L) from case no. 2, and panels M-O the bone marrow biopsy from case no. 3. A, D, G, J: Hematoxylin and eosin-stained 
sections of case nos. 1 and 2 show increased vascularity and a polymorphous infiltrate. The inset in A shows atypical clear cells 
in the vicinity of a vessel. J: The bone marrow biopsy from case no. 2 shows a "granulomatous" appearance. The inset in A 
highlights the polymorphous nature of the infiltrate and the presence of clear cells in close proximity to vessels. M: CD3 shows 
a prominent T-cell infiltrate in the bone marrow of case no. 3. B, E, H, K, N: Immunostaining for CD21 in case nos. 1-3. There is 
mild expansion of follicular dendritic cell meshwork (FDC) in the cecal (B) and tonsillar biopsies (E) in case no. 1 and focal 
expansion in the lung biopsy (H) in case no. 2, but no evidence of FDC in the bone marrow biopsy (K) of case no. 2. The bone 
marrow biopsy in case no. 3 (N) shows a regressed follicle. C, F, I, L, and O: CD10 immunostaining in case nos. 1-3. C and F: 
Double immunostaining for CD20 in brown (DAB) and CD10 in blue (fast blue) highlight numerous CD20-negative, CD10- 
positive cells, consistent with T cells. Single layer CD10 immunostaining (I, L, and O) shows many CD 10-positive lymphoid cells 
in the bone marrow biopsy in case no. 3 (O) and in the lung biopsy (I), but not in the bone marrow biopsy (L) of case no. 2. 
(Original magnifications: A-l, X 40; J, M-O, X 100; K, L, A inset, X 1000.)
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gestive o f  lymphoma, but not specifically AITL. A  specific 
phenotypic or molecular marker would thus be the only means 
o f definite diagnosis o f  AITL at these sites, in the absence o f  an 
accompanying lymph node biopsy. In our study, aberrant ex ­
pression o f  CD 10, a feature shown to be a sensitive and spe­
cific marker o f  neoplastic cells in affected lymph nodes, was 
consistently seen in all involved extranodal sites, except 5 o f  6 
involved bone marrow trephines. Its value is especially high­
lighted in case no. 2 in which the misdiagnosis o f  reactive (fo l­
licular) hyperplasia on lung biopsy may have been averted if  
aberrant CD 10 expression had been assessed. Although se­
quential double immunostaining using CD20/CD10 is useful 
to demonstrate aberrant CD 10 expression by the neoplastic T 
cells, comparison o f  consecutive sections with routinely per­
formed single layer immunohistochemistry using CD20, CD3, 
and CD 10 would have sufficed in many cases.
Bone marrow is biopsied as a part o f  the staging proce­
dure and is often involved at diagnosis.3,10 In their series o f  8 
cases, Ghani and Krause described focal infiltrates with promi­
nent epithelioid cells imparting a “granulomatoid appearance” 
as the predominant pattern o f  involvem ent.10 In the same 
study, paratrabecular involvem ent described as typical for 
AITL by Pangalis et a l17 was a rare feature, and an increase in 
vascularity, prominent in involved lymph nodes, was seen in 
only 3 o f  their cases.10 In our study, although focal involve­
ment w as seen in all involved bone marrow biopsies, two 
thirds (4 o f  6 cases) o f  which showed a paratrabecular distri­
bution, a “granulomatoid” appearance was seen only in one 
third o f  the cases (2 o f  6 cases). An increase in vascularity 
was also observed only in the latter 2 cases. FDC, a promi­
nent feature in involved lymph nodes, was observed only in 
case no. 3 in the form o f  regressed follicles. In all 6 cases, 
the morphologic, immunophenotypic, and molecular genetic 
features on bone marrow trephine enabled a diagnosis o f  
peripheral T-cell lymphoma but were not sufficient to subtype 
further as AITL. Aberrant CD 10 expression, a useful feature 
in this situation, was however present only in one case (case 
no. 3).
Skin rash is a common symptom at presentation.22 Un­
fortunately, because o f  the lack o f  involved skin biopsies in our 
series, w e were unable to assess the usefulness o f  aberrant 
CD 10 expression at this site.
CD10, a transmembrane protein with neutral endopepti- 
dase activity, is expressed in follicle center B cells and is a 
reliable marker o f  follicular lymphoma.5 In the latter, CD 10, 
although strongly expressed within the neoplastic follicles, is 
down-regulated in clonally identical interfollicular neoplastic 
cells.6 The expression o f  CD10 in follicular lymphoma cells 
may thus be dependent on a signal from the FDC. In vitro stud­
ies have shown that highly purified FDCs are able to induce the 
proliferation o f  allogeneic T cells or T-cell lines 2 There is, 
however, no direct evidence for ongoing interactions between 
the neoplastic cells o f  T-cell lymphomas and FDC. Neverthe-
60
less, AITL is characterized by an expansion o f  FDC mesh­
work.11 In lymph nodes and extranodal sites, aberrant CD 10 
expression correlates w ell with the presence and distribution o f  
FDC. This correlation is especially w ell highlighted in the 
cases with bone marrow involvement in our study, where ab­
errant CD 10 expression in the marrow is confined to the only 
case associated with FDC. Conversely, in case nos. 2 and 5-8, 
the neoplastic cells are CD 10 negative in the marrow when 
devoid o f  associated FDC, but CD 10 positive in other involved  
sites that harboured FDC. This suggests an analogy with fol­
licular lym phoma where, despite clonal identity, there is 
down-regulation o f  CD10 in neoplastic cells that lack associa­
tion with FDC and indicates a possible role o f  FDC in this 
phenomenon. In support o f  this theory, Kim et al have shown 
in a recent study that FDC and endothelial cells in AITL ex ­
press Fas ligand (FasL) whereas the CD 10-expressing tumor T 
cells express Fas (CD95) and caspase 3, indicating Fas-FasL 
interaction between the neoplastic T cells and the FDC and 
suggest that the follicular milieu is necessary for CD 10 expres­
sion by tumor cells, a feature that may play a functional role in 
regulating apoptosis.12
In summary, aberrant expression o f  CD 10 by neoplastic 
T cells in AITL is maintained in most involved extranodal sites 
and shows good correlation with the presence and distribution 
o f  FDC. This immunophenotypic feature may thus be used to 
make a diagnosis o f  AITL in an extranodal site, even in the 
absence o f  accompanying lymph node histology.
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